US20010016659A1 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors - Google Patents
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors Download PDFInfo
- Publication number
- US20010016659A1 US20010016659A1 US09/773,672 US77367201A US2001016659A1 US 20010016659 A1 US20010016659 A1 US 20010016659A1 US 77367201 A US77367201 A US 77367201A US 2001016659 A1 US2001016659 A1 US 2001016659A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- phenyl
- acid
- halogen
- heteroatoms selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *=O.[H-] Chemical compound *=O.[H-] 0.000 description 20
- YXOQBACGFNDSNY-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=N1 YXOQBACGFNDSNY-UHFFFAOYSA-N 0.000 description 6
- INPUVQTZZNETMR-UHFFFAOYSA-N CNC(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 Chemical compound CNC(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 INPUVQTZZNETMR-UHFFFAOYSA-N 0.000 description 6
- RPGKLBGQTBMKTQ-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC(C)=CC=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC(C)=CC=C2)=CC=N1 RPGKLBGQTBMKTQ-UHFFFAOYSA-N 0.000 description 5
- IFXPTMRQFDAEHQ-UHFFFAOYSA-N CC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 Chemical compound CC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 IFXPTMRQFDAEHQ-UHFFFAOYSA-N 0.000 description 4
- YIZLIZODTYLGQM-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=C(Cl)C=C(C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=C(Cl)C=C(C)C=C2)=CC=N1 YIZLIZODTYLGQM-UHFFFAOYSA-N 0.000 description 4
- PRWVRDZBKDSXLR-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC(Cl)=C(C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC(Cl)=C(C)C=C2)=CC=N1 PRWVRDZBKDSXLR-UHFFFAOYSA-N 0.000 description 4
- LNKHTFLIYAKPQF-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1OC Chemical compound CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1OC LNKHTFLIYAKPQF-UHFFFAOYSA-N 0.000 description 4
- ZCAMFZFGGCKMDE-UHFFFAOYSA-N CC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3)C=C1 Chemical compound CC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3)C=C1 ZCAMFZFGGCKMDE-UHFFFAOYSA-N 0.000 description 3
- HEBREMVVGGTWJD-UHFFFAOYSA-N CC1=CC=C(OC2=CC=C3C(=O)N(C)C(=O)C3=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=C3C(=O)N(C)C(=O)C3=C2)C=C1 HEBREMVVGGTWJD-UHFFFAOYSA-N 0.000 description 3
- YKROASXVLAVTRB-UHFFFAOYSA-N CC1=CC=C(OC2=CC=NC(C(=O)N(C)C)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=NC(C(=O)N(C)C)=C2)C=C1 YKROASXVLAVTRB-UHFFFAOYSA-N 0.000 description 3
- DBIRAEMOQHXKJG-UHFFFAOYSA-N CC1=CC=C(OC2=CC=NC(C(N)=O)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=NC(C(N)=O)=C2)C=C1 DBIRAEMOQHXKJG-UHFFFAOYSA-N 0.000 description 3
- FIXWGHHHZNQQAF-UHFFFAOYSA-N CC1=CC=C(OC2=CN=CC(C(=O)NCCN(C)C)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CN=CC(C(=O)NCCN(C)C)=C2)C=C1 FIXWGHHHZNQQAF-UHFFFAOYSA-N 0.000 description 3
- IXPLQAICHVIVLS-UHFFFAOYSA-N CC1=CC=C(OC2=CN=CC(C(=O)NCCN3CCOCC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CN=CC(C(=O)NCCN3CCOCC3)=C2)C=C1 IXPLQAICHVIVLS-UHFFFAOYSA-N 0.000 description 3
- FRYWSDRPFRIBJM-UHFFFAOYSA-N CCNC(c1nccc(Oc2ccc(C)cc2)c1)=O Chemical compound CCNC(c1nccc(Oc2ccc(C)cc2)c1)=O FRYWSDRPFRIBJM-UHFFFAOYSA-N 0.000 description 3
- BGVBBMZMEKXUTR-UHFFFAOYSA-N CNC(=O)C1=CC(Cl)=CC=N1 Chemical compound CNC(=O)C1=CC(Cl)=CC=N1 BGVBBMZMEKXUTR-UHFFFAOYSA-N 0.000 description 3
- FBGJBJUHGMCOSA-UHFFFAOYSA-N CNC(=O)C1=CC(SC2=CC(C)=CC=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(SC2=CC(C)=CC=C2)=CC=N1 FBGJBJUHGMCOSA-UHFFFAOYSA-N 0.000 description 3
- UEXQPQNNDNVQCY-UHFFFAOYSA-N CNC(=O)C1=CC(SC2=CC=C(C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(SC2=CC=C(C)C=C2)=CC=N1 UEXQPQNNDNVQCY-UHFFFAOYSA-N 0.000 description 3
- BSFDFMVNTSXKGR-UHFFFAOYSA-N COC1=NC=C(NC(=O)C2=CC(OC3=CC=C(C)C=C3)=CC=C2)C=C1 Chemical compound COC1=NC=C(NC(=O)C2=CC(OC3=CC=C(C)C=C3)=CC=C2)C=C1 BSFDFMVNTSXKGR-UHFFFAOYSA-N 0.000 description 3
- CAZWIMGCKKDNSZ-UHFFFAOYSA-N CC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 Chemical compound CC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 CAZWIMGCKKDNSZ-UHFFFAOYSA-N 0.000 description 2
- UHJNOSYKOLRPJA-UHFFFAOYSA-N CC1=CC=C(OC2=CC=C(S(C)(=O)=O)C=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=C(S(C)(=O)=O)C=C2)C=C1 UHJNOSYKOLRPJA-UHFFFAOYSA-N 0.000 description 2
- GPPQHMDYRCHRGN-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(F)C=C3)=C2)C=C1 GPPQHMDYRCHRGN-UHFFFAOYSA-N 0.000 description 2
- KNNHCZGVRVHQTA-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N(C)C)C=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N(C)C)C=C3)=C2)C=C1 KNNHCZGVRVHQTA-UHFFFAOYSA-N 0.000 description 2
- XCTWICSPMCXVTC-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N4CCOCC4)C=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N4CCOCC4)C=C3)=C2)C=C1 XCTWICSPMCXVTC-UHFFFAOYSA-N 0.000 description 2
- CBPPMYJEVFFDBQ-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=CN=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=CN=C3)=C2)C=C1 CBPPMYJEVFFDBQ-UHFFFAOYSA-N 0.000 description 2
- TXIIOPNMUHGGMY-UHFFFAOYSA-N CC1=CC=C(OC2=CC=NC(C(=O)NCCN3CCOCC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=NC(C(=O)NCCN3CCOCC3)=C2)C=C1 TXIIOPNMUHGGMY-UHFFFAOYSA-N 0.000 description 2
- VUTVZVTYPBYKNK-UHFFFAOYSA-N CC1=CC=CC(OC2=CC=NC(C(N)=O)=C2)=C1 Chemical compound CC1=CC=CC(OC2=CC=NC(C(N)=O)=C2)=C1 VUTVZVTYPBYKNK-UHFFFAOYSA-N 0.000 description 2
- YBCTUCXIBHYMCZ-UHFFFAOYSA-N CN(C)CCNC(=O)C1=CN=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=C1 Chemical compound CN(C)CCNC(=O)C1=CN=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=C1 YBCTUCXIBHYMCZ-UHFFFAOYSA-N 0.000 description 2
- LKVYVXGEQAAQLI-UHFFFAOYSA-N CN1C(=O)C2=CC=C(OC3=CC=C(N)C=C3)C=C2C1=O Chemical compound CN1C(=O)C2=CC=C(OC3=CC=C(N)C=C3)C=C2C1=O LKVYVXGEQAAQLI-UHFFFAOYSA-N 0.000 description 2
- GBICJVQWVCIPPM-UHFFFAOYSA-N CNC(=O)C1=CC(C(=O)NC2=CC=C(C)C=C2)=CC=C1 Chemical compound CNC(=O)C1=CC(C(=O)NC2=CC=C(C)C=C2)=CC=C1 GBICJVQWVCIPPM-UHFFFAOYSA-N 0.000 description 2
- MHLGPZZBETWDMS-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC(C)=C(C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC(C)=C(C)C=C2)=CC=N1 MHLGPZZBETWDMS-UHFFFAOYSA-N 0.000 description 2
- YWJASMSJTYTKCT-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC(C)=CC=C2C)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC(C)=CC=C2C)=CC=N1 YWJASMSJTYTKCT-UHFFFAOYSA-N 0.000 description 2
- OCXJEAHLLLWZSR-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CN=C1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CN=C1 OCXJEAHLLLWZSR-UHFFFAOYSA-N 0.000 description 2
- RRAIWDROLCSOHQ-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 Chemical compound CNS(=O)(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 RRAIWDROLCSOHQ-UHFFFAOYSA-N 0.000 description 2
- YUFBVCPZDNGYEX-LGMDPLHJSA-N CO/N=C(/C)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 Chemical compound CO/N=C(/C)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 YUFBVCPZDNGYEX-LGMDPLHJSA-N 0.000 description 2
- CYAIBMJRQQNPDF-UHFFFAOYSA-N COC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=N1 Chemical compound COC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=N1 CYAIBMJRQQNPDF-UHFFFAOYSA-N 0.000 description 2
- SPPJUUNCUKYHSS-UHFFFAOYSA-N COC(c1cc(Oc(cc2)ccc2N)cnc1)=O Chemical compound COC(c1cc(Oc(cc2)ccc2N)cnc1)=O SPPJUUNCUKYHSS-UHFFFAOYSA-N 0.000 description 2
- OVZREFXODGABHX-UHFFFAOYSA-N CC(=O)C1=CC=C(N2CCN(C(=O)C3=CC(OC4=CC=C(C)C=C4)=CC=C3)CC2)C=C1 Chemical compound CC(=O)C1=CC=C(N2CCN(C(=O)C3=CC(OC4=CC=C(C)C=C4)=CC=C3)CC2)C=C1 OVZREFXODGABHX-UHFFFAOYSA-N 0.000 description 1
- NCLRUYUHGZFTIP-UHFFFAOYSA-N CC(=O)C1=CC=C(NC(=O)NC2=CC=C(Cl)C(C(F)(F)F)=C2)C=C1 Chemical compound CC(=O)C1=CC=C(NC(=O)NC2=CC=C(Cl)C(C(F)(F)F)=C2)C=C1 NCLRUYUHGZFTIP-UHFFFAOYSA-N 0.000 description 1
- XZICJZAZWUKDKL-UHFFFAOYSA-N CC(=O)C1=CC=C(OC2=CC=C(C)C=N2)C=C1 Chemical compound CC(=O)C1=CC=C(OC2=CC=C(C)C=N2)C=C1 XZICJZAZWUKDKL-UHFFFAOYSA-N 0.000 description 1
- HAOGGAGMGJDGTM-UHFFFAOYSA-N CC(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 Chemical compound CC(=O)C1=CC=CC(OC2=CC=C(C)C=C2)=C1 HAOGGAGMGJDGTM-UHFFFAOYSA-N 0.000 description 1
- JNEZLBMITZLSBE-UHFFFAOYSA-N CC(C)[Si](OCCNC(=O)C1=NC=CC(Cl)=C1)(C(C)C)C(C)C Chemical compound CC(C)[Si](OCCNC(=O)C1=NC=CC(Cl)=C1)(C(C)C)C(C)C JNEZLBMITZLSBE-UHFFFAOYSA-N 0.000 description 1
- WMSYCZQEYWKNHX-UHFFFAOYSA-N CC(C)[Si](OCCNC(=O)C1=NC=CC(OC2=CC=C(N)C=C2)=C1)(C(C)C)C(C)C Chemical compound CC(C)[Si](OCCNC(=O)C1=NC=CC(OC2=CC=C(N)C=C2)=C1)(C(C)C)C(C)C WMSYCZQEYWKNHX-UHFFFAOYSA-N 0.000 description 1
- CTTOEQGSSNACRY-UHFFFAOYSA-N CC(C)[Si](OCCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=C1)(C(C)C)C(C)C Chemical compound CC(C)[Si](OCCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=C1)(C(C)C)C(C)C CTTOEQGSSNACRY-UHFFFAOYSA-N 0.000 description 1
- WXXDBPIOFOYRLP-UHFFFAOYSA-N CC1=CC=C(Br)C(C(F)(F)F)=C1 Chemical compound CC1=CC=C(Br)C(C(F)(F)F)=C1 WXXDBPIOFOYRLP-UHFFFAOYSA-N 0.000 description 1
- NTRYMISIIKPLLW-UHFFFAOYSA-N CC1=CC=C(C)C(OC2=CC=NC(C(N)=O)=C2)=C1 Chemical compound CC1=CC=C(C)C(OC2=CC=NC(C(N)=O)=C2)=C1 NTRYMISIIKPLLW-UHFFFAOYSA-N 0.000 description 1
- ZUSRGUGEKSFKTN-UHFFFAOYSA-N CC1=CC=C(C)N1C1=C(N)C=C(C(C)(C)C)C=C1 Chemical compound CC1=CC=C(C)N1C1=C(N)C=C(C(C)(C)C)C=C1 ZUSRGUGEKSFKTN-UHFFFAOYSA-N 0.000 description 1
- CYTOTVJOUQEGER-UHFFFAOYSA-N CC1=CC=C(C)N1C1=C([N+](=O)[O-])C=C(C(C)(C)C)C=C1 Chemical compound CC1=CC=C(C)N1C1=C([N+](=O)[O-])C=C(C(C)(C)C)C=C1 CYTOTVJOUQEGER-UHFFFAOYSA-N 0.000 description 1
- JDFNHFHOMMSCEZ-UHFFFAOYSA-N CC1=CC=C(OC2=CC(C(=O)O)=CC=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC(C(=O)O)=CC=C2)C=C1 JDFNHFHOMMSCEZ-UHFFFAOYSA-N 0.000 description 1
- FDOLYWDBQOCBKI-UHFFFAOYSA-N CC1=CC=C(OC2=CC=C(C)N=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=C(C)N=C2)C=C1 FDOLYWDBQOCBKI-UHFFFAOYSA-N 0.000 description 1
- OXCHBXPUIZPFLQ-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)N3CCN(C4=CC=C(F)C=C4)CC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)N3CCN(C4=CC=C(F)C=C4)CC3)=C2)C=C1 OXCHBXPUIZPFLQ-UHFFFAOYSA-N 0.000 description 1
- QOZSEHUUKMMENN-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)N3CCN(C4=NC=CC=C4)CC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)N3CCN(C4=NC=CC=C4)CC3)=C2)C=C1 QOZSEHUUKMMENN-UHFFFAOYSA-N 0.000 description 1
- OZAAFABJPIBIDX-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N4CCN(C5=NC=CC=C5)CC4)C=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NC3=CC=C(N4CCN(C5=NC=CC=C5)CC4)C=C3)=C2)C=C1 OZAAFABJPIBIDX-UHFFFAOYSA-N 0.000 description 1
- WOSKYMKWRIHKNO-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NCC3CCCO3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NCC3CCCO3)=C2)C=C1 WOSKYMKWRIHKNO-UHFFFAOYSA-N 0.000 description 1
- VZTKWLRKVXNGSH-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NCCN3CCCCC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NCCN3CCCCC3)=C2)C=C1 VZTKWLRKVXNGSH-UHFFFAOYSA-N 0.000 description 1
- OPXHLSARTYUGBX-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NCCN3CCOCC3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NCCN3CCOCC3)=C2)C=C1 OPXHLSARTYUGBX-UHFFFAOYSA-N 0.000 description 1
- AUCBAFQDRYILQA-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(=O)NCCNC3=CC=CC=C3)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(=O)NCCNC3=CC=CC=C3)=C2)C=C1 AUCBAFQDRYILQA-UHFFFAOYSA-N 0.000 description 1
- SAZGZUQFBHSHIZ-UHFFFAOYSA-N CC1=CC=C(OC2=CC=CC(C(N)=O)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=CC(C(N)=O)=C2)C=C1 SAZGZUQFBHSHIZ-UHFFFAOYSA-N 0.000 description 1
- PSBUSUDDJLJAIH-UHFFFAOYSA-N CC1=CC=C(OC2=CC=NC(C(=O)NCCO)=C2)C=C1 Chemical compound CC1=CC=C(OC2=CC=NC(C(=O)NCCO)=C2)C=C1 PSBUSUDDJLJAIH-UHFFFAOYSA-N 0.000 description 1
- IZSXUMMFPOSLSP-UHFFFAOYSA-N CCCNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CN=C1 Chemical compound CCCNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CN=C1 IZSXUMMFPOSLSP-UHFFFAOYSA-N 0.000 description 1
- BPIZCMKBUHTCLB-UHFFFAOYSA-N CCN1C(CNC(c2cccc(Oc3ccc(C)cc3)c2)=O)CCC1 Chemical compound CCN1C(CNC(c2cccc(Oc3ccc(C)cc3)c2)=O)CCC1 BPIZCMKBUHTCLB-UHFFFAOYSA-N 0.000 description 1
- MPMGIXBMHIXPAW-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC(C)=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC(C)=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=CC=N1 MPMGIXBMHIXPAW-UHFFFAOYSA-N 0.000 description 1
- AWRSJUZJLQWBJA-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(N)C=C2)=CC=C1OC Chemical compound CNC(=O)C1=CC(OC2=CC=C(N)C=C2)=CC=C1OC AWRSJUZJLQWBJA-UHFFFAOYSA-N 0.000 description 1
- RXZZBPYPZLAEFC-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(N)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(N)C=C2)=CC=N1 RXZZBPYPZLAEFC-UHFFFAOYSA-N 0.000 description 1
- HBQDXJJZDPLOFI-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)C(F)(F)F)C(Cl)=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)C(F)(F)F)C(Cl)=C2)=CC=N1 HBQDXJJZDPLOFI-UHFFFAOYSA-N 0.000 description 1
- JNWMCRIBVQCVQU-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=C(OC)C=CC(C(F)(F)F)=C3)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=C(OC)C=CC(C(F)(F)F)=C3)C=C2)=CC=N1 JNWMCRIBVQCVQU-UHFFFAOYSA-N 0.000 description 1
- CCVFWUBEHCKRFY-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(C)(C)C)=CC=C3N3C(C)=CC=C3C)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(C)(C)C)=CC=C3N3C(C)=CC=C3C)C=C2)=CC=N1 CCVFWUBEHCKRFY-UHFFFAOYSA-N 0.000 description 1
- WINHEDROZCCEOE-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Br)C=C3)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Br)C=C3)C=C2)=CC=N1 WINHEDROZCCEOE-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(C(F)(F)F)=C(Cl)C=C3)C=C2)=CC=N1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- BMWVTMCFKJXWGA-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC4=C(C=CC=C4)C=C3OC)C=C2)=CC=C1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC4=C(C=CC=C4)C=C3OC)C=C2)=CC=C1 BMWVTMCFKJXWGA-UHFFFAOYSA-N 0.000 description 1
- RHRMYJDVQDNOJF-UHFFFAOYSA-N CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(OC4=CC(C(=O)NC)=NC=C4)C=C3)C=C2)=CC=N1 Chemical compound CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(OC4=CC(C(=O)NC)=NC=C4)C=C3)C=C2)=CC=N1 RHRMYJDVQDNOJF-UHFFFAOYSA-N 0.000 description 1
- DJPFPKJMRXUDQO-UHFFFAOYSA-N CNC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=N1 Chemical compound CNC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=N1 DJPFPKJMRXUDQO-UHFFFAOYSA-N 0.000 description 1
- BLNKJKXISNHWFE-UHFFFAOYSA-N CNC(=O)C1=CC=C(OC2=CC=C(NC(=O)NC3=CC=C(OC4=CC=C(C(=O)NC)C=C4)C=C3)C=C2)C=C1 Chemical compound CNC(=O)C1=CC=C(OC2=CC=C(NC(=O)NC3=CC=C(OC4=CC=C(C(=O)NC)C=C4)C=C3)C=C2)C=C1 BLNKJKXISNHWFE-UHFFFAOYSA-N 0.000 description 1
- GBHKXRPUMLUAOE-UHFFFAOYSA-N CNC(=O)C1=CC=CC(C(=O)NC2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 Chemical compound CNC(=O)C1=CC=CC(C(=O)NC2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 GBHKXRPUMLUAOE-UHFFFAOYSA-N 0.000 description 1
- WPBIMOGKLSJKPE-UHFFFAOYSA-N CNC(=O)C1=CC=CC(NC(=O)C2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 Chemical compound CNC(=O)C1=CC=CC(NC(=O)C2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 WPBIMOGKLSJKPE-UHFFFAOYSA-N 0.000 description 1
- WCAAMQDJUGLXNR-UHFFFAOYSA-N CNC(=O)C1=CC=CC(OC2=CC=C(N)C=C2)=C1 Chemical compound CNC(=O)C1=CC=CC(OC2=CC=C(N)C=C2)=C1 WCAAMQDJUGLXNR-UHFFFAOYSA-N 0.000 description 1
- SQSSBCSNKRMGDM-UHFFFAOYSA-N CNC(=O)C1=NC=CC(OC2=CC=C(N)C(C)=C2)=C1.Cl Chemical compound CNC(=O)C1=NC=CC(OC2=CC=C(N)C(C)=C2)=C1.Cl SQSSBCSNKRMGDM-UHFFFAOYSA-N 0.000 description 1
- VMVMCVSHNRKGHX-UHFFFAOYSA-N CNC(=O)C1=NC=CC(OC2=CC=C(N)C=C2Cl)=C1 Chemical compound CNC(=O)C1=NC=CC(OC2=CC=C(N)C=C2Cl)=C1 VMVMCVSHNRKGHX-UHFFFAOYSA-N 0.000 description 1
- YQUUUSYWVYJHSY-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 Chemical compound CNS(=O)(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=C1 YQUUUSYWVYJHSY-UHFFFAOYSA-N 0.000 description 1
- BUXRPBLXFQHMCT-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(OC2=CC=C(N)C=C2)=C1 Chemical compound CNS(=O)(=O)C1=CC=CC(OC2=CC=C(N)C=C2)=C1 BUXRPBLXFQHMCT-UHFFFAOYSA-N 0.000 description 1
- NIEIVYUCXJAMOE-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(OC2=CC=CC=C2)=C1 Chemical compound CNS(=O)(=O)C1=CC=CC(OC2=CC=CC=C2)=C1 NIEIVYUCXJAMOE-UHFFFAOYSA-N 0.000 description 1
- IKVRSBJUUTZSEZ-GZTJUZNOSA-N CO/N=C(\C)C1=CC=C(OC2=CC=C(N)C=C2)C=C1.Cl Chemical compound CO/N=C(\C)C1=CC=C(OC2=CC=C(N)C=C2)C=C1.Cl IKVRSBJUUTZSEZ-GZTJUZNOSA-N 0.000 description 1
- FZJWBVQKMJQYAJ-UHFFFAOYSA-N COC(=O)C1=CC(C(=O)NC2=CC=C(C)C=C2)=CC=C1 Chemical compound COC(=O)C1=CC(C(=O)NC2=CC=C(C)C=C2)=CC=C1 FZJWBVQKMJQYAJ-UHFFFAOYSA-N 0.000 description 1
- VTENWIPSWAMPKI-UHFFFAOYSA-N COC(=O)C1=CC(Cl)=CC=N1.Cl Chemical compound COC(=O)C1=CC(Cl)=CC=N1.Cl VTENWIPSWAMPKI-UHFFFAOYSA-N 0.000 description 1
- MIYSVZONDCVLQK-UHFFFAOYSA-N COC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1OC Chemical compound COC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1OC MIYSVZONDCVLQK-UHFFFAOYSA-N 0.000 description 1
- MPLSAOVNAXJHHI-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=CC=C2)C=C1OC Chemical compound COC(=O)C1=CC2=C(C=CC=C2)C=C1OC MPLSAOVNAXJHHI-UHFFFAOYSA-N 0.000 description 1
- IDPXJPCOUTVHBL-UHFFFAOYSA-N COC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=N1 Chemical compound COC(=O)C1=CC=C(OC2=CC=C(C)C=C2)C=N1 IDPXJPCOUTVHBL-UHFFFAOYSA-N 0.000 description 1
- KYMNBFIAWXIYEP-UHFFFAOYSA-N COC(=O)C1=CC=C(OC2=CC=C(N)C=C2)C=N1 Chemical compound COC(=O)C1=CC=C(OC2=CC=C(N)C=C2)C=N1 KYMNBFIAWXIYEP-UHFFFAOYSA-N 0.000 description 1
- MGGGYJYLSKMWHH-UHFFFAOYSA-N COC(=O)C1=CC=CC(C(=O)NC2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 Chemical compound COC(=O)C1=CC=CC(C(=O)NC2=CC=C(NC(=O)NC3=CC=C(Cl)C(C(F)(F)F)=C3)C=C2)=C1 MGGGYJYLSKMWHH-UHFFFAOYSA-N 0.000 description 1
- UNDHRPGPHLTPTD-UHFFFAOYSA-N COC(=O)C1=CN=CC(OC2=CC=C(C)C=C2)=C1 Chemical compound COC(=O)C1=CN=CC(OC2=CC=C(C)C=C2)=C1 UNDHRPGPHLTPTD-UHFFFAOYSA-N 0.000 description 1
- BILJMVTZCRRVSV-UHFFFAOYSA-N COC1=C(N)C=C(C(F)(F)F)C(Cl)=C1 Chemical compound COC1=C(N)C=C(C(F)(F)F)C(Cl)=C1 BILJMVTZCRRVSV-UHFFFAOYSA-N 0.000 description 1
- RTBQQRFTCVDODF-UHFFFAOYSA-N COC1=CC2=C(C=CC=C2)C=C1C(=O)O Chemical compound COC1=CC2=C(C=CC=C2)C=C1C(=O)O RTBQQRFTCVDODF-UHFFFAOYSA-N 0.000 description 1
- XTRFUJHTLUJITO-UHFFFAOYSA-N COC1=CC2=C(C=CC=C2)C=C1N Chemical compound COC1=CC2=C(C=CC=C2)C=C1N XTRFUJHTLUJITO-UHFFFAOYSA-N 0.000 description 1
- KDXOGBSFQDSJGC-UHFFFAOYSA-N COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 KDXOGBSFQDSJGC-UHFFFAOYSA-N 0.000 description 1
- XMTBTJLMJWUGHT-UHFFFAOYSA-N COC1=CC=C(OC2=CC=C(C)C=C2)C=C1C(=O)O Chemical compound COC1=CC=C(OC2=CC=C(C)C=C2)C=C1C(=O)O XMTBTJLMJWUGHT-UHFFFAOYSA-N 0.000 description 1
- MQDXDPIOPSWVKU-UHFFFAOYSA-N COCCNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1 Chemical compound COCCNC(=O)C1=CC(OC2=CC=C(C)C=C2)=CC=C1 MQDXDPIOPSWVKU-UHFFFAOYSA-N 0.000 description 1
- OXTSDPIAFOGEFS-UHFFFAOYSA-N COc(ccc(Oc(cc1)ccc1N)c1)c1C(O)=O Chemical compound COc(ccc(Oc(cc1)ccc1N)c1)c1C(O)=O OXTSDPIAFOGEFS-UHFFFAOYSA-N 0.000 description 1
- VJEFBHVSDPCMIK-UHFFFAOYSA-N NC1=CC=C(NC(=O)NC2=CC=C(Cl)C(C(F)(F)F)=C2)C=C1 Chemical compound NC1=CC=C(NC(=O)NC2=CC=C(Cl)C(C(F)(F)F)=C2)C=C1 VJEFBHVSDPCMIK-UHFFFAOYSA-N 0.000 description 1
- VXQFTFYXKZDKJL-UHFFFAOYSA-N NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3)C=C1 Chemical compound NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3)C=C1 VXQFTFYXKZDKJL-UHFFFAOYSA-N 0.000 description 1
- NTQCONSUJVLCLR-UHFFFAOYSA-N NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 Chemical compound NC1=CC=C(OC2=CC3=C(C=C2)C(=O)NC3=O)C=C1 NTQCONSUJVLCLR-UHFFFAOYSA-N 0.000 description 1
- ZIKOFLSRJZCPKF-UHFFFAOYSA-N NC1=CC=C(OC2=CC=CC(C(=O)O)=C2)C=C1 Chemical compound NC1=CC=C(OC2=CC=CC(C(=O)O)=C2)C=C1 ZIKOFLSRJZCPKF-UHFFFAOYSA-N 0.000 description 1
- DQZBEHNJVNQKKO-UHFFFAOYSA-N NC1=CC=C(OC2=CC=NC(C(=O)NCCN3CCOCC3)=C2)C=C1 Chemical compound NC1=CC=C(OC2=CC=NC(C(=O)NCCN3CCOCC3)=C2)C=C1 DQZBEHNJVNQKKO-UHFFFAOYSA-N 0.000 description 1
- ILCRJWJKUBSZJP-UHFFFAOYSA-N O=C(NC1=CC=C(C(=O)NC2=CC(C(=O)NC3=CC=CN=C3)=CC=C2)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 Chemical compound O=C(NC1=CC=C(C(=O)NC2=CC(C(=O)NC3=CC=CN=C3)=CC=C2)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 ILCRJWJKUBSZJP-UHFFFAOYSA-N 0.000 description 1
- FCMMZPCXSNEKGZ-UHFFFAOYSA-N O=C(NC1=CC=C(C(=O)O)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 Chemical compound O=C(NC1=CC=C(C(=O)O)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 FCMMZPCXSNEKGZ-UHFFFAOYSA-N 0.000 description 1
- IUJXCEYSFVUIFK-UHFFFAOYSA-N O=C(NC1=CC=C(CC2=CC=CC(C(=O)O)=C2)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 Chemical compound O=C(NC1=CC=C(CC2=CC=CC(C(=O)O)=C2)C=C1)NC1=CC=C(Cl)C(C(F)(F)F)=C1 IUJXCEYSFVUIFK-UHFFFAOYSA-N 0.000 description 1
- QVKCGPPLJDEBSV-UHFFFAOYSA-N O=C(NC1=CC=C(O)C=C1Cl)C(F)(F)F Chemical compound O=C(NC1=CC=C(O)C=C1Cl)C(F)(F)F QVKCGPPLJDEBSV-UHFFFAOYSA-N 0.000 description 1
- KUCGTTGYCVRYEJ-UHFFFAOYSA-N O=C(NC1=CC=C(OC2=CC(C(=O)O)=CN=C2)C=C1)NC1=CC(C(F)(F)F)=C(Cl)C=C1 Chemical compound O=C(NC1=CC=C(OC2=CC(C(=O)O)=CN=C2)C=C1)NC1=CC(C(F)(F)F)=C(Cl)C=C1 KUCGTTGYCVRYEJ-UHFFFAOYSA-N 0.000 description 1
- SUDRCFXNZASXTF-UHFFFAOYSA-N O=C(NCCN1CCOCC1)C1=CC(Cl)=CC=N1 Chemical compound O=C(NCCN1CCOCC1)C1=CC(Cl)=CC=N1 SUDRCFXNZASXTF-UHFFFAOYSA-N 0.000 description 1
- NHXFINXXELODNV-UHFFFAOYSA-N O=C1NC(=O)C2=CC(O)=CC=C12 Chemical compound O=C1NC(=O)C2=CC(O)=CC=C12 NHXFINXXELODNV-UHFFFAOYSA-N 0.000 description 1
- NLNNRNIJRFYGFB-UHFFFAOYSA-N O=C1NCC2=C1C=CC(O)=C2 Chemical compound O=C1NCC2=C1C=CC(O)=C2 NLNNRNIJRFYGFB-UHFFFAOYSA-N 0.000 description 1
- RZUIGBFTFRSOCV-UHFFFAOYSA-N O=C=NC1=CC=C(Br)C(C(F)(F)F)=C1 Chemical compound O=C=NC1=CC=C(Br)C(C(F)(F)F)=C1 RZUIGBFTFRSOCV-UHFFFAOYSA-N 0.000 description 1
- OWRDCJWLDOCBDK-UHFFFAOYSA-N O=[NH+][O-].[Ar].[H][Ar] Chemical compound O=[NH+][O-].[Ar].[H][Ar] OWRDCJWLDOCBDK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- the p 21 ras oncogene is a major contributor to the development and progression of human solid cancers and is mutated in 30% of all human cancers (Bolton et al. Ann. Rep. Med. Chem. 1994, 29, 165-74; Bos. Cancer Res. 1989, 49, 4682-9).
- the ras protein In its normal, unmutated form, the ras protein is a key element of the signal transduction cascade directed by growth factor receptors in almost all tissues (Avruch et al. Trends Biochem. Sci. 1994, 19, 279-83).
- ras is a guanine nucleotide binding protein, and cycling between a GTP-bound activated and a GDP-bound resting form is strictly controlled by ras′ endogenous GTPase activity and other regulatory proteins.
- the endogenous GTPase activity is alleviated and, therefore, the protein delivers constitutive growth signals to downstream effectors such as the enzyme raf kinase. This leads to the cancerous growth of the cells which carry these mutants (Magnuson et al. Semin. Cancer Biol. 1994, 5, 247-53).
- the present invention provides compounds which are inhibitors of the enzyme raf kinase. Since the enzyme is a downstream effector of p2 1 ras, the inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase. In particular, the compounds are useful in the treatment of human or animal solid cancers, e.g., murine cancer, since the progression of these cancers is dependent upon the ras protein signal transduction cascade and therefore susceptible to treatment by interruption of the cascade, i.e., by inhibiting raf kinase.
- solid cancers e.g., murine cancer
- the compounds of the invention are useful in treating cancers, including solid cancers, such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
- carcinomas e.g., of the lungs, pancreas, thyroid, bladder or colon
- myeloid disorders e.g., myeloid leukemia
- adenomas e.g., villous colon adenoma
- the present invention therefore provides compounds generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit the raf kinase pathway.
- the invention also provides a method for treating a raf mediated disease state in humans or mammals.
- the invention is directed to compounds which inhibit the enzyme raf kinase and also compounds, compositions and methods for the treatment of cancerous cell growth mediated by raf kinase wherein a compound of Formula I is administered or pharmaceutically acceptable salt thereof.
- D is —NH—C(O)—NIH—
- A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L 1 ) q , where L is a 5 or 6 membered cyclic structure bound directly to D, L 1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L 1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and
- B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,
- L 1 is substituted by at least one substituent selected from the group consisting of —SO 2 R x , —C(O)R, and —C(NR y )R z ,
- R y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,
- R z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
- R x is R, or NR a R b where R a and R b are
- R f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- R a and R b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- R a or R b is —C(O)—, a C 1 -C 5 divalent alkylene group or a substituted C 1 -C 5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C 1 -C 5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
- B is substituted, L is substituted or L 1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;
- each W is independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)NR 7 R 7 , —C(O)—R 7 , —NO 2 , —OR 7 , -SR 7 , -NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , —Q—Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , —OR 7 , —SR 7 , — NR 7 R 7 , —NO 2 , —NR 7 C(O)R 7 , —NR 7 C(O)OR 7 and halogen up to per-halo; with each
- Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by ZAl, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of —CN, —C0 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 7 , — NO 2 , —OR 7 , —SR 7 —NR 7 R 7 , —NR 7 C(O)OR 7 , —NR 7 C(O)R 7 , and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —CO 2 R 7 , — COR 7 , —C(O)NR 7 R 7 , —OR 7 , ——OR 7
- suitable hetaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms.
- Each ring typically has 3-7 atoms.
- B can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-l-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol
- B can be 4-methyl-phenyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl, 1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1,2,4-thiadiazol-2-yl.
- Suitable alkyl groups and alkyl portions of groups, e.g., alkoxy, etc. throughout include methyl, ethyl, propyl, butyl, etc., including all straight-chain and branched isomers such as isopropyl, isobutyl, sec-butyl, tert-butyl, etc.
- Suitable aryl groups which do not contain heteroatoms include, for example, phenyl and 1- and 2-naphthyl.
- cycloalkyl refers to cyclic structures with or without alkyl substituents such that, for example, “C 4 cycloalkyl” includes methyl substituted cyclopropyl groups as well as cyclobutyl groups.
- cycloalkyl as used herein also includes saturated heterocyclic groups.
- Suitable halogen groups include F, Cl, Br, and/or I, from one to per-substitution (i.e. all H atoms on a group replaced by a halogen atom) being possible where an alkyl group is substituted by halogen, mixed substitution of halogen atom types also being possible on a given moiety.
- the invention also relates to compounds per se, of formula I.
- the present invention is also directed to pharmaceutically acceptable salts of formula I.
- suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1 -naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid.
- pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + Na + or K + ), alkaline earth cations (e.g., Mg +2 , Ca +2 or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, lysine, pyridine, N,N-dimethylarninopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (D
- a number of the compounds of Formula I possess asymmetric carbons and can therefor exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess raf inhibitory activity.
- the compounds of Formula I may be prepared by the use of known chemical reactions and procedures, some from starting materials which are commercially available. Nevertheless, general preparative methods are provided below to aid one skilled in the art in synthesizing these compounds, with more detailed examples being provided in the Experimental section which follows.
- Substituted anilines may be generated using standard methods (March. Advanced Organic Chemistry, 3 rd Ed.; John Wiley: New York (1985). Larock. Comprehensive Organic Transformations; VCH Publishers: New York (1989)).
- aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H 2 or a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride (Rylander. Hydrogenation Methods; Academic Press: London, UK ( 1985)).
- Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH 4 (Seyden-Penne.
- Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO 3 , or an alternative NO 2 + source. Nitroaryls may be further elaborated prior to reduction. Thus, nitroaryls substituted with
- potential leaving groups may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme II) or phenoxide. Nitroaryls may also undergo Ullman-type coupling reactions (Scheme II).
- Nitroaryls may also undergo transition metal mediated cross coupling reactions.
- nitroaryl electrophiles such as nitroaryl bromides, iodides or triflates
- palladium mediated cross coupling reactions with aryl nucleophiles, such as arylboronic acids (Suzuki reactions, exemplified below), aryltins (Stille reactions) or arylzincs (Negishi reaction) to afford the biaryl (5).
- aryl nucleophiles such as arylboronic acids (Suzuki reactions, exemplified below), aryltins (Stille reactions) or arylzincs (Negishi reaction) to afford the biaryl (5).
- Either nitroaryls or anilines may be converted into the corresponding arenesulfonyl chloride (7) on treatment with chlorosulfonic acid.
- Reaction of the sulfonyl chloride with a fluoride source, such as KF then affords sulfonyl fluoride (8).
- Reaction of sulfonyl fluoride 8 with trimethylsilyl trifluoromethane in the presence of a fluoride source, such as tris(dimethylamino)sulfonium difluorotrimethylsiliconate (TASF) leads to the corresponding trifluoromethylsulfone (9).
- TASF tris(dimethylamino)sulfonium difluorotrimethylsiliconate
- sulfonyl chloride 7 may be reduced to the arenethiol (10), for example with zinc amalgum.
- Reaction of thiol 10 with CHCIF 2 in the presence of base gives the difluoromethyl mercaptam (11), which may be oxidized to the sulfone (12) with any of a variety of oxidants, including CrO 3 -acetic anhydride (Sedova et al. Zh. Org. Khim. 1970, 6, (568).
- non-symmetrical urea formation may involve reaction of an aryl isocyanate (14) with an aryl amine (13).
- the heteroaryl isocyanate may be synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichioromethyl chioroformate (diphosgene), bis(trichloromethyl) carbonate (triphosgene), or N,N′-carbonyldiimidazole (CDI).
- the isocyanate may also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement.
- reaction of acid derivative 16 with an azide source, followed by rearrangement affords the isocyanate.
- the corresponding carboxylic acid (17) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPPA) or a similar reagent.
- DPPA diphenylphosphoryl azide
- ureas may be further manipulated using methods familiar to those skilled in the art.
- the invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- the compounds may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations.
- administration by injection includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
- One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions.
- Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example, lecithin, or condensation products or an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., sodium EDTA
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium EDTA, sodium sulfate, sodium bicarbonate
- the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsi ying agents may be naturally-occurring gums, for example gum acacia or gum tragacanthl, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the compounds may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily rectal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily topical dosage regime will preferably be from 0.1 to 200 mg administered between one to four times daily.
- the daily inhalation dosage regime will preferably be from 0.01 to 10 mg/Kg of total body weight.
- the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the condition undergoing therapy.
- the compounds can be produced from known compounds (or from starting materials which, in turn, can be produced from known compounds), e.g., through the general preparative methods shown below.
- the activity of a given compound to inhibit raf kinase can be routinely assayed, e.g., according to procedures disclosed below.
- the following examples are for illustrative purposes only and are not intended, nor should they be construed to limit the invention in any way.
- N-cyclohexyl—N′-(methylpolystyrene)carbodiimide was purchased from Calbiochem-Novabiochem Corp. 3-tert-Butylaniline, 5-tert-butyl-2-methoxyaniline, 4-bromo-3-(trifluoromethyl)aniline, 4-chloro-3-(trifluoromethyl)aniline 2-methoxy-5-(trifluoromethyl)aniline, 4-tert-butyl-2-nitroaniline, 3-amino-2-naphthol, ethyl 4-isocyanatobenzoate, N-acetyl-4-chloro-2-methoxy-5-(trifluoromethyl)aniline and 4-chloro-3-(trifluoromethyl) phenyl isocyanate were purchased and used without further purification.
- TLC Thin-layer chromatography
- Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating.
- Column chromatography flash chromatography
- Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 ⁇ A.
- Liquid-cesium secondary ion mass spectra FAB-MS
- FAB-MS Liquid-cesium secondary ion mass spectra
- CI-MS Chemical ionization mass spectra
- the direct insertion desorption chemical ionization (DCI) probe (Vaccumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared ( ⁇ 1-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan.
- HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu using a variable ion time according to the number of ions in the source.
- GC-MS Gas chromatography—ion selective mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas chromatograph equipped with an HP-1 methyl silicone column (0.33 mM coating; 25 m ⁇ 0.2 mm) and a Hewlett Packard 5971 Mass Selective Detector (ionization energy 70 eV). Elemental analyses are conducted by Robertson Microlit Labs, Madison N.J.
- Step 1 a Synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide via the Menisci reaction
- the resulting opaque brown solution was diluted with H 2 O (700 mL) followed by a 10% NaOH solution (250 mL). The resulting mixture was extracted with EtOAc (3 ⁇ 500 mL). The organic phases were washed separately with a saturated NaCl solution (3 ⁇ 150 mL), then they were combined, dried (MgSO 4 ) and filtered through a pad of silica gel with the aid of EtOAc. The resulting brown oil was purified by column chromatography (gradient from 50% EtOAc/50% hexane to 80% EtOAc/20% hexane). The resulting yellow oil crystallized at 0° C.
- Step 1 b Synthesis of 4-chloropyridine-2-carbonyl chloride HCI salt via picolinic acid
- Step 3 a Synthesis of 4-chloro—N-methyl-2-pyridinecarboxamide from methyl 4-chloropyridine-2-carboxylate
- Step 3 b Synthesis of 4-chloro—N-methyl-2-pyridinecarboxamide from 4-chloropyridine-2-carbonyl chloride
- the aqueous phase was back-e,xtracted with EtOAc (300 mL).
- the combined organic layers were washed with a saturated NaCl solution (4 ⁇ 1000 mL), dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- the resulting solids were dried under reduced pressure at 35° C.
- reaction mixture was cooled to room temp., diluted with CH 2 Cl 2 (10 mL) and sequentially washed with a 1 N HCl solution (115 mL), a 1 N NaOH solution (15 mL) and a saturated NaCl solution (15mL), dried ( MgSO 4 ) and concentrated under reduced pressure.
- Step 1 Synthesis of 3-Chloro-4-(2,2,2-trifluoroacetylamino)phenol Iron (3.24 g, 58.00 mmol) was added to stirring TFA (200 mL). To this slurry was added 2-chloro-4-nitrophenol (10.0 g, 58.0 mmol) and trifluoroacetic anhydride (20 mL). This gray slurry was stirred at room temp. for 6 d. The iron was filtered from solution and the remaining material was concentrated under reduced pressure. The resulting gray solid was dissolved in water (20 mL). To the resulting yellow solution was added a saturated NaHCO 3 solution (50 mL). The solid which precipitated from solution was removed.
- the filtrate was slowly quenched with the sodium bicarbonate solution until the product visibly separated from solution (determined was using a mini work-up vial).
- the slightly cloudy yellow solution was extracted with EtOAc (3 ⁇ 125 mL).
- the combined organic layers were washed with a saturated NaCl solution (125 mL), dried (MgSO 4 ) and concentrated under reduced pressure.
- the 1H NMR (DMSO-d 6 ) indicated a 1:1 ratio of the nitrophenol starting material and the intended product 3-chloro-4-(2,2,2-trifluoroacetylamino)phenol.
- the crude material was taken on to the next step without ffirther purification.
- Step 2 Synthesis of 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl (222-trifluoro)acetamide
- A15 Synthesis of an Aniline via Electrophilic Nitration followeded by Reduction. Synthesis of 4-(3-Methylsulfamoylphenoxy)aniline.
- A17 Synthesis of N-( ⁇ -Silyloxyalkyl)amides. Synthesis of 4-(4-(2-(N-(2-Triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyaniline.
- Step 1 4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide
- Step 2 Synthesis of 4-(5-(2-Methoxycarbonyl)pyridyloxy)-1-nitrobenzene.
- a mixture of 4-(5-(2-methyl)pyridyloxy)-1-nitrobenzene (1.70 g, 7.39 mmol) and selenium dioxide (2.50 g, 22.2 mmol, 3.0 equiv.) in pyridine (20 mL) was heated at the reflux temperature for 5 h, then cooled to room temperature. The resulting slurry was filtered, then concentrated under reduced pressure. The residue was dissolved in MeOH (100 mL).
- Step 3 Synthesis of 4-(5-(2-Methoxycarbonyl)pyridyloxy)aniline.
- a slurry of 4-(5-(2-methoxycarbonyl)pyridyloxy)—-mnitrobenzene (0.50 g) and 10% Pd/C (0.050 g) in a mixture of EtOAc (20 mL) and MeOH (5 mL) was placed under a H 2 atmosphere (balloon) overnight.
- the resulting mixture was filtered through a pad of Celite®, and the filtrate was concentrated under reduced pressure.
- the residue was purified by column chromatography (SiO 2 ; 70% EtOAc/30% hexane) to give 4-(5-(2-methoxycarbonyl) pyridyloxy)aniline (0.40 g).
- Step 1 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene: To a solution of 4-(4-methylthiophenoxy)-1-nitrobenzene (2.0 g, 7.7 mmol) in CH 2 C 12 (75 mL) at 0° C. was slowly added m—CPBA (57-86%, 4.0 g), and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was treated with a 1N NaOH solution (25 mL).
- Step 2 4-(4-Methylsulfonylphenoxy)-1-aniline: 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method A18, step 3.
- Step 1 Synthesis of 4-bromo-3-(trifluoromethyl)aniline HCl salt
- 4-bromo-3-(trifluoromethyl)aniline 64 g, 267 mmol
- Et 2 O 500 mL
- an HCl solution 1 M in Et 2 O; 300 mL
- the resulting pink-white precipitate was removed by filtration and washed with Et 2 O (50 mL) and to afford 4-bromo-3-(trifluoromethyl)aniline HC1 salt (73 g, 98%).
- C1 a General Method for the Synthesis of Ureas by Reaction of an Isocyanate with an Aniline. Synthesis of N-(4-Chloro-3-(trifluoromethyl)plienyl)—N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- C1 b General Method for the Synthesis of Ureas by Reaction of an Isocyanate with an Aniline. Synthesis of N-(4-Bromo-3-(trifluoromethyl)plienyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- C1 d General Method for the Synthesis of Ureas by Reaction of an Isocyanate with an Aniline. Synthesis of N-(4-Chloro-3-(trifluoromethyl)phenyl)-N′-(4-aminophenyl) Urea
- C1 e General Method for the Synthesis of Ureas by Reaction of an Isocyanate with an Aniline. Synthesis of N-(4-Chloro-3-(trifluoromethyl)phenyl)-N′-(4-ethoxycarbonylphenyl) Urea
- C2 a General Method for Urea Synthesis by Reaction of an Aniline with N,N′-Carbonyl Diimidazole followeded by Addition of a Second Aniline. Synthesis of N-(2-Methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- C2 b General Method for Urea Synthesis by Reaction of an Aniline with N,N′-Carbonyl Diimidazole followeded by Addition of a Second Aniline. Symmetrical Urea's as Side Products of a N,N′-Carbonyl Diimiidazole Reaction Procedure. Synthesis of Bis(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- the second aniline was added (0.10 M in dichloroethane, 0.5 mL, 1.0 equiv.), followed by diisopropylethylamine (0.35 M in dichloroethane, 0.2 mL, 1.2 equiv.).
- the resulting mixture was heated at 80° C. for 4 h, cooled to room temperature and treated with MeOH (0.5 mL).
- the resulting mixture was concentrated under reduced pressure and the products were purified by reverse phase HPLC.
- D1 a Conversion of co-Aminophenyl Ureas into ⁇ -(Aroylamino)phenyl Ureas.
- D1 b Conversion of (o—Carboxyphenyl Ureas into ⁇ -(Arylcarbamoyl)phenyl Ureas. Synthesis of N-(4-Chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-methylcarbamoylphenyl)carbamoylphenyl) Urea
- N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(N-(3-(N-(3-pyridyl) carbamoyl)phenyl)carbamoyl)phenyl) urea (0.024 g, 59%): TLC (70% EtOAc/30% hexane) R f 0.12.
- Step 1 Synthesis of N-(4-Chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-carboxypyridyl) oxyphenyl) Urea
- N-(4-Chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-methoxycarbonylpyridyl)oxiphenyl) urea was synthesized from 4-chloro-3-(trifluoromethyl)phenyl isocyanate and 4-(3-(5-methoxycarbonylpyridyl) oxyaniline (Method A14, Step 2) in a manner analogous to Method C1 a.
- Step 2 Synthesis of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-(2-dimethylaminoethyl)carbamoyl)pyridyl)oxyphenyl) urea
- N,N-dimethylethylenediamine (0.22 mg, 0.17 mmol)
- HOBT 0.028 g, 0.17 mmol
- N-methylmorpholine 0.035 g, 0.28 mmol
- EDCl-HCl 0.032 g, 0.17 mmol
- Entry 1 4-(3-N-Methylcarbamoylphenoxy)aniline was prepared according to Method A13. According to Method C3, 3-tert-butylaniline was reacted with bis(trichloromethyl)carbonate followed by 4-(3-N-Methylcarbamoylphenoxy)aniline to afford the urea.
- Entry 2 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone were reacted according to Method A13, Step 1 to afford the 4-(4-acetylphenoxy)-1-nitrobenzene.
- 4-(4-Acetylphenoxy)— 1-nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline.
- 3-tert-butylaniline was reacted with bis(trichloromethyl) carbonate followed by 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 7 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized according to Method A12. According to Method 2d, 5-tert-butyl-2-methoxyaniline was reacted with CDI followed by 4-(1-oxoisoindolin-5-yloxy)aniline to afford the urea.
- Entry 8 4-(3-N-Methylcarbamoylphenoxy)aniline was synthesized according to Method A13. According to Method C2a, 2-methoxy-5-(trifluoromethyl)aniline was reacted with CDI followed by 4-(3-N-methylcarbamoylphenoxy)aniline to afford the urea.
- Entry 9 4-Hydroxyacetophenone was reacted with 2-chloro-5-nitropyridine to give 4-(4-acetylphenoxy)-5-nitropyridine according to Method A3, Step 2. According to Method A8, Step 4, 4-(4-acetylphenoxy)-5-nitropyridine was reduced to 4-(4-acetylphenoxy)-5-aminopyridine.
- 2-Methoxy-5-(trifluoromethyl)aniline was converted to 2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. The isocyanate was reacted with 4-(4-acetylphenoxy)-5-aminopyridine according to Method C1 a to afford the urea.
- Entry 10 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone were reacted according to Method A13, Step 1 to afford the 4-(4-acetylphenoxy)-1-nitrobenzene.
- 4-(4-Acetylphenoxy)-1-nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline.
- Method C3 5-(trifluoromethyl)-2-methoxybuLtylaniline was reacted with bis(trichloromethyl) carbonate followed by 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 11 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
- Method C4 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 12 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3 b to form 4-chloro-2-pyridinecarboxamide.
- 4-Chloro-2-pyridinecarboxamide was reacted with 3-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 3-(2-carbamoyl-4-pyridyloxy)aniline.
- Method C2 a 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 3-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 14 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with annmonia according to Method A2, Step 3 b to form 4-chloro-2-pyridinecarboxamide.
- 4-Chloro-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 4-(2-carbamoyl-4-pyridyloxy)aniline.
- Method C4 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 16 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was synthesized according to Method A5. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B 1. The isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-methylaniline according to Method C1 c to afford the urea.
- Entry 17 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline according to Method C1 a to afford the urea.
- Entry 18 According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b, to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 19 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline.
- Entry 20 According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 21 4-(4-Methylthiophenoxy)-1-nitrobenzene was oxidized according to Method A19, Step 1 to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene. The nitrobenzene was reduced according to Method A19, Step 2 to give 4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1 a, 5-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(4-methylsulfonylphenoxy)-1-aniline to afford the urea.
- Entry 22 4-(3-carbamoylphenoxy)-1-nitrobenzene was reduced to 4-(3-carbamoylphenoxy)aniline according to Method A15, Step 4. According to Method C1 a, 5-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-carbamoylphenoxy)aniline to afford the urea.
- Entry 24 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
- 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 25 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized according to Method A12.5-(Trifluoromethyl)-2-methoxyaniline was treated with CDI, followed by 4-(1-oxoisoindolin-5-yloxy)aniline according to Method C2d to afford the urea.
- Entry 26 4-Hydroxyacetophenone was reacted with 4-fluoronitrobenzene according to Method A13, Step 1 to give 4-(4-acetylphenoxy)nitrobenzene.
- the nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline, which was converted to the 4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt according to Method A16.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 27 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbarnoyl)phenylthio)aniline.
- 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 29 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
- 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 30 4-Chloropyridine-2-carbonyl chloride was reacted with isopropylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy) aniline.
- 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- Entry 31 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. S-(Trifluoromethyl)-2-methcoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1 a to afford the urea.
- N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with 4-(2-aminoethyl) m orpholine to afford the amide according to Method D4, Step 2.
- Entry 32 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluororriethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1 a to afford the urea.
- N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with methylamine according to Method D4, Step 2 to afford the amide.
- Entry 33 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1 a to afford the urea.
- N-(5-(Trifluoromethyl)-2-methoxyphenyl)—,A′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with N,N-dimethylethylenediamine according to Method D4, Step 2 to afford the amide.
- Entry 34 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A1.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 3-aminopyridine according to Method D1 c.
- Entry 35 4-(3-Carboxyphenoxy)aniline was synthesized according to Method All. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl 3-i isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with N-(4-fluorophenyl)piperazine according to Method D1 c.
- Entry 36 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 4-fluoroaniline according to Method D1 c.
- Entry 38 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 5-amino-2-methoxypyridine according to Method D1 c.
- Entry 39 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 4-morpholinoaniline according to Method D1 c.
- Entry 40 4-(3-Carboxyphenoxy)aniline was synthesized according to Method Al 1.
- 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.
- 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1 f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with N-(2-pyridyl)piperazine according to Method D1 c.
- Entry 41 4-(3-(N-Methylcarbamoyl)phenoxy)aniline was synthesized according to Method A13. According to Method C3, 4-chloro-3-(trifluoromethyl)aniline was converted to the isocyanate, then reacted with 4-(3-(N-Methylcarbamoyl)phenoxy)aniline to afford the urea.
- Entry 42 4-(2-N-Methylcarbamyl-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-N-methylcarbamyl-4-pyridyloxy)aniline according to Method C1 a to afford the urea.
- Entry 43 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3 b to form 4-chloro-2-pyridinecarboxamide.
- 4-Chloro-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to form 4-(2-carbamoyl-4-pyridyloxy)aniline.
- Method C1 a 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 44 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3 b to form 4-chloro-2-pyridinecarboxamide.
- 4-Chloro-2-pyridinecarboxamide was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(2-carbamoyl-4-pyridyloxy)aniline.
- Method C1 a 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-carbamoyl-4-pyridyloxy,ianiline to afford the urea.
- Entry 45 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3 a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
- Step 4 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 46 5-(4-Aminophenoxy)isoindoline-1,3-dione was synthesized according to Method A3. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)isoindoline- 1,3-dione to afford the urea.
- Entry 47 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was synthesized according to Method A5. According to Method Clc, 4-chloro-3-(trifluoromethlyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)isoindoline-1,3-dione to afford the urea.
- Entry 48 4-(3-N-Methylsulfarnoyl)phenyloxy)aniline was synthesized according to Method A15. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-N-methylsulfamoyl)phenyloxy)aniline to afford the urea.
- Entry 49 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline to afford the urea.
- Entry 50 According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline to afford the urea.
- Entry 51 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy) aniline.
- Step 4 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 52 According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline to afford the urea.
- Entry 53 4-(4-Methylthiophenoxy)-1-nitrobenzene was oxidized according to Method A19, Step 1 to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene. The nitrobenzene was reduced according to Method A19, Step 2 to give 4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-methylsulfonylphenoxy)—1-aniline to afford the urea.
- Entry 54 4-Bromobenzenesulfonyl chloride was reacted with methylamine according to Method A15, Step 1 to afford N-methyl-4-bromobenzenesulfonamide. N-Methyl-4-bromobenzenesulfonamide was coupled with phenol according to Method A15, Step 2 to afford 4-(4-(N-methylsulfamoyl)phenoxy)benzene. 4-(4-(N-Methylsulfamoyl)phenoxy)benzene was converted into 4-(4-(N-methylsulfamoyl)phenoxy)-1-nitrobenzene according to Method A15, Step 3.
- Entry 56 5-Hydroxy-2-methylpyridine was coupled with 1-fluoro-4-nitrobenzene according to Method A18, Step 1 to give 4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene.
- the methylpyridine was oxidized according to the carboxylic acid, then esterified according to Method A18, Step 2 to give 4-( 5-(2-methoxyc arbonyl)pyridyloxy)-1-nitrobenzene.
- the nitrobenzene was reduced according the Method A18, Step 3 to give 4-(5-(2-methoxycarbonyl) pyridyloxy)aniline.
- the aniline was reacted with 4-chloro-3-(trifluoromethyl)phenyl isocyanate according to Method C1 a to give N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(methoxycarbonyl)-5-pyridyloxy)phenyl) urea.
- the methyl ester was reacted with methylamine according to Method D2 to afford N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-5-pyridyloxy)phenyl) urea.
- N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was prepared according to Method Cld. N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was coupled with mono-methyl isophthalate according to Method DIa to afford N-(4-chloro-3-(trifluoromethyl)phenyl-N′-(4-(3-methoxycarbonylphenyl)carboxyaminophenyl) urea.
- Entry 59 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
- Step 4 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 60 4-Hydroxyacetophenone was reacted with 4-fluoronitrobenzene according to Method A13, Step 1 to give 4-(4-acetylphenoxy)nitrobenzene.
- the nitrobenzene was reduced according to Method 13, Step 4 to afford 4-(4-acetylphenoxy)aniline, which was converted to the 4-(4-(1-(N-methoxy)iminoethyl) phenoxyaniline HCl salt according to Method A16.
- Method C1 a 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 61 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 4-(2-aminoethyl)morpholine according to Method A13, Step 3 to give 4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4L-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)aniline.
- Entry 62 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 1-(2-arninoethyl)piperidine according to Method A13, Step 3 to give 4-(3-(N-(2-piperidylethyl)carbamoyl)phienoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(2-4-piperidylethyl) carbamoyl)phenoxy)—1 -nitrobenzene was reduced to 4-(3-(N-(2-piperidylethyl) carbamoyl)phenoxy)aniline.
- Entry 63 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with tetrahydrofurfurylamine according to Method A13, Step 3 to give 4-(3-(N-(tetrahydrofurylmethyl) carbamoyl)phenoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(tetrahydrofurylmethyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4-(3-(N-(tetrahydrofurylmethyl) carbamoyl)phenoxy)aniline.
- Entry 64 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 2-aminomethyl-1-ethylpyrrolidine according to Method A13, Step 3 to give 4.-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)-1-nitrobenzene.
- Step 4 4-(3-(N-((1-methylpyrrolidinyl) m ethyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4-(3-(N-((1-methylpyrrolidinyl) m ethyl)carbamoyl)phenoxy)aniline.
- Method C1 a 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4.-(3-(N-((1-methylpyrrolidinyl) m ethyl)carbamoyl)phenoxy)aniline to afford the urea.
- Entry 65 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
- Step 4 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
- 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-(2-(N-methylcarbamoyl) phenylthio)aniline to afford the urea.
- Entry 66 4-Chloropyridine-2-carbonyl chloride was reacted with isopropylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline.
- Method C1 a 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-carboxyphenyl) urea was coupled with 3-methylcarbamoylaniline according to Method D1 b to give N-(4-chloro-3-(trifluoromethyl)phenyl-N′-(4-(3-methylcarbamoylphenyl)carbamoylphenyl) urea.
- Entry 68 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione was synthesized according to Method A9. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione to afford the urea.
- Entry 69 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbarnoyl)phenylthio)aniline.
- Step 4 According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to afford the urea.
- Entry 70 4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline was synthesized according to Method A10. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridyloxy)ianiline to afford the urea.
- Entry 71 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1 a to afford the urea.
- N-(4-Chloro-3-(trifluoromethyl) phenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxyphenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with 4-(2-aminoethyl) m orpholine to afford the amide.
- Entry 72 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy) aniline according to Method C1 a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with methylamine according to Method D4, Step 2 to afford the amide.
- Entry 73 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl) pyridyloxy)aniline according to Method C1 a to afford the urea.
- N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)pheryl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with N,N-dimethylethylenediamine according to Method D4, Step 2 to afford the amide.
- Entry 74 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to Method A2, Step 3 b to form 4-chloro-N-(2-triisopropylsilyloxy) ethylpyridine-2-carboxamide. 4-chloro-N-(2-triisopropylsilyloxy) ethylpyridine-2-carboxamide was reacted with triisopropylsilyl chloride, followed by 4-aminophenol according to Method A17 to form 4-(4-(2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyaniline.
- Entry 75 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl) pyridyloxy)aniline according to Method C1 f to afford the urea, which was coupled with 3-aminopyridine according to Method D1 c.
- Entry 76 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with N-(4-acetylphenyl)piperazine according to Method D1 c.
- Entry 77 4-(3-Carboxyphenoxy)aniline was synthesized according to Method Al 1. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with 4-fluoroaniline according to Method D1 c.
- Entry 78 4-(3-Carboxyphenoxy)aniline was synthesized according to Method[ A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with 4-(dimethylamino)aniline according to Method D1 c.
- Entry 79 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with N-phenylethylenediamine according to Method D1 c.
- Entry 80 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-1-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with 2-methoxyethylamine according to Method D1 c.
- Entry 81 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 5.-amino-2-methoxypyridine according to Method D1 c.
- Entry 82 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl) phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with 4-morpholinoaniline according to Method D1 c.
- Entry 83 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1 f to afford the urea, which was coupled with N-(2-pyridyl)lpiperazine according to Method D1 c.
- Entry 84 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to Method A2, Step 3 b to form 4-chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide.
- 4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide was reacted with triisopropylsilyL chloride, followed by 4-aminophenol according to Method A17 to form 4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline.
- Entry 85 4-(2-(N-Methylcarbaamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Bromo-3-(trifluoromethyl)aniline was converted to 4--bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1 a, 4 -2) bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 86 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1 a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline to afford the urea.
- Entry 87 According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl ilsocyanate according to Method Bi.
- Entry 88 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline.
- 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 89 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 90 According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 91 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylarnine according to Method A2, Step 3 b .
- the resulting 4-chloro-N,N-dimethyl-2-pyridinecarbox-aide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
- 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 92 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
- 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 93 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3 b .
- the chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline.
- 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 94 4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline was synthesized according to Method A10. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1 a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-(2-Mo]pholin-4-ylethyl)carbamoyl)pyridyloxy)aniline to afford the urea.
- Entry 95 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 96 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B 1.
- Entry 97 According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3 b , to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-2(1 (trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 98 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3 a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
- 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7.
- 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1.
- Entry 99 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline.
- 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7.
- Entry 100 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3 b .
- the resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline.
- 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7.
- Entry 101 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3 a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
- 2-Amino-3-methoxynaphthalene was synthesized as described Method A1.
- 2-amino-3-methoxynaphthalene was reacted with bis(trichloromethyl) carbonate followed by 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to form the urea.
- Entry 102 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline was synthesized according to Method A4. 5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline was reacted with CDI followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline according to Method C2 d to afford the urea.
- Entry 103 4-Chloro-N-methyl-2-pyridinecarboxamide was synthesized according to Method A2, Step 3 b. 4 -Chloro-N-methyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline.
Abstract
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Description
- This is a continuation of Ser. No. 09/425,228 filed Oct. 22, 1999, which is a continuation-in-part of Ser. No. 09/257,266 filed Feb. 25, 1999 and claims priority to provisional application Ser. No. 60/115,877 filed Jan. 13, 1999.
- This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
- The p21ras oncogene is a major contributor to the development and progression of human solid cancers and is mutated in 30% of all human cancers (Bolton et al. Ann. Rep. Med. Chem. 1994, 29, 165-74; Bos. Cancer Res. 1989, 49, 4682-9). In its normal, unmutated form, the ras protein is a key element of the signal transduction cascade directed by growth factor receptors in almost all tissues (Avruch et al. Trends Biochem. Sci. 1994, 19, 279-83). Biochemically, ras is a guanine nucleotide binding protein, and cycling between a GTP-bound activated and a GDP-bound resting form is strictly controlled by ras′ endogenous GTPase activity and other regulatory proteins. In the ras mutants in cancer cells, the endogenous GTPase activity is alleviated and, therefore, the protein delivers constitutive growth signals to downstream effectors such as the enzyme raf kinase. This leads to the cancerous growth of the cells which carry these mutants (Magnuson et al. Semin. Cancer Biol. 1994, 5, 247-53). It has been shown that inhibiting the effect of active ras by inhibiting the raf kinase signaling pathway by administration of deactivating antibodies to raf kinase or by co-expression of dominant negative raf kinase or dominant negative MEK, the substrate of raf kinase, leads to the reversion of transformed cells to the normal growth phenotype (see: Daum et al. Trends Biochem. Sci. 1994, 19, 474-80; Fridman et al. J. Biol. Chem. 1994, 269, 30105-8. Kolch et al. (Nature 1991, 349, 426-28) have further indicated that inhibition of raf expression by antisense RNA blocks cell proliferation in membrane-associated oncogenes. Similarly, inhibition of raf kinase (by antisense oligodeoxynucleotides) has been correlated in vitro and in vivo with inhibition of the growth of a variety of human tumor types (Monia et al., Nat. Med. 1996, 2, 668-75).
- The present invention provides compounds which are inhibitors of the enzyme raf kinase. Since the enzyme is a downstream effector of p21ras, the inhibitors are useful in pharmaceutical compositions for human or veterinary use where inhibition of the raf kinase pathway is indicated, e.g., in the treatment of tumors and/or cancerous cell growth mediated by raf kinase. In particular, the compounds are useful in the treatment of human or animal solid cancers, e.g., murine cancer, since the progression of these cancers is dependent upon the ras protein signal transduction cascade and therefore susceptible to treatment by interruption of the cascade, i.e., by inhibiting raf kinase. Accordingly, the compounds of the invention are useful in treating cancers, including solid cancers, such as, for example, carcinomas (e.g., of the lungs, pancreas, thyroid, bladder or colon), myeloid disorders (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
- The present invention therefore provides compounds generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit the raf kinase pathway. The invention also provides a method for treating a raf mediated disease state in humans or mammals. Thus, the invention is directed to compounds which inhibit the enzyme raf kinase and also compounds, compositions and methods for the treatment of cancerous cell growth mediated by raf kinase wherein a compound of Formula I is administered or pharmaceutically acceptable salt thereof.
- A—D—B (I)
- In formula I, D is —NH—C(O)—NIH—,
- A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L1)q, where L is a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and
- B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,
- wherein L1 is substituted by at least one substituent selected from the group consisting of —SO2Rx, —C(O)R, and —C(NRy)Rz,
- Ry is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,
- Rz is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
- Rx is R, or NRaRb where Ra and Rb are
- a) independently hydrogen,
- a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
- —OSi(Rf)3 where Rf is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
- c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
- where B is substituted, L is substituted or L1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;
- wherein each W is independently selected from the group consisting of —CN, —CO2R7, —C(O)NR7R7, —C(O)—R7, —NO2, —OR7, -SR7, -NR7R7, —NR7C(O)OR7, —NR7C(O)R7, —Q—Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, —OR7, —SR7, — NR7R7, —NO2, —NR7C(O)R7, —NR7C(O)OR7 and halogen up to per-halo; with each R7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is —O—, —S—, —N(R7)—, —(CH2).-, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m, CHXa, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, and Xa is halogen; and
- Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by ZAl, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of —CN, —C02R7, —C(O)R7, —C(O)NR7R7, — NO2, —OR7, —SR7 —NR7R7, —NR7C(O)OR7, —NR7C(O)R7, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —CO2R7, — COR7, —C(O)NR7R7, —OR7, —SR7, —NO2, —NR7R7, —NR7C(O)R7, and —NR7C(O)OR7, with R7 as defined above.
- In formula I, suitable hetaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms. Each ring typically has 3-7 atoms. For example, B can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-l-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,3,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8- isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, or additionally optionally substituted phenyl, 2- or 3-thienyl, 1,3,4-thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl, etc. For example, B can be 4-methyl-phenyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl, 1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1,2,4-thiadiazol-2-yl.
- Suitable alkyl groups and alkyl portions of groups, e.g., alkoxy, etc. throughout include methyl, ethyl, propyl, butyl, etc., including all straight-chain and branched isomers such as isopropyl, isobutyl, sec-butyl, tert-butyl, etc.
- Suitable aryl groups which do not contain heteroatoms include, for example, phenyl and 1- and 2-naphthyl.
- The term “cycloalkyl”, as used herein, refers to cyclic structures with or without alkyl substituents such that, for example, “C4 cycloalkyl” includes methyl substituted cyclopropyl groups as well as cyclobutyl groups. The term “cycloalkyl”, as used herein also includes saturated heterocyclic groups.
- Suitable halogen groups include F, Cl, Br, and/or I, from one to per-substitution (i.e. all H atoms on a group replaced by a halogen atom) being possible where an alkyl group is substituted by halogen, mixed substitution of halogen atom types also being possible on a given moiety.
- The invention also relates to compounds per se, of formula I. The present invention is also directed to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1 -naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid. In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li+Na+ or K+), alkaline earth cations (e.g., Mg+2, Ca+2 or Ba+2), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, lysine, pyridine, N,N-dimethylarninopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- A number of the compounds of Formula I possess asymmetric carbons and can therefor exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art. The present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess raf inhibitory activity.
- The compounds of Formula I may be prepared by the use of known chemical reactions and procedures, some from starting materials which are commercially available. Nevertheless, general preparative methods are provided below to aid one skilled in the art in synthesizing these compounds, with more detailed examples being provided in the Experimental section which follows.
-
- Scheme I Reduction of Nitroaryls to Aryl Amines
-
-
- Scheme II Selected Nucleophilic Aromatic Substitution using Nitroaryls
- Nitroaryls may also undergo transition metal mediated cross coupling reactions. For example, nitroaryl electrophiles, such as nitroaryl bromides, iodides or triflates, undergo palladium mediated cross coupling reactions with aryl nucleophiles, such as arylboronic acids (Suzuki reactions, exemplified below), aryltins (Stille reactions) or arylzincs (Negishi reaction) to afford the biaryl (5).
- Either nitroaryls or anilines may be converted into the corresponding arenesulfonyl chloride (7) on treatment with chlorosulfonic acid. Reaction of the sulfonyl chloride with a fluoride source, such as KF then affords sulfonyl fluoride (8). Reaction of sulfonyl fluoride 8 with trimethylsilyl trifluoromethane in the presence of a fluoride source, such as tris(dimethylamino)sulfonium difluorotrimethylsiliconate (TASF) leads to the corresponding trifluoromethylsulfone (9). Alternatively, sulfonyl chloride 7 may be reduced to the arenethiol (10), for example with zinc amalgum. Reaction of thiol 10 with CHCIF2 in the presence of base gives the difluoromethyl mercaptam (11), which may be oxidized to the sulfone (12) with any of a variety of oxidants, including CrO3-acetic anhydride (Sedova et al. Zh. Org. Khim. 1970, 6, (568).
- Scheme III Selected Methods of Fluorinated Aryl Sulfone Synthesis
- As shown in Scheme IV, non-symmetrical urea formation may involve reaction of an aryl isocyanate (14) with an aryl amine (13). The heteroaryl isocyanate may be synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichioromethyl chioroformate (diphosgene), bis(trichloromethyl) carbonate (triphosgene), or N,N′-carbonyldiimidazole (CDI). The isocyanate may also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement. Thus, reaction of acid derivative 16 with an azide source, followed by rearrangement affords the isocyanate. The corresponding carboxylic acid (17) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPPA) or a similar reagent.
- Scheme IV Selected Methods of Non-Symmetrical Urea Formation
- Finally, ureas may be further manipulated using methods familiar to those skilled in the art.
- The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- The compounds may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations. The term ‘administration by injection’ includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example, lecithin, or condensation products or an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
- The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsi ying agents may be naturally-occurring gums, for example gum acacia or gum tragacanthl, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- The compounds may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
- For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regime will preferably be from 0.1 to 200 mg administered between one to four times daily. The daily inhalation dosage regime will preferably be from 0.01 to 10 mg/Kg of total body weight.
- It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be appreciated by one skilled in the art that the specific dose level for a given patient depends on a variety of factors, including specific activity of the compound administered, age, body weight, health, sex, diet, time and route of administration, rate of excretion, etc. It will be further appreciated by one skilled in the art that the optimal course of treatment, ie., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
- It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the condition undergoing therapy.
- The entire disclosure of all applications, patents and publications cited above and below are hereby incorporated by reference, including provisional application Ser. No.. 60/115,877, filed Jan. 13, 1999 and non-provisional application Ser. No. 09/257,266 filed Feb. 25, 1999.
- The compounds can be produced from known compounds (or from starting materials which, in turn, can be produced from known compounds), e.g., through the general preparative methods shown below. The activity of a given compound to inhibit raf kinase can be routinely assayed, e.g., according to procedures disclosed below. The following examples are for illustrative purposes only and are not intended, nor should they be construed to limit the invention in any way.
- All reactions were performed in flame-dried or oven-dried glassware under a positive pressure of dry argon or dry nitrogen, and were stirred magnetically unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Unless otherwise stated, the term ‘concentration under reduced pressure’ refers to use of a Buchi rotary evaporator at approximately 15 mmHg. Unless otherwise stated, the term ‘under high vacuum’ refers to a vacuum of 0.4 - 1.0 mmHg.
- All temperatures are reported uncorrected in degrees Celsius (° C.). Unless otherwise indicated, all parts and percentages are by weight.
- Commercial grade reagents and solvents were used without further purification. N-cyclohexyl—N′-(methylpolystyrene)carbodiimide was purchased from Calbiochem-Novabiochem Corp. 3-tert-Butylaniline, 5-tert-butyl-2-methoxyaniline, 4-bromo-3-(trifluoromethyl)aniline, 4-chloro-3-(trifluoromethyl)aniline 2-methoxy-5-(trifluoromethyl)aniline, 4-tert-butyl-2-nitroaniline, 3-amino-2-naphthol, ethyl 4-isocyanatobenzoate, N-acetyl-4-chloro-2-methoxy-5-(trifluoromethyl)aniline and 4-chloro-3-(trifluoromethyl) phenyl isocyanate were purchased and used without further purification. Syntheses of 3-amino-2-methoxyquinoline (E. Cho et al. WO 98/00402; A. Cordi et al. EP 542,609; IBIDBioorg. Med. Chem.. 3, 1995, 129), 4-(3-carbamoylphenoxy)-1-nitrobenzene (K. Ikawa Yakugaku Zasshi 79, 1959, 760; Chem. Abstr. 53, 1959, 12761b), 3-tert-butylphenyl isocyanate (0. Rohr et al. DE 2,436,108) and 2-methoxy-5- (trifluoromethyl)phenyl isocyanate (K. Inukai et al. JP 42,025,067; IBID Kogyo Kagaku Zasshi 70, 1967, 49 1) have previously been described.
- Thin-layer chromatography (TLC) was performed using Whatman® pre-coated glass-backed silica gel 60A F-254 250 μm plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science® silica gel.
- Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected. Fourier transform infrared spectra were obtained using a Mattson 4020 Galaxy Series spectrophotometer. Proton (1H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me4Si (6 0.00) or residual protonated solvent (CHCI3 δ7.26; MeOH δ3.30; DMSO δ2.49) as standard. Carbon (13C) NMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDCl3 δ77.0; MeOD-d3; δ49.0; DMSO-d6 δ39.5) as standard. Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were either obtained as electron impact (EI) mass spectra or as fast atom bombardment (FAB) mass spectra. Electron impact mass spectra (EI-MS) were obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Vacumetrics Desorption Chemical Ionization Probe for sample introduction. The ion source was maintained at 250° C. Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 μA. Liquid-cesium secondary ion mass spectra (FAB-MS), an updated version of fast atom bombardment were obtained using a Kratos Concept 1-H spectrometer. Chemical ionization mass spectra (CI-MS) were obtained using a Hewlett Packard MS-Engine (5989A) with methane or ammonia as the reagent gas (1×10−4 torr to 2.5×10−4 torr). The direct insertion desorption chemical ionization (DCI) probe (Vaccumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared (˜1-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan. HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu using a variable ion time according to the number of ions in the source. Gas chromatography—ion selective mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas chromatograph equipped with an HP-1 methyl silicone column (0.33 mM coating; 25 m×0.2 mm) and a Hewlett Packard 5971 Mass Selective Detector (ionization energy 70 eV). Elemental analyses are conducted by Robertson Microlit Labs, Madison N.J.
- All compounds displayed NMR spectra, LRMS and either elemental analysis or HRMS consistent with assigned structures.
List of Abbreviations and Acronyms: AcOH acetic acid anh anhydrous atm atmosphere(s) BOC tert-butoxycarbonyl CDI 1,1’-carbonyl diimidazole conc concentrated d day(s) dec decomposition DMAC N,N-dimethylacetamide DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone DMF N,N-dimethylformamide DMSO dimethylsulfoxide DPPA diphenylphosphoryl azide EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide EtOAc ethyl acetate EtOH ethanol (100%) Et2O diethyl ether Et3N triethylamine h hour(s) HOBT 1-hydroxybenzotriazole m-CPBA 3-chloroperoxybenzoic acid MeOH methanol pet. ether petroleum ether (boiling range 30-60° C.) temp. temperature THF tetrahydrofuran TFA trifluoroAcOH Tf trifluoromethanesulfonyl - A. General Methods for Synthesis of Substituted Anilines
-
- Step 1. Methyl 3-methoxy-2-naphthoate
-
- Step 2. 3-Methoxy-2-naphthoic acid
- A solution of methyl 3-methoxy-2-naphthoate (6.28 g, 29.10 imnol) and water (10 mL) in MeOH (100 mL) at room temp. was treated with a 1 N NaOH solution (33.4 mL, 33.4 nunol). The mixture was heated at the reflux temp. for 3 h, cooled to room temp., and made acidic with a 10% citric acid solution. The resulting solution was extracted with EtOAc (2×100 mL). The combined organic layers were washed with a saturated NaCl solution, dried (MgSO4) and concentrated under reduced pressure. The residue was triturated with hexane then washed several times with hexane to give 3-methoxy-2-naphthoic acid as a white solid (5.40 g, 92%):1H-NMR (DMSO-d6) δ3.88 (s, 3H), 7.34-7.41 (m, 2H), 7.49-7.54 (m, 1H), 7.83 (d, J=8.09 Hz, 1H), 7.91 (d, J=8.09 Hz, 1H), 8.19 (s, 1H), 12.83 (br s, 1H).
- Step 3. 2-(N-(Carbobenzyloxy)amino-3-methoxynaphthalene
-
- Step 4. 2-Amino-3-methoxynaphthalene
- A slurry of 2-(N-(carbobenzyloxy)amino-3-methoxynaphthalene (5.0 g, 16.3 mmol) and 10% Pd/C (0.5 g) in EtOAc (70 mL) was maintained under a H2 atm (balloon) at room temp. overnight. The resulting mixture was filtered through Celite® and concentrated under reduced pressure to give 2-amino-3-methoxynaphthalene as a pale pink powder (2.40 g, 85%): 1H-NMR (DMSO-d6) δ3.86 (s, 3H), 6.86 (s, 2H), 7.04-7.16 (m, 2H), 7.43 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.0 Hz, 1H); El-MS m/z 173 (M+).
-
- Step 1a. Synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide via the Menisci reaction
- Caution: this is a highly hazardous, potentially explosive reaction. To a stirring solution of 4-chloropyridine (10.0 g) in N-methylformamide (250 mL) at room temp. was added conc. H2SO4 (3.55 mL) to generate an exotherm. To this mixture was added H202 (30°/O wt in H20, 17 mL) followed by FeSO4-7H2O (0.56 g) to generate another exotherm. The resulting mixture was stirred in the dark at room temp. for 1 h, then warned slowly over 4 h to 45° C. . When bubbling had subsided, the reaction was heated at 60° C. for 16 h. The resulting opaque brown solution was diluted with H2O (700 mL) followed by a 10% NaOH solution (250 mL). The resulting mixture was extracted with EtOAc (3×500 mL). The organic phases were washed separately with a saturated NaCl solution (3×150 mL), then they were combined, dried (MgSO4) and filtered through a pad of silica gel with the aid of EtOAc. The resulting brown oil was purified by column chromatography (gradient from 50% EtOAc/50% hexane to 80% EtOAc/20% hexane). The resulting yellow oil crystallized at 0° C. over 72 h to give 4-chloro—N-methyl-2-pyridinecarboxamide (0.61 g, 5.3%): TLC (50% EtOAc/50% hexane) Rf 0.50; 1H NMR (CDCl3) δ3.04 (d, J=5.1 Hz, 3H), 7.43 (dd, J=5.4, 2.4 Hz, 1H), 7.96 (br s, 1H), 8.21 (s, 1H), 8.44 (d, J=5.1 Hz, 1 H); Cl-MS m/z 171 ((M+H)+).
- Step 1b. Synthesis of 4-chloropyridine-2-carbonyl chloride HCI salt via picolinic acid
-
- Step 2. Synthesis of methyl 4-chloropyridine-2-carboxylate HCI salt
-
- Step 3a. Synthesis of 4-chloro—N-methyl-2-pyridinecarboxamide from methyl 4-chloropyridine-2-carboxylate
- A suspension of methyl 4-chloropyridine-2-carboxylate HCI salt (89.0 g, 428 mmol) in MeOH (75 mL) at 0° C. was treated with a 2.0 M methylamine solution in THF (1 L) at a rate which kept the internal temp. below 5° C. The resulting mixture was stored at 3° C. for 5 h, then concentrated under reduced pressure. The resulting solids were suspended in EtOAc (1 L) and filtered. The filtrate was washed with a saturated NaCl solution (500 mL), dried (Na2SO4) and concentrated under reduced pressure to afford 4-chloro—N-methyl-2-pyridinecarboxamide as pale-yellow crystals (71.2 g, 97%): mp 41-43° C. ; 1H-NMR (DMSO-d6) δ2.81 (s, 3H), 7.74 (dd, J=5.1, 2.2 Hz, 1H), 8.00 (d, J=2.2, 1H), 8.61 (d, J=5.1 Hz, 1H), 8.85 (br d, 1H); Cl-MS m/z 171 ((M+H)+).
- Step 3b. Synthesis of 4-chloro—N-methyl-2-pyridinecarboxamide from 4-chloropyridine-2-carbonyl chloride
- 4-Chloropyridine-2-carbonyl chloride HCI salt (7.0 g, 32.95 mmol) was added in portions to a mixture of a 2.0 M methylamine solution in THF (100 mL) and MeOH (20 mL) at 0° C. The resulting mixture was stored at 3° C. for 4 h, then concentrated under reduced pressure. The resulting nearly dry solids were suspended in EtOAc (100 mL) and filtered. The filtrate was washed with a saturated NaCl solution (2×100 mL), dried (Na2SO4) and concentrated under reduced pressure to provide 4-chloro—N-methyl-2-pyridinecarboxamide as a yellow, crystalline solid (4.95 g, 88%): mp 37-40° C.
- Step 4. Synthesis of 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline
- A solution of 4-aminophenol (9.60 g, 88.0 mmol) in anh. DMF (150 mL) was treated with potassium tert-butoxide (10.29 g, 91.7 mmol), and the reddish-brown mixture was stirred at room temp. for 2 h. The contents were treated with 4-chloro-.N-methyl-2-pyridinecarboxamide (15.0 g, 87.9 mmol) and K2CO3 (6.50 g, 47.0 mmol) and then heated at 80° C. for 8 h. The mixture was cooled to room temp. and separated between EtOAc (500 mL) and a saturated NaCl solution (500 mL). The aqueous phase was back-e,xtracted with EtOAc (300 mL). The combined organic layers were washed with a saturated NaCl solution (4×1000 mL), dried (Na2SO4) and concentrated under reduced pressure. The resulting solids were dried under reduced pressure at 35° C. for 3 h to afford 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline as a light-brown solid 17.9 g, 84%): 1H-NMR (DMSO-d6) δ2.77 (d, J=4.8 Hz, 3H), 5.17 (br s, 2H), 6.64, 6.86 (AA′BB′ quartet, J=8.4 Hz, 4H), 7.06 (dd, JT5.5, 2.5 Hz, 1H), 7.33 (d, J=2.5 Hz, 1H), 8.44 (d, J=5.5 Hz, 1H), 8.73 (br d, 1H); HPLC ES-MS m/z 244 ((M+H)+).
-
- Step 1. Synthesis of 5-hydroxyisoindoline-1,3-dione
- To a mixture of ammonium carbonate (5.28 g, 54.9 mmol) in conc. AcOH (25 mL) was slowly added 4-hydroxyphthalic acid (5.0 g, 27.45 mmol). The resulting mixture was heated at 120° C. for 45 min., then the clear, bright yellow mixture was heated at 160° C. for 2 h. The resulting mixture was maintained at 160° C. and was concentrated to approximately 15 mL, then was cooled to room temp. and adjusted pH 10 with a 1N NaOH solution. This mixture was cooled to 0° C. and slowly acidified to pH 5 using a 1N HCl solution. The resultant precipitate was collected by filtration and dried under reduced pressure to yield 5-hydroxyisoindoline-1,3-dione as a pale yellow powder as product (3.24 g, 72%):1H NMR (DMSO-d6) δ7.00-7.03 (m, 2H), 7.56 (d, J=9.3Hz, 1H).
- Step 2. Synthesis of 5-(4-nitrophenoxy)isoindoline-1,3-dione
- To a stirring slurry of NaH (1.1 g, 44.9 inmol) in DMF (40 mL) at 0° C. was added a solution of 5-hydroxyisoindoline- 1,3-dione (3.2 g, 19.6 mmol) in DMF (40 mL) dropwise. The bright yellow-green mixture was allowed to return to room temp. and was stirred for 1 h, then 1-fluoro-4-nitrobenzene (2.67 g, 18.7 mmol) was added via syringe in 3-4 portions. The resulting mixture was heated at 70° C. overnight, then cooled to room temp. and diluted slowly with water (150 mL), and extracted with EtOAc (2×100 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure to give 5-(4-nitrophenoxy)isoindoline-1,3-dione as a yellow solid (3.3 g, 62%): TLC (30%/c, EtOAc/70% hexane) Rf 0.28; 1H NMR (DMSO-d6) δ7.32 (d, J=12 Hz, 2H), 7.52-7.57 (m, 2H), 7.89(d, J=7.8 Hz, 1H), 8.29 (d, J=9 Hz, 2H), 11.43 (br s, 1H); CL-MS m/z 285 ((M+H)+, 100%).
- Step 3. Synthesis of 5-(4-aminophenoxy)isoindoline-1,3-dione
- A solution of 5-(4-nitrophenoxy)isoindoline-1,3-dione (0.6 g, 2.11 mmol) in conc. AcOH (12 mL) and water (0.1 mL) was stirred under stream of argon while iron powder (0.59 g, 55.9 mmol) was added slowly. This mixture stirred at room temp. for 72 h, then was diluted with water (25 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure to give 5-(4-aminophenoxy)isoindoline-1,3-dione as a brownish solid (0.4 g, 75%): TLC (50% EtOAc/50% hexane) Rf 0.27; 1H NMR (DMSO-d6) δ5.14 (br s, 2H), 6.62 (d, J=8.7 Hz, 2H), 6.84 (d, J=8.7 Hz, 2H), 7.03 (d, J=2.1 Hz, 1H), 7.23 (dd, 1H), 7.75 (d, J=8.4 Hz, 1H), 11.02 (s, 1H); HPLC ES-MS m/z 255 ((M+H)+, 100%).
-
- Step 1. Synthesis of 1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyrrole
- To a stirring solution of 2-mitro-4-tert-butylanilne (0.5 g, 2.57 mmol) in cyctohexane (10 mL) was added AcOH (0.1 mL) and acetonylacetone (0.299 g, 2.63 mmnol) via syringe. The reaction mixture was heated at 120 GC for 72 h with azeotropic removal of volatiles. The reaction mixture was cooled to room temp., diluted with CH2Cl2 (10 mL) and sequentially washed with a 1 N HCl solution (115 mL), a 1 N NaOH solution (15 mL) and a saturated NaCl solution (15mL), dried ( MgSO4) and concentrated under reduced pressure. The resulting orange-brown solids were purified via column chromatography (60 g SiO2; gradient from 6% EtOAc/94% hexane to 25% EtOAc/75% hexane) to give 1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyrrole as an orange-yellow solid (0.34 g, 49%): TLC (15% EtOAc/85% hexane) Rf 0.67; 1H NMR (CDCl3) d 1.34 (s, 9H), 1.89 (s, 6H), 5.84 (s, 2H), 7.19-7.24 (m, 1H), 7.62 (dd, 1H), 7.88 (d, J=2.4 Hz, 1H); Cl-MS m/z 273 ((M+H)+, 50%).
- Step 2. Synthesis of 5-tert--Butyl-2-(2,5-dimethylpyrrolyl)aniline
- A slurry of 1-(4-tert-butyl-2-nitrophenyl)-2,5-dimethylpyrrole (0.341 g, 1.25 mmol), 10%Pd/C (0.056 g) and EtOAc (50 mL) under an H2 atmosphere (balloon) was stirred for 72 h, then filtered through a pad of Celite®. The filtrate was concentrated under reduced pressure to give 5-tert--butyl-2-(2,5-dimethylpyrrolyl)aniline as yellowish solids (0.30 g, 99%): TLC (10% EtOAc/90% hexane) Rf 0.43; 1H NMR (CDCl3) 5 1.28 (s, 9H), 1.87-1.91 (m, 8H), 5.85 (br s, 2H), 6.73-6.96 (m, 3H), 7.28 (br s, 1H).
-
- A solution of 4-amino-3-methylphenol (5.45 g, 44.25 mmol) in dry dimethylacetamide (75 mL) was treated with potassium tert-butoxide (10.86 g, 96.77 mmol) and the black mixture was stirred at room temp. until the flask had reached room temp. The contents were then treated with 4-chloro-N-methyl-2-pyridinecarboxamide (Method A2, Step 3b; 7.52 g, 44.2 mmol) and heated at 110° C. for 8 h. The mixture was cooled to room temp. and diluted with water (75 mL). The organic layer was extracted with EtOAc (5×100 mL). The combined organic layers were washed with a saturated NaCl solution (200 mL), dried (MgSO4) and concentrated under reduced pressure. The residual black oil was treated with Et2O (50 mL) and sonicated. The solution was then treated with HCl (1 M in Et2O; 100 mL) and stirred at room temp. for 5 min. The resulting dark pink solid (7.04 g, 24.1 mmol) was removed by filtration from solution and stored under anaerobic conditions at 0° C. prior to use: 1H NMR (DMSO-d6) δ2.41 (s, 3H), 2.78 (d, J=4.4 Hz, 3H), 4.93 (br s, 2H), 7.19 (dd, J=8.5, 2.6 Hz, 1H), 7.23 (dd, J=5.5, 2.6 Hz, 1H), 7.26 (d, J=2.6 Hz, 1H), 7.55 (d, J=2.6 Hz, 1H), 7.64 (d, J=8.8 Hz, 1H), 8.55 (d, J=5.9 Hz, 1H), 8.99 (q, J=4.8 Hz, 1H).
-
- Step 1: Synthesis of 3-Chloro-4-(2,2,2-trifluoroacetylamino)phenol Iron (3.24 g, 58.00 mmol) was added to stirring TFA (200 mL). To this slurry was added 2-chloro-4-nitrophenol (10.0 g, 58.0 mmol) and trifluoroacetic anhydride (20 mL). This gray slurry was stirred at room temp. for 6 d. The iron was filtered from solution and the remaining material was concentrated under reduced pressure. The resulting gray solid was dissolved in water (20 mL). To the resulting yellow solution was added a saturated NaHCO3 solution (50 mL). The solid which precipitated from solution was removed. The filtrate was slowly quenched with the sodium bicarbonate solution until the product visibly separated from solution (determined was using a mini work-up vial). The slightly cloudy yellow solution was extracted with EtOAc (3×125 mL). The combined organic layers were washed with a saturated NaCl solution (125 mL), dried (MgSO4) and concentrated under reduced pressure. The 1H NMR (DMSO-d6) indicated a 1:1 ratio of the nitrophenol starting material and the intended product 3-chloro-4-(2,2,2-trifluoroacetylamino)phenol. The crude material was taken on to the next step without ffirther purification.
- Step 2: Synthesis of 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl (222-trifluoro)acetamide
- A solution of crude 3-chloro-4-(2,2,2-trifluoroacetylamino)phenol (5.62 g, 23.46 mmol) in dry dimethylacetamide (50 mL) was treated with potassium tert-butoxide (5.16 g, 45.98 mmol) and the brownish black mixture was stirred at room temp. until the flask had cooled to room temp. The resulting mixture was treated with 4-chloro-N-methyl-2-pyridinecarboxamide (Method A2, Step 3b; 1.99 g, 11.7 mmol) and heated at 100° C. under argon for 4 d. The black reaction mixture was cooled to room temp. and then poured into cold water (100 mL). The mixture was extracted with EtOAc (3×75 mL) and the combined organic layers were concentrated under reduced pressure. The residual brown oil was purified by column chromatography (gradient from 20% EtOAc/pet. ether to 40% EtOAc/pet. ether) to yield 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl (222-trifluoro)acetamide as a yellow solid (8.59 g, 23.0 mmol).
- Step 3. Synthesis of 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline
- A solution of crude 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chlorophenyl (222-trifluoro)acetamide (8.59 g, 23.0 mmol) in dry 4-dioxane (20 mL) was treated with a 1N NaOH solution (20 mL). This brown solution was allowed to stir for 8 h. To this solution was added EtOAc (40 mL). The green organic layer was extracted with EtOAc (3×40 mL) and the solvent was concentrated to yield 4-(2-(N-Methylcarbamoyl)-4-pyTidyloxy)-2-chloroaniline as a green oil that solidified upon standing (2.86 g, 10.30 mmol):1H NMR (DMSO-d6) δ2.77 (d, J=4.8 Hz, 3H), 5.51 (s, 2H), 6.60 (dd, J=8.5, 2.6 Hz, 1H), 6.76 (d, J=2.6 Hz, 1H), 7.03 (d, J=8.5 Hz, 1H), 7.07 (dd, J=5.5, 2.6, Hz, 1H), 7.27 (d, J=2.6 Hz, 1H), 8.46 (d, J=5.5 Hz, 1H), 8.75 (q, J=4.8, 1H).
-
- A suspension of 3-chloro-6-(N-acetyl)-4-(trifluoromethyl)anisole (4.00 g, 14.95 mmol) in a 6M HCl solution (24 mL) was heated at the reflux temp. for 1 h. The resulting solution was allowed to cool to room temp. during which time it solidified slightly. The resulting mixture was diluted with water (20 mL) then treated with a combination of solid NaOH and a saturated NaHCO3 solution until the solution was basic. The organic layer was extracted with CH2Cl2 (3×50 mL). The combined organics were dried (MgSO4) and concentrated under reduced pressure to yield 4-chloro-2-methoxy-5-(trifluoromethyl)aniline as a brown oil (3.20 g, 14.2 mmol): 1H NMR (DMSO-d6) δ3.84 (s, 3H), 5.30 (s, 2H), 7.01 (s, 2H).
-
- Step 1. 4-(3-Methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene:
-
- Step 2. 4-(3-Carboxy-4-methoxyphenoxy)-1-nitrobenzene:
- A mixture of 4-(3-methoxycarbonyl-4-methoxyphenoxy)-1-nitrobenzene (1.2 g), KOH (0.33 g) and water (5 mL) in MeOH (45 mL) was stirred at room temp. overnight and then heated at the reflux temp. for 4 h. The resulting mixture was cooled to room temp. and concentrated under reduced pressure. The residue was dissolved in water (50 mL), and the aqueous mixture was made acidic with a 1N HCl solution. The resulting mixture was extracted with EtOAc (50 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure to give 4-(3-carboxy-4-methoxyphenoxy)-1-nitrobenzene (1.04 g).
- Step 3. 4-(3-(N-Methylcarbamoly)4-methoxyphenoxy)-1-nitrobenzene:
-
- Step 4. 4-(3-(N-Methylcarbamoly)-4-methoxyphenoxy)aniline:
- A slurry of 4-(3-(N-methylcarbamoly)-4-methoxyphenoxy)-1-nitrobenzene (0.78 g, 2.60 mmol) and 10% Pd/C (0.20 g) in EtOH (55 mL) was stirred under 1 atm of H2 (balloon) for 2.5 d, then was filtered through a pad of Celite®. The resulting solution was concentrated under reduced pressure to afford 4-(3-(N-methylcarbamoly)-4-methoxyphenoxy)ahiline as an off-white solid (0.68 g, 96%): TLC (0.1% Et3N/99.9% EtOAc) Rf 0.36.
-
- Step 1. Synthesis of 5-(4-Nitrophenoxy)-2-methylisoindoline-1,3-dione:
- A slurry of 5-(4-nitrophenoxy)isoindoline-1,3-dione (A3 Step 2; 1.0 g, 3.52 mmol) and NaH (0.13 g, 5.27 mmol) in DMF (15 mL) was stirred at room temp. for 1 h, then treated with methyl iodide (0.3 mL, 4.57 mmol). The resulting mixture was stirred at room temp. overnight, then was cooled to ° C. and treated with water (10 mL). The resulting solids were collected and dried under reduced pressure to give 5-(4-nitrophenoxy)-2-methylisoindoline-1,3-dione as a bright yellow solid (0.87 g, 83%): TLC (35% EtOAc/65% hexane) Rf 0.61.
- Step 2. Synthesis of 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione:
- A slurry of nitrophenoxy)-2-methylisoindoline-1,3-dione (0.87 g, 2.78 mmol) and 10% Pd/C (0.10 g) in MeOH was stirred under 1 atm of H2 (balloon) overnight. The resulting mixture was filtered through a pad of Celite® and concentrated under reduced pressure. The resulting yellow solids were dissolved in EtOAc (3 mL) and filtered through a plug of SiO2 (60% EtOAc/40% hexane) to afford 5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione as a yellow solid (0.67 g, 86%): TLC (40% EtOAc/60% hexane) Rf 0.27.
-
- Step 1. Synthesis of 4-Chloro-2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridine
-
- Step 2. Synthesis of 4-(2-(N-(2-Morpholin-4-ylethyl)carb amoyl)pyridyloxy)aniline.
- A solution of 4-aminophenol (0.49 g, 4.52 mmol) and potassium tert-butoxide (0.53 g, 4.75 mol) in DMF (8 mL) was stirred at room temp. for 2 h, then was sequentially treated with 4-chloro-2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridine (1.22 g, 4.52 mmol) and K2CO3 (0.31 g, 2.26 mmol). The resulting mixture was heated at 75° C. overnight, cooled to room temp., and separated between EtOAc (25 mL) and a saturated NaCl solution (25 mL). The aqueous layer was back extracted with EtOAc (25 mL). The combined organic layers were washed with a saturated NaCl solution (3×25 mL) and concentrated under reduced pressure. The resulting brown solids were purified by column chromatography (58 g; gradient from 100% EtOAc to 25% MeOH/75% EtOAc) to afford 4-(2-(N-(2-niorpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline (1.0 g, 65%): TLC (10% MeOH/90% EtOA~c) Rf 0.32.
-
- A slurry of 4-(3-carboxyphenoxy)-1-nitrobenzene (5.38 g, 20.7 mmol) and 10% Pd/C (0.50 g) in MeOH (120 mL) was stirred under an H2 atmosphere (balloon) for 2 d. The resulting mixture was filtered through a pad of Celite®, then concentrated under reduced pressure to afford 4-(3-carboxyphenoxy)aniline as a brown solid (2.26 g, 48%): TLC (10% MeOH/90% CH2Cl2) Rf 0.44 (streaking).
-
- Step 1. Synthesis of 5-hydroxyisoindolin-1-one
- To a solution of 5-hydroxyphthalimide (19.8 g, 121 mmol) in AcOH (500 mL) was slowly added zinc dust (47.6 g, 729 mmol) in portions, then the mixture was heated at the reflux temp. for 40 min., filtered hot, and concentrated under reduced pressure. The reaction was repeated on the same scale and the combined oily residue was purified by column chromatography (1.1 Kg SiO2; gradient from 60% EtOAc/40% hexane to 25% MeOH/75% EtOAc) to give 5-hydroxyisoindolin-1-one (3.77 g): TLC (100% EtOAc) Rf 0.17; HPLC ES-MS m/z 150 ((M+H)+).
- Step 2. Synthesis of 4-(1-isoindolinon-5-yloxy)-1-nitrobenzene
- To a slurry of NaH (0.39 g, 16.1 mmol) in DMF at 0° C. was added 5-hydroxyisoindolin-1-one (2.0 g, 13.4 mmol) in portions. The resulting slurry was allowed to warm to room temp. and was stirred for 45 min., then 4-fluoro-1-nitrobenzene was added and then mixture was heated at 70° C. for 3 h. The mixture was cooled to 0° C. and treated with water dropwise until a precipitate formed. The resulting solids were collected to give 4-(1-isoindolinon-5-yloxy)-1-nitrobenzene as a dark yellow solid (3.23 g, 89%): TLC (100% EtOAc) Rf 0.35.
- Step 3. Synthesis of 4-(1-oxoisoindolin-5-yloxy)aniline
- A slurry of 4-(1-isoindolinon-5-yloxy)-1-nitrobenzene (2.12 g, 7.8 mmol) and 10% Pd/C (0.20 g) in EtOH (50 mL) was stirred under an H2 atmosphere (balloon) for 4 h, then filtered through a pad of Celite®. The filtrate was concentrated under reduced pressure to afford 4-(1-oxoisoindolin-5-yloxy)aniline as a dark yellow solid: TLC (100% EtOAc) Rf 0.15.
-
- Step 1. Synthesis of 4-(3-ethoxyearbonylphenoxy)-1-nitrobenzene
-
- Step 2. Synthesis of 4-(3-carboxyphenoxy)-1-nitrobenzene
-
- Step 3. Synthesis of 4-(3-(N-methylcarbamoyl)phenoxy)-1-nitrobenzene
-
- Step 4. Synthesis of 4-(3-(N-methylcarbamoyl)phenoxy)aniline
- A slurry of 4-(3-(N-methylcarbamoyl)phenoxy)-1-nitrobenzene (1.89 g, 6.95 mmol) and 5% Pd/C (0.24 g) in EtOAc (20 mL) was stirred under an H2 atm (balloon) overnight. The resulting mixture was filtered through a pad of Celite® and concentrated under reduced pressure. The residue was purified by column chromatography (5% MeOH/95% CH2Cl2). The resulting oil solidified under vacuum overnight to give 4-(3-(N-methylcarbamoyl) phenoxy)aniline as a yellow solid (0.95 g, 56%).
-
- Step 1. Synthesis of 4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobenzene
- To a slurry of NaH (0.63 g, 26.1 mmol) in DMF (20 mL) was added a solution of methyl 5-hydroxynicotinate (2.0 g, 13.1 mmol) in DMF (10 mL). The resulting mixture was added to a solution of 4-fluoronitrobenzene (1.4 mL, 13.1 mmol) in DMF (10 mL) and the resulting mixture was heated at 70° C. overnight, cooled to room temp., and treated with MeOH (5 mL) followed by water (50 mL). The resulting mixture was extracted with EtOAc (100 mL). The organic phase was concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc/70% hexane) to afford 4-(3-(5-methoxycarbonyl)pyridyloxy)— 1-nitrobenzene (0.60 g).
- Step 2. Synthesis of 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline
- A slurry of 4-(3-(5-methoxycarbonyl)pyridyloxy)-1-nitrobenzene (0.60 g, 2.20 mmol) and 10% Pd/C in MeOH/EtOAc was stirred under an H2 atmosphere (balloon) for 72 h. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 10% EtOAc/90% hexane to 30% EtOAc/70% hexane to 50% EtOAc/50% hexane) to afford 4-(3-(5-methoxycarbonyl) pyridyloxy)aniline (0.28 g, 60%): 1H NMR (CDCl3) δ3.92 (s, 3H), 6.71 (d, 2H), 6.89 (d, 2H), 7.73 (, 1H), 8.51 (d, 1H), 8.87 (d, 1H).
- A15. Synthesis of an Aniline via Electrophilic Nitration Followed by Reduction. Synthesis of 4-(3-Methylsulfamoylphenoxy)aniline.
- Step 1. Synthesis of N-methyl-3-bromobenzenesulfonamide
- To a solution of 3-bromobenzenesulfonyl chloride (2.5 g, 11.2 mmol) in THF (15 mL) at 0 ° C. was added methylamine (2.0 M in THF; 28 mL, 56 mmol). The resulting solution was allowed to warm to room temp. and was stirred at room temp. overnight. The resulting mixture was separated between EtOAc (25 mL) and a 1 M HCl solution (25 mL). The aqueous phase was back-extracted with EtOAc (2×25 mL). The combined organic phases were sequentially washed with water (2×25 mL) and a saturated NaCl solution (25 mL), dried (MgSO4) and concentrated under reduced pressure to give N-methyl-3-bromobenzenesulfonamide as a white solid (2.8 g, 99%).
- Step 2. Synthesis of 4-(3-(N-methylsulfamoyl)phenyloxy)benzene
-
- Step 3. Synthesis of 4-(3-(N-methylsulfamoyl)phenyloxy)-1-nitrobenzene
-
- Step 4. Synthesis of 4-(3-(N-methylsulfamoyl)phenyloxy)aniline
- A slurry of 4-(3-(N-methylsulfamoyl)phenyloxy)-1-nitrobenzene (0.30 g) and 10% Pd/C (0.030 g) in EtOAc (20 mL) was stirred under an H2 atmosphere (balloon) overnight. The resulting mixture was filtered through a pad of Celite®. The filtrate was concentrated under reduced pressure. The residue was purified by colunm chromatography (30% EtOAc/70% hexane) to give 4-(3-(N-methylsulfamoyl)phenyloxy)aniline (0.070 g).
-
- To a slurry of 4-(4-acetylphenoxy)aniline HCl salt (prepared in a manner analogous to Method A13, step 4; 1.0 g, 3.89 mmol) in a mixture of EtOH (10 mL) and pyridine (1.0 mL) was added O-methylhydroxylamine HCl salt (0.65 g, 7.78 mmol, 2.0 equiv.). The resulting solution was heated at the reflux temperature for 30 min, cooled to room temperature and concentrated under reduced pressure. The resulting solids were triturated with water (10 mL) and washed with water to give 4-(4-(1-(N-methoxy)iminoethyl) phenoxyaniline HCl salt as a yellow solid (0.85 g): TLC (50% EtOAc/50% pet. ether) Rf 0.78; 1H NMR (DMSC)—d6) δ3.90 (s, 3H), 5.70 (s, 3H); HPLC-MS m/z 257 ((M+H)+).
-
- Step 1. 4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide
- To a solution of 4-chloro-N-(2-hydroxyethyl)pyridine-2-carboxamide (prepared in a manner analogous to Method A2, Step 3b; 1.5 g, 7.4 mmol) in anh DMF (7 mL) was added triisopropylsilyl chloride (1.59 g, 8.2 mmol, 1.1 equiv.) and imidazole (1.12 g, 16.4 mmol, 2.2 equiv.). The resulting yellow solution was stirred for 3 h at room temp, then was concentrated under reduced pressure. The residue was separated between water (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (3×10 mL). The combined organic phases were dried (MgSO4), and concentrated under reduced pressure to afford 4-chloro-2-(N-(2-triisopropylsilyloxy) ethyl)pyridinecarboxamide as an orange oil (2.32 g, 88%). This material was used in the next step without fuirther purification.
- Step 2. 4-(4-(2-(N-(2-Triisopropylsilyloxy)ethylcarb amoyl)pyridyloxyaniline
- To a solution of 4-hydroxyaniline (0.70 g, 6.0 mmol) in anh DMF (8 mL) was added potassium tert-butoxide (0.67 g, 6.0 nimol, 1.0 equiv.) in one portion causing an exotherm. When this mixture had cooled to room temperature, a solution of 4-chloro-2-(N-(2-triisopropylsilyloxy)ethyl)pyridinecarboxamide (2.32 g, 6 mmol, 1 equiv.) in DMF (4 mL) was added followed by K2CO3 (0.42 g, 3.0 mmol, 0.50 equiv.). The resulting -Mixture was heated at 80° C. overnight. An additional portion of potassium tert-butoxide (0.34 g, 3 mmol, 0.5 equiv.) was then added and the mixture was stirred at 80° C. an additional 4 h. The mixture was cooled to 0° C. with an ice/water bath, then water (approx. 1 mL) was slowly added dropwise. The organic layer was extracted with EtOAc (3×10 mL). The combined organic layers were washed with a saturated NaCl solution (20 mL), dried (MgSO4) and concentrated under reduced pressure. The brown oily residue was purified by column chromatography (SiO2; 30% EtOAc/ 70% pet ether) to afford 4-(4-(2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyaniline as a clear light brown oil (0.99 g, 38%).
-
- Step 1.4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene.
-
- Step 2. Synthesis of 4-(5-(2-Methoxycarbonyl)pyridyloxy)-1-nitrobenzene. A mixture of 4-(5-(2-methyl)pyridyloxy)-1-nitrobenzene (1.70 g, 7.39 mmol) and selenium dioxide (2.50 g, 22.2 mmol, 3.0 equiv.) in pyridine (20 mL) was heated at the reflux temperature for 5 h, then cooled to room temperature. The resulting slurry was filtered, then concentrated under reduced pressure. The residue was dissolved in MeOH (100 mL). The solution was treated with a conc HCl solution (7 mL), then heated at the reflux temperature for 3 h, cooled to room temperature and concentrated under reduced pressure. The residue was separated between EtOAc (50 mL) and a 1N NaOH solution (50 mL). The aqueous layer was extracted with EtOAc (2×50 mL). The combined organic layers were sequentially washed with water (2×50 mL) and a saturated NaCl solution (50 mL), dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2; 50% EtOAc/50% hexane) to afford 4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nitrobenzene (0.70 g).
- Step 3. Synthesis of 4-(5-(2-Methoxycarbonyl)pyridyloxy)aniline. A slurry of 4-(5-(2-methoxycarbonyl)pyridyloxy)—-mnitrobenzene (0.50 g) and 10% Pd/C (0.050 g) in a mixture of EtOAc (20 mL) and MeOH (5 mL) was placed under a H2 atmosphere (balloon) overnight. The resulting mixture was filtered through a pad of Celite®, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2; 70% EtOAc/30% hexane) to give 4-(5-(2-methoxycarbonyl) pyridyloxy)aniline (0.40 g).
- A19. Synthesis of co-Sulfonylphenyl Anilines. Synthesis of 4-(4-Methylsulfonylphenyoxy)aniline.
- Step 1. 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene: To a solution of 4-(4-methylthiophenoxy)-1-nitrobenzene (2.0 g, 7.7 mmol) in CH2C12 (75 mL) at 0° C. was slowly added m—CPBA (57-86%, 4.0 g), and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was treated with a 1N NaOH solution (25 mL). The organic layer was sequentially washed with a 1N NaOH solution (25 mL), water (25 mL) and a saturated NaCl solution (25 mL), dried (MgSO4), and concentrated under reduced pressure to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene as a solid (2.1 g).
- Step 2. 4-(4-Methylsulfonylphenoxy)-1-aniline: 4-(4-Methylsulfonylphenoxy)-1-nitrobenzene was reduced to the aniline in a manner analogous to that described in Method A18, step 3.
- B. Synthesis of Urea Precursors
-
-
- Step 2. Synthesis of 4-bromo-3-(trifluoromethyl)phenyl isocyanate
- A suspension of 4-bromo-3-(trifluoromethyl)aniline HCl salt (36.8 g, 133 mmol) in toluene (278 mL) was treated with trichloromethyl chloroformate dropwise and the resulting mixture was heated at the reflux temp. for 18 h. The resulting mixture was concentrated under reduced pressure. The residue was treated with toluene (500 mL), then concentrated under reduced pressure. The residue was treated with CH2C12 (500 mL), then concentrated under reduced pressure. The CH2C12 treatment/concentration protocol was repeated and resulting amber oil was stored at −20° C. for 16 h, to afford 4-bromo-3-(trifluoromethyl)phenyl isocyanate as a tan solid (35.1 g, 86%): GC-MS m/z 265 (M+).
- C. Methods of Urea Formation
-
- A solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate (14.60 g, 65.90 mmol) in CH2C12 (35 mL) was added dropwise to a suspension of 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (Method A2, Step 4; 16.0 g, 65.77 mmol) in CH2C12 (35 mL) at 0° C. The resulting mixture was stirred at room temp. for 22 h. The resulting yellow solids were removed by filtration, then washed with CH2Cl2(2×30 mL) and dried under reduced pressure (approximately 1 mmHg) to afford N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as an off-white solid (28.5 g, 93%): mp 207-209° C. ; 1H-NMR (DMSO-d6) δ2.77 (d, J=4.8 Hz, 3H), 7.16 (m, 3H), 7.37 (d, J=2.5 Hz, 1H), 7.62 (m, 4H), 8.11 (d, J=2.5 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.77 (br d, 1H), 8.99 (s, 1H), 9.21 (s, 1H); HPLC ES-MS m/z 465 ((M+H )+).
-
- A solution of 4-bromo-3-(trifluoromethyl)phenyl isocyanate (Method BI, Step 2; 8.0 g, 30.1 mmol) in CH2Cl2(80 mL) was added dropwise to a solution of 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (Method A2, Step 4; 7.0 g, 28.8 mmol) in CH2Cl2(40 nmL) at 0° C. The resulting mixture was stirred at room temp. for 16 h. The resulting yellow solids were removed by filtration, then washed with CH2Cl2(2×50 mL) and dried under reduced pressure (approximately 1 mmHg) at 40° C. to afford N-(4-bromo-3-(trifluoromethyl)phenyl)— N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as a pale-yellow solid (13.2 g, 90%): mp 203-205° C.; 1H-NMR (DMSO-d6) δ2.77 (d, J=4.8 Hz, 3H), 7.16 (m, 3iH), 7.37 (d, J=2.5 Hz, 1H), 7.58 (m, 3H), 7.77 (d, J=8.8 Hz, 1H), 8.11 (d, J=2.5 Hz, 1H), 8.49 (d, J=5.5 Hz, 1H), 8.77 (br d, 1H), 8.99 (s, 1H), 9.21 (s, 1H); HPLC ES-MS m/z 509 ((M+H)+).
-
- A solution of 2-methyl-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))aniline (Method A5; 0.11 g, 0.45 mmol) in CH2Cl2(1 mL) was treated with Et3N (0.16 mL) and 4-chloro-3-(trifluoromethyl)phenyl isocyanate (0.10 g, 0.45 mmol). The resulting brown solution was stirred at room temp. for 6 d, then was treated with water (5 mL). The aqueous layer was back-extracted with EtOAc (3×5 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure to yield N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(2-methyl-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea as a brown oil (0.11 g, 0.22 mmol): 1H NMR (DMSO-d6) δ2.27 (s, 3H), 2.77 (d, J=4.8 Hz, 3H), 7.03 (dd, J=3.5, 2.6 Hz, 1H), 7.11 (d, J=2.9 Hz, 1H), 7.15 (dd, J=5.5, 2.6, Hz, 1H), 7.38 (d, J=2.6 Hz, 1H), 7.62 (app d, J=2.6 Hz, 2H), 7.84 (d, J=8.8 Hz, 1H), 8.12 (s, 1H), 8.17 (s, 1H); 8.50 (d, J=5.5 Hz, 1H), 8.78 (q, J=5.2, 1H), 9.52 (s, 1H); HPLC ES-MS m/z 479 ((M+H )+).
-
- To a solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate (2.27 g, 10.3 mmol) in CH2Cl2(308 mL) was added p-phenylenediamine (3.32 g, 30.7 mmol) in one part. The resulting mixture was stirred at room temp. for 1 h, treated with CH2Cl2(100 mL), and concentrated under reduced pressure. The resulting pink solids were dissolved in a mixture of EtOAc (110 mL) and MeOH (15mL), and the clear solution was washed with a 0.05 N HCl solution. The organic layer was concentrated under reduced pressure to afford impure N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-aminophenyl) urea (3.3 g): TLC (100% EtOAc) Rf 0.72.
-
- To a solution of ethyl 4-isocyanatobenzoate (3.14 g, 16.4 mmol) in CH2Cl2(30 mL) was added 4-chloro-3-(trifluoromethyl)aniline (3.21 g, 16.4 nimol), and the solution was stirred at room temp. overnight. The resulting slurry was diluted with CH2Cl2(50 mL) and filtered to afford N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-ethoxycarbonylphenyl) urea as a white solid (5.93 g, 97%): TLC (40% EtOAc/60% hexane) Rf 0.44.
-
- To a solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate (1.21g, 5.46 mmol), in CH2Cl2(8 mL) was added 4-(3-carboxyphenoxy)aniline (Method A11; 0.81 g, 5.76 mmol) and the resulting mixture was stirred at room temp. overnight, then treated with MeOH (8 mL), and stirred an additional 2 h. The resulting mixture was concentrated under reduced pressure. The resulting brown solids were triturated with a 1:1 EtOAc/hexane solution to give N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-carboxyphenyl) urea as an off-white solid (1.21 g, 76%).
- C2a. General Method for Urea Synthesis by Reaction of an Aniline with N,N′-Carbonyl Diimidazole Followed by Addition of a Second Aniline. Synthesis of N-(2-Methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- To a solution of 2-methoxy-5-(trifluoromethyl)aniline (0.15 g) in anh CH2Cl2(15 mL) at 0° C. was added CDI (0.13 g). The resulting solution was allowed to warm to room temp. over 1 h, was stirred at room temp. for 16 h, then was treated with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.18 g). The resulting yellow solution was stirred at room temp. for 72 h, then was treated with H2O (125 mL). The resulting aqueous mixture was extracted with EtOAc (2×150 mL). The combined organics were washed with a saturated NaCl solution (100 mL), dried (MgSO4) and concentrated under reduced pressure. The residue was triturated (90% EtOAc/10% hexane). The resulting white solids were collected by filtration and washed with EtOAc. The filtrate was concentrated under reduced pressure and the residual oil purified by column chromatography (gradient from 33% EtOAc/67% hexane to 50% EtOAc/50% hexane to 100% EtOAc) to give N-(2-methoxy-5-(trifluoromethyl)phenyl)— N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as a light tan solid (0.098 g, 30%): TLC (100% EtOAc) Rf 0.62; 1H NMR (DMSO-d6) δ2.76 (d, J=4.8 Hz, 3H), 3.96 (s, 3H), 7.1-7.6 and 8.4-8.6 (m, 11H), 8.75 (d, J=4.8 Hz, 1H), 9.55 (s, 1 H); FAB-MS m/z 461 ((M+H)+).
-
- To a stirring solution of 3-amino-2-methoxyquinoline (0.14 g) in anhydrous CH2Cl2(15 mL) at 0° C. was added CDI (0.13 g). The resulting solution was allowed to warm to room temp. over 1 h then was stirred at room temp. for 16 h. The resulting mixture was treated with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.18 g). The resulting yellow solution stirred at room temp. for 72 h, then was treated with water (125 mL). The resulting aqueous mixture was extracted with EtOAc (2×150 mL). The combined organic phases were washed with a saturated NaCl solution (100 ml), dried (MgSO4) and concentrated under reduced pressure. The residue was triturated (90% EtOAc/10% hexane). The resulting white solids were collected by filtration and washed with EtOAc to give bis(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea (0.081 g, 44%): TLC (100% EtOAc) Rf 0.50; 1H NMR (DMSO-d6) δ2.76 (d, J=5.1 Hz, 6H), 7.1-7.6 (m, 12H), 8.48 (d, J=5.4 Hz, 1H), 8.75 (d, J=4.8 Hz, 2H), 8.86 (s, 2H); HPLC ES-MS m/z 513 ((M+H)+).
-
- To a stirring solution of 2-methoxy-5-(trifluoromethyl)phenyl isocyanate (0.10 g, 0.47 mmol) in CH2Cl2(1.5 mL) was added 5-(4-aminophenoxy)isoindoline-1,3-dione (Method A3, Step 3; 0.12 g, 0.47 mmol) in one portion. The resulting mixture was stirred for 12 h, then was treated with CH2Cl2(10 mL) and MeOH (5 mL). The resulting mixture was sequentially washed with a 1N HCl solution (15 mL) and a saturated NaCl solution (15 mL), dried (MgSO4) and concentrated under reduced pressure to afford N-(2-methoxy-5-(trifluoromethyl) phenyl-N′-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea as a white solid (0.2 g, 96%): TLC (70% EtOAc/30% hexane) Rf 0.50; 1H NMR (DMSO-d6) δ3.95 (s, 3H), 7.31-7.10 (m, 6H), 7.57 (d, J=9.3Hz, 2H), 7.80 (d, J=8.7 Hz, 1H), 8.53 (br s, 2H), 9.57 (s, 1H), 11.27 (br s, 1H); HPLC ES-MS 472.0 ((M+H)+, 100%).
- C2d. General Method for Urea Synthesis by Reaction of an Aniline with N,N′-Carbonyl Diimidazole Followed by Addition of a Second Aniline.
- Synthesis of N-(5-(tert-Butyl)-2-(2,5-dimethylpyrrolyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) Urea
- To a stirring solution of CDI (0.21g, 1.30 mmol) in CH2Cl2(2 mL) was added 5-(tert-butyl)— 2-(2,5-dimethylpyrrolyl)aniline (Method A4, Step 2; 0.30 g, 1.24 mmol) in one portion. The resulting mixture was stirred at room temp. for 4 h, then 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (0.065 g, 0.267mmol) was then added in one portion. The resulting mixture was heated at 36° C. overnight, then cooled to room temp. and diluted with EtOAc (5 mL). The resulting mixture was sequentially washed with water (15 mL) and a 1N HCl solution (15 mL), dried (MgSO4), and filtered through a pad of silica gel (50 g) to afford N-(5-(tert-butyl)-2-(2,5-dimethylpyrrolyl) phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea as a yellowish solid (0.033 g, 24%): TLC (40% EtOAc/60% hexane) Rf 0.24; 1H NMR (acetone-d6) δ1.37 (s, 9H), 1.89 (s, 6H), 2.89 (d, J=4.8Hz, 3H), 5.83 (s, 2H), 6.87-7.20 (m, 6H), 7.17 (dd, 1H), 7.51-7.58 (m, 3H), 8.43 (d, J=5.4Hz, 1H), 8.57 (d, J=2.1 Hz, 1H), 8.80 (br s, 1H); HPLC ES-MS 512 ((M+H)+, 100%).
- C3. Combinatorial Method for the Synthesis of Diphenyl Ureas Using Triphosgene
- One of the anilines to be coupled was dissolved in dichloroethane (0.10 M). This solution was added to a 8 mL vial (0.5 mL) containing dichloroethane (1 mL). To this was added a bis(trichloromethyl) carbonate solution (0.12 M in dichloroethane, 0.2 mL, 0.4 equiv.), followed by diisopropylethylamine (0.35 M in dichloroethane, 0.2 mL, 1.2 equiv.). The vial was capped and heat at 80° C. for 5 h, then allowed to cool to room temp for approximately 10 h. The second aniline was added (0.10 M in dichloroethane, 0.5 mL, 1.0 equiv.), followed by diisopropylethylamine (0.35 M in dichloroethane, 0.2 mL, 1.2 equiv.). The resulting mixture was heated at 80° C. for 4 h, cooled to room temperature and treated with MeOH (0.5 mL). The resulting mixture was concentrated under reduced pressure and the products were purified by reverse phase HPLC.
-
- To a stirring solution of phosgene (1.9 M in toluene; 2.07 mLO.21g, 1.30 mmol) in CH2Cl2(20 mL) at 0° C. was added anh pyridine (0.32 mL) followed by 2-methoxy-5-(trifluoromethyl)aniline (0.75 g). The yellow solution was allowed to warm to room temp during which a precipitate formed. The yellow mixture was stirred for 1 h, then concentrated under reduced pressure. The resulting solids were treated with anh toluene (20 mL) followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline (prepared as described in Method A2; 0.30 g) and the resulting suspension was heated at 80° C. for 20 h, then allowed to cool to room temp. The resulting mixture was diluted with water (100 mL), then was made basic with a saturated NaHCO3 solution (2-3 mL). The basic solution was extracted with EtOAc (2× 250 mL). The organic layers were separately washed with a saturated NaCl solution, combined, dried (MgSO4), and concentrated under reduced pressure. The resulting pink-brown residue was dissolved in MeOH and absorbed onto SiO2 (100 g). Colunm chromatography (300 g SiO2; gradient from 1% Et3N/33% EtOAc/66% hexane to 1% Et3N/99% EtOAc to 1% Et3N/20% MeOH/79% EtOAc) followed by concentration under reduced pressure at 45° C. gave a warm concentrated EtOAc solution, which was itreated with hexane (10 mL) to slowly form crystals of N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea (0.44 g): TLC (1% Et3N/99%° EtOAc) Rf 0.40.
- D. Interconversion of Ureas
- D1a. Conversion of co-Aminophenyl Ureas into ω-(Aroylamino)phenyl Ureas.
-
- To a solution of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-aminophenyl) urea (Method C1d; 0.050 g, 1.52 mmol), mono-methyl isophthalate (0.25 g, 1.38 mmol), HOBTeH2O (0.41 g, 3.03 mmol) and N-methylmorpholine (0.33 mL, 3.03 mmol) in DMF (8 mL) was added EDCl -HCl (0.29 g, 1.52 mmol). The resulting mixture was stirred at room temp. overnight, diluted with EtOAc (25 mL) and sequentially washed with water (25 mL) and a saturated NaHCO3 solution (25 mL). The organic layer was dried (Na2SO4) and concentrated under reduced pressure. The resulting solids were triturated with an EtOAc solution (80% EtOAc/20% hexane) to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-metboxycarbonylphenyl) carboxyaminophenyl) urea (0.27 g, 43%): mp 121-122; TLC (80% EtOAc/20% hexane) Rf0.75.
-
- To a solution of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-methylcarbamoylphenyl) carboxyaminophenyl) urea (0.14 g, 0.48 mmol), 3-methylcarbamoylaniline (0.080 g, 0.53 mmol), HOBT-H2O (0.14 g, 1.07 mmol), and N-methylmorpholine (0.5mL, 1.07 mmol) in DMF (3 mL) at 0° C. was added EDCl-HCl (0.10 g, 0.53 mmol). The resulting mixture was allowed to warm to room temp. and was stirred overnight. The resulting mixture was treated with water (I OmL), and extracted with EtOAc (25 mL). The organic phase was concentrated under reduced pressure. The resulting yellow solids were dissolved in EtOAc (3 mL) then filtered through a pad of silica gel (17 g, gradient from 70% EtOAc/30% hexane to 10% MeOH/90% EtOAc) to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-methylcarbamoylphenyl) carbamoylphenyl) urea as a white solid (0.097 g, 41%/(,): mp 225-229; TLC (100% EtOAc) Rf 0.23.
-
- A mixture of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(3-carboxyphenyl) urea (Method C1f; 0.030 g, 0.067 mmol) and N-cyclohexyl-N′-(methylpolystyrene)carbodiimide (55 mg) in 1,2-dichloroethane (1 mL) was treated with a solution of 3-aminopyridine in CH2Cl2(1 M; 0.074 mL, 0.074 nmmol). (In cases of insolubility or turbidity, a small amount of DMSO was also added.) The resulting mixture was heated at 36° C. overnight. Turbid reactions were then treated with THF (1 mL) and heating was continued for 18 h. The resulting mixtures were treated with poly(4-(isocyanatomethyl)styrene) (0.040 g) and the resulting mixture was stirred at 36° C. for 72 h, then cooled to room temp. and filtered. The resulting solution was filtered through a plug of silica gel (1 g). Concentration under reduced pressure afforded N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(N-(3-(N-(3-pyridyl) carbamoyl)phenyl)carbamoyl)phenyl) urea (0.024 g, 59%): TLC (70% EtOAc/30% hexane) Rf 0.12.
- D2. Conversion of ω-Carboalkoxyaryl Ureas into ω-Carbamoylaryl Ureas.
-
- To a sample of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-carbomethoxyphenyl) carboxyaminophenyl) urea (0.17 g, 0.34 mmol) was added methylamine (2 M in THF; 1 mL, 1.7 mmol) and the resulting mixture was stirred at room temp. overnight, then concentrated under reduced pressure to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(3-methylcarbamoylphenyl) carboxyaminophenyl) urea as a white solid: mp 247; TLC (100% EtOAc) Rf 0.35.
-
- To a slurry of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-ethoxycarbonylphenyl) urea (Method C1e; 5.93 g, 15.3 imnol) in MeOH (75 mL) was added an aqueous KOH solution (2.5 N, 10 mL, 23 mmol). The resulting mixture was heated at the reflux temp. for 12 h, cooled to room temp., and concentrated under reduced pressure. The residue was diluted with water (50 mL), then treated with a 1 N HCl solution to adjust the pH to 2 to 3. The resulting solids were collected and dried under reduced pressure to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-carboxyphenyl) urea as a white solid (5.05 g, 92%).
-
- Step 1. Synthesis of N-(4-Chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-carboxypyridyl) oxyphenyl) Urea
-
- Step 2. Synthesis of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-(2-dimethylaminoethyl)carbamoyl)pyridyl)oxyphenyl) urea A mixture of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-carboxypyridyl)oxyphenyl) urea (0.050 g, 0.011 mmol), N,N-dimethylethylenediamine (0.22 mg, 0.17 mmol), HOBT (0.028 g, 0.17 mmol), N-methylmorpholine (0.035 g, 0.28 mmol), and EDCl-HCl (0.032 g, 0.17 mmol) in DMF (2.5 mL) was stirred at room temp. overnight. The resulting solution was separated between EtOAc (50 mL) and water (50 mL). The organic phase was washed with water (35 mL), dried (MgSO4) and concenbated under reduced pressure. The residue was dissolved in a minimal amount of CH2C12 (approximately 2 mL). The resulting solution was treated with Et2O dropwise to give N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-((4-(3-(5-(2-dimethylaminoethyl)carbamoyl)pyridyl)oxyphenyl) urea as a white precipitate (0.48 g, 84%: 1H NMR (DMSO-d6) δ2.10 s, 6H), 3.26 (s, H), 7.03 (d, 2H), 7.52 (d, 2H), 7.60 (m, 3H), 8.05 (s, 1H), 8.43 (s, 1H), 8.58 (t, 1H), 8.69 (s, 1H), 8.90 (s, 1H), 9.14 (s, 1H); HPLC ES-MS m/z 522 ((M+H)+).
-
- To a solution of N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(4-(2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyphenyl) urea (prepared in a manner analogous to Method C1a; 0.25 g, 0.37 mmol) in anh THF (2 mL) was tetrabutylammonium fluoride (1.0 M in THF; 2 mL). The mixture was stirred at room temperature for 5 min, then was treated with water (10 mL). The aqueous mixture was extracted with EtC)Ac (3×10 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2; gradient from 100% hexane to 40% EtOAc/60% hexane) to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(4-(2-(N-(2-hydroxy)ethylcarbamoyl)pyridyloxyphenyl) urea as a white solid (0.019 g, 10%).
- Listed below are compounds listed in the Tables below which have been synthesized according to the Detailed Experimental Procedures given above:
- Entry 1: 4-(3-N-Methylcarbamoylphenoxy)aniline was prepared according to Method A13. According to Method C3, 3-tert-butylaniline was reacted with bis(trichloromethyl)carbonate followed by 4-(3-N-Methylcarbamoylphenoxy)aniline to afford the urea.
- Entry 2: 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone were reacted according to Method A13, Step 1 to afford the 4-(4-acetylphenoxy)-1-nitrobenzene. 4-(4-Acetylphenoxy)— 1-nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline. According to Method C3, 3-tert-butylaniline was reacted with bis(trichloromethyl) carbonate followed by 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 3: According to Method C2d, 3-tert-butylaniline was treated with CDI, followed by 4-(3-N-methylcarbamoyl)-4-methoxyphenoxy)aniline, which had been prepared according to Method A8, to afford the urea.
- Entry 4: 5-tert-Butyl-2-methoxyaniline was converted to 5-tert-butyl-2-methoxyphenyl isocyanate according to Method B1. 4-(3-N-Methylcarbamoylphenoxy)anilin,e, prepared according to Method A13, was reacted with the isocyanate according to Method C1a to afford the urea.
- Entry 5: According to Method C2d, 5-tert-butyl-2-methoxyaniline was reacted with CDI followed by 4-(3-N-methylcarbamoyl)-4-methoxyphenoxy)aniline, which had been prepared according to Method A8, to afford the urea.
- Entry 6: 5-(4-Aminophenoxy)isoindoline-1,3-dione was prepared according to Method A3. According to Method 2d, 5-tert-butyl-2-methoxyaniline was reacted with CDI followed by 5-(4-aminophenoxy)isoindoline-1,3-dione to afford the urea.
- Entry 7: 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized according to Method A12. According to Method 2d, 5-tert-butyl-2-methoxyaniline was reacted with CDI followed by 4-(1-oxoisoindolin-5-yloxy)aniline to afford the urea.
- Entry 8: 4-(3-N-Methylcarbamoylphenoxy)aniline was synthesized according to Method A13. According to Method C2a, 2-methoxy-5-(trifluoromethyl)aniline was reacted with CDI followed by 4-(3-N-methylcarbamoylphenoxy)aniline to afford the urea.
- Entry 9: 4-Hydroxyacetophenone was reacted with 2-chloro-5-nitropyridine to give 4-(4-acetylphenoxy)-5-nitropyridine according to Method A3, Step 2. According to Method A8, Step 4, 4-(4-acetylphenoxy)-5-nitropyridine was reduced to 4-(4-acetylphenoxy)-5-aminopyridine. 2-Methoxy-5-(trifluoromethyl)aniline was converted to 2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. The isocyanate was reacted with 4-(4-acetylphenoxy)-5-aminopyridine according to Method C1a to afford the urea.
- Entry 10: 4-Fluoro-1-nitrobenzene and p-hydroxyacetophenone were reacted according to Method A13, Step 1 to afford the 4-(4-acetylphenoxy)-1-nitrobenzene. 4-(4-Acetylphenoxy)-1-nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline. According to Method C3, 5-(trifluoromethyl)-2-methoxybuLtylaniline was reacted with bis(trichloromethyl) carbonate followed by 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 11: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. According to Method C4, 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 12: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3b to form 4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was reacted with 3-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 3-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C2a, 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 3-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 13: 4-Chloro-N-methyl-2-pyridinecarboxamide was synthesized according to Method A2, Step 3b. 4-Chloro-N-methyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. According to Method C2a, 2-rnethoxy-5-(trifluoromethyl)aniline was reacted with CDI followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 14: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with annmonia according to Method A2, Step 3b to form 4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 4-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C4, 2-methoxy-5-(trifluoromethyl)aniline was reacted with phosgene followed by 4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 15: According to Method C2d, 5-(triflouromethyl)-2-methoxyaniline was reacted with CDI followed by 4-(3-N-methylcarbamoyl)-4-methoxyphenoxy)aniline, which had been prepared according to Method A8, to afford the urea.
- Entry 16: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was synthesized according to Method A5. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B 1. The isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-methylaniline according to Method C1c to afford the urea.
- Entry 17: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline according to Method C1a to afford the urea.
- Entry 18: According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline according to Method C1a to afford the urea.
- Entry 19: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3b. The resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N-ethylcarbamoyl)-4-pyridylo y)aniline according to Method C1a to afford the urea.
- Entry 20: According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline according to Method C1a to afford the urea.
- Entry 21: 4-(4-Methylthiophenoxy)-1-nitrobenzene was oxidized according to Method A19, Step 1 to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene. The nitrobenzene was reduced according to Method A19, Step 2 to give 4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1a, 5-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(4-methylsulfonylphenoxy)-1-aniline to afford the urea.
- Entry 22: 4-(3-carbamoylphenoxy)-1-nitrobenzene was reduced to 4-(3-carbamoylphenoxy)aniline according to Method A15, Step 4. According to Method C1a, 5-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-carbamoylphenoxy)aniline to afford the urea.
- Entry 23: 5-(4-Aminophenoxy)isoindoline-1,3-dione was synthesized according to Method A3. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluorornethyl)-2-methoxyphenyl isocyanate according to Method B1.5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 5-(4-aminophenoxy)isoindoline-1,3-dione according to Method C1a to afford the urea.
- Entry 24: 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3b. The resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline according to Method C1a to afford the urea.
- Entry 25: 4-(1-Oxoisoindolin-5-yloxy)aniline was synthesized according to Method A12.5-(Trifluoromethyl)-2-methoxyaniline was treated with CDI, followed by 4-(1-oxoisoindolin-5-yloxy)aniline according to Method C2d to afford the urea.
- Entry 26: 4-Hydroxyacetophenone was reacted with 4-fluoronitrobenzene according to Method A13, Step 1 to give 4-(4-acetylphenoxy)nitrobenzene. The nitrobenzene was reduced according to Method A13, Step 4 to afford 4-(4-acetylphenoxy)aniline, which was converted to the 4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt according to Method A16.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(4-(1-(N-methoxy)iminoethyl)phenoxyaniline HCl salt to Method C1a to afford the urea.
- Entry 27: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbarnoyl)phenylthio)aniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline according to Method C1a to afford the urea.
- Entry 28: 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione was synthesized according to Method A9. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1.5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione according to Method C1a to afford the urea.
- Entry 29: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline according to Method C1a to afford the urea.
- Entry 30: 4-Chloropyridine-2-carbonyl chloride was reacted with isopropylamine according to Method A2, Step 3b. The resulting 4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy) aniline. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline according to Method C1a to afford the urea.
- Entry 31: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. S-(Trifluoromethyl)-2-methcoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with 4-(2-aminoethyl)morpholine to afford the amide according to Method D4, Step 2.
- Entry 32: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluororriethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with methylamine according to Method D4, Step 2 to afford the amide.
- Entry 33: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 5-(Trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)—,A′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with N,N-dimethylethylenediamine according to Method D4, Step 2 to afford the amide.
- Entry 34: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A1.5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 3-aminopyridine according to Method D1c.
- Entry 35: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method All. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl 3-i isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with N-(4-fluorophenyl)piperazine according to Method D1c.
- Entry 36: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 4-fluoroaniline according to Method D1c.
- Entry 37: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 4-(dimethylamino)aniline according to Method D1c.
- Entry 38: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 5-amino-2-methoxypyridine according to Method D1c.
- Entry 39: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with 4-morpholinoaniline according to Method D1c.
- Entry 40: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method Al 1. 5-(Trifluoromethyl)-2-methoxyaniline was converted into 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method B1. 4-(3-Carboxyphenoxy)aniline was reacted with 5-(trifluoromethyl)-2-methoxyphenyl isocyanate according to Method C1f to afford N-(5-(trifluoromethyl)-2-methoxyphenyl)-N′-(3-carboxyphenyl) urea, which was coupled with N-(2-pyridyl)piperazine according to Method D1c.
- Entry 41: 4-(3-(N-Methylcarbamoyl)phenoxy)aniline was synthesized according to Method A13. According to Method C3, 4-chloro-3-(trifluoromethyl)aniline was converted to the isocyanate, then reacted with 4-(3-(N-Methylcarbamoyl)phenoxy)aniline to afford the urea.
- Entry 42: 4-(2-N-Methylcarbamyl-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-N-methylcarbamyl-4-pyridyloxy)aniline according to Method C1a to afford the urea.
- Entry 43: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3b to form 4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to form 4-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C1a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-carbamoyl-4-pyridyloxy)aniline to afford the urea.
- Entry 44: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia according to Method A2, Step 3b to form 4-chloro-2-pyridinecarboxamide. 4-Chloro-2-pyridinecarboxamide was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(2-carbamoyl-4-pyridyloxy)aniline. According to Method C1 a, 4-chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-carbamoyl-4-pyridyloxy,ianiline to afford the urea.
- Entry 45: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 46: 5-(4-Aminophenoxy)isoindoline-1,3-dione was synthesized according to Method A3. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)isoindoline- 1,3-dione to afford the urea.
- Entry 47: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-methylaniline was synthesized according to Method A5. According to Method Clc, 4-chloro-3-(trifluoromethlyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)isoindoline-1,3-dione to afford the urea.
- Entry 48: 4-(3-N-Methylsulfarnoyl)phenyloxy)aniline was synthesized according to Method A15. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-N-methylsulfamoyl)phenyloxy)aniline to afford the urea.
- Entry 49: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline to afford the urea.
- Entry 50: According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline to afford the urea.
- Entry 51: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3b. The resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy) aniline. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 52: According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline to afford the urea.
- Entry 53: 4-(4-Methylthiophenoxy)-1-nitrobenzene was oxidized according to Method A19, Step 1 to give 4-(4-methylsulfonylphenoxy)-1-nitrobenzene. The nitrobenzene was reduced according to Method A19, Step 2 to give 4-(4-methylsulfonylphenoxy)-1-aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-methylsulfonylphenoxy)—1-aniline to afford the urea.
- Entry 54: 4-Bromobenzenesulfonyl chloride was reacted with methylamine according to Method A15, Step 1 to afford N-methyl-4-bromobenzenesulfonamide. N-Methyl-4-bromobenzenesulfonamide was coupled with phenol according to Method A15, Step 2 to afford 4-(4-(N-methylsulfamoyl)phenoxy)benzene. 4-(4-(N-Methylsulfamoyl)phenoxy)benzene was converted into 4-(4-(N-methylsulfamoyl)phenoxy)-1-nitrobenzene according to Method A15, Step 3. 4-(4-(N-Methylsulfamoyl)phienoxy)-1-nitrobenzene was reduced to 4-(4-N-methylsulfamoyl)phenyloxy)aniline according to Method A15, Step 4. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-N-methylsulfamoyl)phenyloxy)aniline to afford the urea.
- Entry 55: 5-Hydroxy-2-methylpyridine was coupled with 1-fluoro-4-nitrobenzene according to Method A18, Step 1 to give 4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene. The methylpyridine was oxidized according to the carboxylic acid, then esterified according to 2& Method A18, Step 2 to give 4-(5-(2-methoxycarbonyl)pyridyloxy)-1-nitrobenzene. The nitrobenzene was reduced according the Method A18, Step 3 to give 4-(5-(2-methoxycarbonyl)pyridyloxy)aniline. The aniline was reacted with 4--chloro-3-(trifluoromethyl)phenyl isocyanate according to Method C1a to afford the urea.
- Entry 56: 5-Hydroxy-2-methylpyridine was coupled with 1-fluoro-4-nitrobenzene according to Method A18, Step 1 to give 4-(5-(2-Methyl)pyridyloxy)-1-nitrobenzene. The methylpyridine was oxidized according to the carboxylic acid, then esterified according to Method A18, Step 2 to give 4-( 5-(2-methoxyc arbonyl)pyridyloxy)-1-nitrobenzene. The nitrobenzene was reduced according the Method A18, Step 3 to give 4-(5-(2-methoxycarbonyl) pyridyloxy)aniline. The aniline was reacted with 4-chloro-3-(trifluoromethyl)phenyl isocyanate according to Method C1a to give N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(methoxycarbonyl)-5-pyridyloxy)phenyl) urea. The methyl ester was reacted with methylamine according to Method D2 to afford N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-5-pyridyloxy)phenyl) urea.
- Entry 57: N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was prepared according to Method Cld. N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was coupled with mono-methyl isophthalate according to Method D1a to afford the urea.
- Entry 58: N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was prepared according to Method Cld. N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-aminophenyl) urea was coupled with mono-methyl isophthalate according to Method DIa to afford N-(4-chloro-3-(trifluoromethyl)phenyl-N′-(4-(3-methoxycarbonylphenyl)carboxyaminophenyl) urea. According to Method D2, N-(4-chloro-3-(trifluoromethyl)phenyl-N′-(4-(3-methoxycarbonylphenyl)carboxyaminophenyl) urea was reacted with methylamine to afford the corresponding methyl amide.
- Entry 59: 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3b. The resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline. According to Method C1a, 4 --chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 60: 4-Hydroxyacetophenone was reacted with 4-fluoronitrobenzene according to Method A13, Step 1 to give 4-(4-acetylphenoxy)nitrobenzene. The nitrobenzene was reduced according to Method 13, Step 4 to afford 4-(4-acetylphenoxy)aniline, which was converted to the 4-(4-(1-(N-methoxy)iminoethyl) phenoxyaniline HCl salt according to Method A16. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-acetylphenoxy)aniline to afford the urea.
- Entry 61: 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 4-(2-aminoethyl)morpholine according to Method A13, Step 3 to give 4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4L-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(N-(2-morpholinylethyl)carbamoyl)phenoxy)aniline to afford the urea.
- Entry 62: 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 1-(2-arninoethyl)piperidine according to Method A13, Step 3 to give 4-(3-(N-(2-piperidylethyl)carbamoyl)phienoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(2-4-piperidylethyl) carbamoyl)phenoxy)—1 -nitrobenzene was reduced to 4-(3-(N-(2-piperidylethyl) carbamoyl)phenoxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl) phenyl isocyanate was reacted with 4-(3-(N-(2-piperidylethyl) carbamoyl)phenoxy)aniline to afford the urea.
- Entry 63: 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with tetrahydrofurfurylamine according to Method A13, Step 3 to give 4-(3-(N-(tetrahydrofurylmethyl) carbamoyl)phenoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-(tetrahydrofurylmethyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4-(3-(N-(tetrahydrofurylmethyl) carbamoyl)phenoxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(N-(tetrahydrofurylmethyl)carbamoyl) phenoxy)aniline to afford the urea.
- Entry 64: 4-(3-Carboxyphenoxy)-1-nitrobenzene was synthesized according to Method A13, Step 2. 4-(3-Carboxyphenoxy)-1-nitrobenzene was coupled with 2-aminomethyl-1-ethylpyrrolidine according to Method A13, Step 3 to give 4.-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)-1-nitrobenzene. According to Method A13 Step 4, 4-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)-1-nitrobenzene was reduced to 4-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4.-(3-(N-((1-methylpyrrolidinyl)methyl)carbamoyl)phenoxy)aniline to afford the urea.
- Entry 65: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. According to Method C1 a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-(2-(N-methylcarbamoyl) phenylthio)aniline to afford the urea.
- Entry 66: 4-Chloropyridine-2-carbonyl chloride was reacted with isopropylamine according to Method A2, Step 3b. The resulting 4-chloro-N-isopropyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-isopropylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 67: N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-ethoxycarbonylphenyl) urea was synthesized according to Method Cl e. N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-ethoxycarbonylphenyl) urea was saponified according to Method D3 to give N-(4-chloro-3-(trifluoromethyl) phenyl-N′-(4-carboxyphenyl) urea. N-(4-Chloro-3-(trifluoromethyl)phenyl-N′-(4-carboxyphenyl) urea was coupled with 3-methylcarbamoylaniline according to Method D1b to give N-(4-chloro-3-(trifluoromethyl)phenyl-N′-(4-(3-methylcarbamoylphenyl)carbamoylphenyl) urea.
- Entry 68: 5-(4-Aminophenoxy)-2-methylisoindoline-1,3-dione was synthesized according to Method A9. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 5-(4-aminophenoxy)-2-methylisoindoline-1,3-dione to afford the urea.
- Entry 69: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbarnoyl)phenylthio)aniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to afford the urea.
- Entry 70: 4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline was synthesized according to Method A10. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-(2-morpholin-4-ylethyl)carbamoyl)pyridyloxy)ianiline to afford the urea.
- Entry 71: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)-2-methoxyphenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy)aniline according to Method C1a to afford the urea. N-(4-Chloro-3-(trifluoromethyl) phenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxyphenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with 4-(2-aminoethyl)morpholine to afford the amide.
- Entry 72: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl)pyridyloxy) aniline according to Method C1a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)phenyl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with methylamine according to Method D4, Step 2 to afford the amide.
- Entry 73: 4-(3-(5-Methoxycarbonyl)pyridyloxy)aniline was synthesized according to Method A14. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl) pyridyloxy)aniline according to Method C1a to afford the urea. N-(5-(Trifluoromethyl)-2-methoxyphenyl)-N′-(4-(3-(5-methoxycarbonylpyridyl)oxy)pheryl) urea was saponified according to Method D4, Step 1, and the corresponding acid was coupled with N,N-dimethylethylenediamine according to Method D4, Step 2 to afford the amide.
- Entry 74: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to Method A2, Step 3b to form 4-chloro-N-(2-triisopropylsilyloxy) ethylpyridine-2-carboxamide. 4-chloro-N-(2-triisopropylsilyloxy) ethylpyridine-2-carboxamide was reacted with triisopropylsilyl chloride, followed by 4-aminophenol according to Method A17 to form 4-(4-(2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyaniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl) pyridyloxyaniline to afford N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(4-(2-(N-(2-triisopropylsilyloxy) ethylcarbamoyl)pyridyloxyphenyl) urea.
- Entry 75: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-(5-methoxycarbonyl) pyridyloxy)aniline according to Method C1f to afford the urea, which was coupled with 3-aminopyridine according to Method D1c.
- Entry 76: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with N-(4-acetylphenyl)piperazine according to Method D1c.
- Entry 77: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method Al 1. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 4-fluoroaniline according to Method D1c.
- Entry 78: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method[ A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 4-(dimethylamino)aniline according to Method D1c.
- Entry 79: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with N-phenylethylenediamine according to Method D1c.
- Entry 80: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-1-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 2-methoxyethylamine according to Method D1c.
- Entry 81: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 5.-amino-2-methoxypyridine according to Method D1c.
- Entry 82: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl) phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with 4-morpholinoaniline according to Method D1c.
- Entry 83: 4-(3-Carboxyphenoxy)aniline was synthesized according to Method A11. 4-Chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(3-carboxyphenoxy)aniline according to Method C1f to afford the urea, which was coupled with N-(2-pyridyl)lpiperazine according to Method D1c.
- Entry 84: 4-Chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to Method A2, Step 3b to form 4-chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide. 4-Chloro-N-(2-triisopropylsilyloxy)ethylpyridine-2-carboxamide was reacted with triisopropylsilyL chloride, followed by 4-aminophenol according to Method A17 to form 4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline. According to Method C1a, 4 -chloro-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyaniline to give N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(4-(2-(N-(2-triisopropylsilyloxy)ethylcarbamoyl)pyridyloxyphenyl) urea. The urea was deprotected according to Method D5 to afford N-(4-chloro-3-((trifluoromethyl)phenyl)-N′-(4-(4-(2-(N-(2-hydroxy)ethylcarbamoyl)pyridyloxyphenyl) urea.
- Entry 85: 4-(2-(N-Methylcarbaamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Bromo-3-(trifluoromethyl)aniline was converted to 4--bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -2) bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 86: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline to afford the urea.
- Entry 87: According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl ilsocyanate according to Method Bi. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline to afford the urea.
- Entry 88: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3b. The resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 89: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4-bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 90: According to Method A2, Step 4, 5-amino-2-methylphenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(2-(N-methylcarbamoyl)-4-pyridyloxy)-4-methylaniline to afford the urea.
- Entry 91: 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylarnine according to Method A2, Step 3b. The resulting 4-chloro-N,N-dimethyl-2-pyridinecarbox-aide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 92: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 4-aminothiophenol according to Method A2, Step 4 to give 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to afford the urea.
- Entry 93: 4-Chloro-N-methylpyridinecarboxamide was synthesized as described in Method A2, Step 3b. The chloropyridine was reacted with 3-aminothiophenol according to Method A2, Step 4 to give 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 3-(4-(2-(N-methylcarbamoyl)phenylthio)aniline to afford the urea.
- Entry 94: 4-(2-(N-(2-Morpholin-4-ylethyl)carbamoyl)pyridyloxy)aniline was synthesized according to Method A10. 4-Bromo-3-(trifluoromethyl)aniline was converted into 4-bromo-3-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -bromo-3-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-(2-Mo]pholin-4-ylethyl)carbamoyl)pyridyloxy)aniline to afford the urea.
- Entry 95: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbarnoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 96: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline was synthesized according to Method A6. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B 1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-2-chloroaniline afford the urea.
- Entry 97: According to Method A2, Step 4, 4-amino-2-chlorophenol was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, which had been synthesized according to Method A2, Step 3b, to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-2(1 (trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)-3-chloroaniline to aff
- Entry 98: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate as was reacted with 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 99: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine according to Method A2, Step 3b. The resulting 4-chloro-N-ethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N-ethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 100: 4-Chloropyridine-2-carbonyl chloride was reacted with dimethylamine according to Method A2, Step 3b. The resulting 4-chloro-N,N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 to give 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was synthesized according to Method A7. 4-Chloro-2-methoxy-5-(trifluoromethyl)aniline was converted into 4-chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate according to Method B1. According to Method C1a, 4 -chloro-2-methoxy-5-(trifluoromethyl)phenyl isocyanate was reacted with 4-(2-(N,N-dimethylcarbamoyl)-4-pyridyloxy)aniline to afford the urea.
- Entry 101: 4-Chloro-N-methyl-2-pyridinecarboxamide, which was synthesized according to Method A2, Step 3a, was reacted with 3-aminophenol according to Method A2, Step 4 to form 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. 2-Amino-3-methoxynaphthalene was synthesized as described Method A1. According to Method C3, 2-amino-3-methoxynaphthalene was reacted with bis(trichloromethyl) carbonate followed by 3-(-2-(N-methylcarbamoyl)-4-pyridyloxy)aniline to form the urea.
- Entry 102: 4-(2-(N-Methylcarbamoyl)-4-pyridyloxy)aniline was synthesized according to Method A2. 5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline was synthesized according to Method A4. 5-tert-Butyl-2-(2,5-dimethylpyrrolyl)aniline was reacted with CDI followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline according to Method C2d to afford the urea.
- Entry 103: 4-Chloro-N-methyl-2-pyridinecarboxamide was synthesized according to Method A2, Step 3b. 4 -Chloro-N-methyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to Method A2, Step 4 using DMAC in place of DMF to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. According to Method C2b, reaction of 3-amino-2-methoxyquinoline with CDI followed by 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline afforded bis(4-(2-(N-methylcarbamoyl)-4-pyridlyoxy)phenyl)urea.
- Listed in the Tables below are compounds which have been synthesized according to the Detailed Experimental Procedures given above:
- The compounds listed in Tables 1-6 below were synthesized according to the general methods shown above, and the more detailed exemplary procedures are in the entry listings above and characterizations are indicated in the tables.
TABLE 1 3-tert-Butylphenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 1 0.22 50% EtOAc/ 50% hexane 418 (M + H) + (HPLC ES − MS) A13 C3 2 0.58 50% EtOAc/ 50% hexane 403 (M + H) + (HPLC ES − MS) A13 C3 3 133- 135 0.68 100% EtOAc 448 (M + H) + (FAB) A8 C2d -
TABLE 2 5-tert-Butyl-2-methoxyphenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 4 5.93 448 (M + H) + (HPLC ES − MS) A13 B1 C1a 5 120- 122 0.67 100% EtOAc 478 (M + H) + (FAB) A8 C2d 6 0.40 50% EtOAc/ 50% hexane 460 (M + H) + (HPLC ES − MS) A3 C2d 7 0.79 50% EtOAc/ 50% hexane 446 (M + H) + (HPLC ES − MS) A12 C2d -
TABLE 3 5-(Trifluoromethyl)-2-methoxyphenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 8 250 (dec) 460 (M + H) + (FAB) A13 C2a 9 206- 208 0.54 10% MeOH/ 90% CH2Cl2 446 (M + H) + (HPLC ES − MS) A3 step 2, A8 step 4, B1, C1a 10 0.33 50% EtOAc/ 50% pet ether 445 (M + H) + (HPLC ES − MS) A13 C3 11 0.20 2% Et3N/ 98% EtOAc 461 (M + H) + (HPLC ES − MS) A2 C4 12 0.27 1% Et3N/ 99% EtOAc 447 (M + H) + (HPLC ES − MS) A2 C4 13 0.62 100% EtOAc 461 (M + H) + (FAB) A2 C2a 14 114- 117 0.40 1% Et3N/ 99% EtOAc 447 (M + H) + (FAB) A2 C4 15 232- 235 0.54 100% EtOAc 490 (M + H) + (FAB) A8 C2d 16 210- 213 0.29 5% MeOH/ 45% EtOAc/ 50% pet ether 475 (M + H) + (HPLC ES − MS) A5 B1 C1c 17 187- 188 0.17 50% EtOAc/ 50% pet ether 495 (M + H) + (HPLC ES − MS) A6 B1 C1a 18 0.48 100% EtOAc 475 (M + H) + (HPLC ES − MS) A2 step 4, B1 C1a 19 194- 196 0.31 5% MeOH/ 45% EtOAc/ 50% pet ether 475 (M + H) + (HPLC ES − MS) A2 B1 C1a 20 214- 216 0.25 5% MeOH/ 45% EtOAc/ 50% pet ether 495 (M + H) + (HPLC ES − MS) A2 C1a 21 208- 210 0.30 50% EtOAc/ 50% hexane 481 (M + H) + (HPLC ES − MS) A19 C2a 22 188- 190 0.30 70% EtOAc/ 50% hexane 447 (M + H) + (HPLC ES − MS) A15, step 4, C1a 23 0.50 70% EtOAc/ 30% hexane 472 (M + H) + (FAB) A3 B1 C1a 24 203- 205 0.13 100% EtOAc 479 (M + H) + (HPLC ES − MS) A2 B1 C1a 25 0.09 75% EtOAc/ 25% hexane 458 (M + H) + (HPLC ES − MS) A12 C2d 26 169- 171 0.67 50% EtOAc/ 50% pet ether 474 (M + H) + (HPLC ES − MS) A13 step 1, A13 step 4, A16, B1 C1a 27 218- 219 0.40 50% EtOAc/ 50% pet ether 477 (M + H) + (HPLC ES − MS) A2 step 3b, A2 step 4, B1, C1a 28 212- 214 0.30 40% EtOAc/ 60% hexane A9 B1 C1a 29 0.33 50% EtOAc/ 50% pet ether 474 (M + H) + (HPLC ES − MS) A2 step 3b, A2 step 4, B1, C1a 30 210- 211 A2 B1 C1a 31 210- 204 0.43 10% MeOH/ CH2Cl2 A14 B1 C1a D4 32 247- 249 0.57 10% MeOH/ CH2Cl2 A14 B1 C1a D4 33 217- 219 0.07 10% MeOH/ CH2Cl2 A14 B1 C1a D4 34 0.11 70% EtOAc/ 30% hexane A11 B1 C1f D1c 35 0.38 70% EtOAc/ 30% hexane A11 B1 C1f D1c 36 0.77 70% MeOH/ 30% hexane A11 B1 C1f D1c 37 0.58 70% EtOAc/ 30% hexane A11 B1 C1f D1c 38 0.58 70% EtOAc/ 30% hexane A11 B1 C1f D1c 39 0.17 70% EtOAc/ 30% hexane A11 B1 C1f D1c 40 0.21 70% EtOAc/ 30% hexane A11 B1 C1f D1c -
TABLE 4 3-(Trifluoromethyl)-4-chlorophenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 41 163- 165 0.08 50% EtOAc/ 50% pet ether 464 (M + H) + (HPLC ES − MS) A13 C3 42 215 0.06 50% EtOAc/ 50% pet ether 465 (M + H) + (HPLC ES − MS) A2 C1a 43 0.10 50% EtOAc/ 50% pet ether 451 (M + H) + (HPLC ES − MS) A2 C1a 44 0.25 30% EtOAc/ 70% pet ether 465 (M + H) + (HPLC ES − MS) A2 C1a 45 0.31 30% eEtOAc/ 70% pet ether 465 (M + H) + (HPLC ES − MS) A2 C1a 46 176- 179 0.23 40% EtOAc/ 60% hexane 476 (M + H) + (FAB) A3 C1a 47 0.29 5% MeOH/ 45% EtOAc/ 50% pet ether 478 (M + H) + (HPLC ES − MS) A5 C1c 48 206- 209 A15 C1a 49 147- 151 0.22 50% EtOAc/ 50% pet ether 499 (M + H) + (HPLC ES − MS) A6 C1a 50 0.54 100% EtOAc 479 (M + H) + (HPLC ES − MS) A2 C1a 51 187- 189 0.33 5% MeOH/ 45% EtOAc/ 50% pet ether 479 (M + H) + (HPLC ES − MS) A2 C1a 52 219 0.18 5% MeOH/ 45% EtOAc/ 50% pet ether 499 (M + H) + (HPLC ES − MS) A2 C1a 53 246- 248 0.30 50% EtOAc/ 50% hexane 485 (M + H) + (HPLC ES − MS) A19, C1a 54 196- 200 0.30 70% EtOAc/ 30% hexane) 502 (M + H) + (HPLC ES − MS) A15 C1a 55 228- 230 0.30 30% EtOAc/ 70% CH2Cl2 466 (M + H) + (HPLC ES − MS) 56 238- 245 57 221- 222 0.75 80% EtOAc/ 20% hexane 492 (M + H) + (FAB) C1d D1a 58 247 0.35 100% EtOAc C1d D1a D2 59 198- 200 0.09 100% EtOAc 479 (M + H) + (HPLC ES − MS) A2 C1a 60 158- 160 0.64 50% EtOAc/ 50% pet ether 61 195- 197 0.39 10% MeOH/ CH2Cl2 A13 C1a 62 170- 172 0.52 10% MeOH/ CH2Cl2 A13 C1a 63 168- 171 0.39 10% MeOH/ CH2Cl2 A13 C1a 64 176- 177 0.35 10% MeOH/ CH2Cl2 A13 C1a 65 130- 133 487 (M + H) + (HPLC ES − MS) A2 B1 C1a 66 155 A2 C1a 67 225- 229 0.23 100% EtOAc C1e D3 D1b 68 234- 236 0.29 40% EtOAc/ 60% hexane A9 C1a 69 0.48 50% EtOAc/ 50% pet ether 481 (M + H) + (HPLC ES − MS) 70 0.46 5% MeOH/ 95% CH2Cl2 564 (M + H) + (HPLC ES − MS) A10 C1a 71 199- 201 0.50 10% MeOH/ CH2Cl2 A14 C1a D4 72 235- 237 0.55 10% MeOH/ CH2Cl2 A14 C1a D4 73 200- 201 0.21 50% MeOH/ CH2Cl2 A14 C1a D4 74 145- 148 75 0.12 70% EtOAc/ 30% hexane 527 (M + H) + (HPLC ES − MS) A11 C1f D1c 76 0.18 70% EtOAc/ 30% hexane A11 C1f D1c 77 0.74 70% EtOAc/ 30% hexane A11 C1f D1c 78 0.58 70% EtOAc/ 30% hexane A11 C1f D1c 79 0.47 70% EtOAc/ 30% hexane 569 (M + H) + (HPLC ES − MS) A11 C1f D1c 80 0.18 70% EtOAc/ 30% hexane 508 (M + H) + (HPLC ES − MS) A11 C1f D1c 81 0.58 70% EtOAc/ 30% hexane 557 (M + H) + (HPLC ES − MS) A11 C1f D1c 82 0.37 70% EtOAc/ 30% hexane 611 (M + H) + (HPLC ES − MS) A11 C1f D1c 83 0.19 70% EtOAc/ 30% hexane A11 C1f D1c 84 179- 183 A2 A17 C1a D5 -
TABLE 5 3-(Trifluoromethyl)-4-bromophenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 85 186- 187 0.13 50% EtOAc/ 50% pet ether 509 (M + H) + (HPLC ES − MS) A2 B1 C1a 86 150- 152 0.31 50% EtOAc/ 50% pet ether 545 (M + H) + (HPLC ES − MS) A6 B1 C1a 87 217- 219 0.16 50% EtOAc/ 50% pet ether 545 (M + H) + (HPLC ES − MS) A2 B1 C1a 88 183- 184 0.31 50% EtOAc/ 50% pet ether 525 (M + H) + (HPLC ES − MS) A2 B1 C1a 89 0.21 50% EtOAc/ 50% pet ether 511 (M + H) + (HPLC ES − MS) A2 B1 C1a 90 0.28 50% EtOAc/ 50% pet ether 525 (M + H) + (HPLC ES − MS) A2 B1 C1a 91 214- 216 0.28 50% EtOAc/ 50% pet ether 522 (M + H) + (HPLC ES − MS) A2 B1 C1a 92 0.47 50% EtOAc/ 50% pet ether 527 (M + H) + (HPLC ES − MS) A2 step 3b, A2 step 4, B1, C1a 93 0.46 50% EtOAc/ 50% pet ether 527 (M + H) + (HPLC ES − MS) A2 step 3b, A2 step 4, B1, C1a 94 145- 150 0.41 5% MeOH/ 95% CH2Cl2 A10 B1 C1a -
TABLE 6 5-(Trifluoromethyl)-4-chloro-2-methoxyphenyl Ureas TLC Mass mp HPLC TLC Solvent Spec. Synth. Entry R (° C.) (min.) Rf System [Source] Method 95 140- 144 0.29 5% MeOH/ 45% EtOAc/ 50% pet ether 495 (M + H) + (HPLC ES − MS) A2 A7 B1 C1a 96 244- 245 0.39 5% MeOH/ 45% EtOAc/ 50% pet ether 529 (M + H) + (HPLC ES − MS) A6 A7 B1 C1a 97 220- 221 0.25 5% MeOH/ 45% EtOAc/ 50% pet ether 529 (M + H) + (HPLC ES − MS) A2 A7 B1 C1a 98 0.27 5% MeOH/ 45% EtOAc/ 50% pet ether 495 (M + H) + (HPLC ES − MS) A2 A7 B1 C1a 99 180- 181 0.52 5% MeOH/ 45% EtOAc/ 50% pet ether 509 (M + H) + (HPLC ES − MS) A2 A7 B1 C1a 100 162- 165 A2 A7 B1 C1a -
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (67)
1. A compound of Formula I:
A—D—B (I)
or a pharmaceutically acceptable salt thereof, wherein
D is -NH—C(O)-NH—,
A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L1)q, where L is a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and
B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,
wherein L1 is substituted by at least one substituent selected from the group consisting of —SO2Rx, —C(O)R, and —C(NRy) Rz,
Ry is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,
Rz is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
Rx is Rz or NRaRb where Ra and Rb are
a) independently hydrogen,
a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
—OSi(Rf)3 where Rf is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
where B is substituted, L is substituted or L1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting of —CN, —CO2R7, —C(O)NR7R7, —C(O)—R7, —NO2, —OR7, —SR7,—NR7R7,—NR7C(O)R7,—NR7C(O)R7, —Q—Ar and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, —OR7, —SR7, — NR7R7, —NO2, —NR7C(O)R7, —NR7C(O)OR7 and halogen up to per-halo; with each R7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2),— CHXa, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, and Xa is halogen; and
Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Zni, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, — NO2, —OR7, —SR7 —NR7R7, —NR7C(O)OR7, —NR7C(O)R7, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —C02R7, —COR7 —C(O)NR7R7, —OR7, —SR7, —NO2, —NR7R7, —NR7C(O)R7, and —NR7C(O)OR7, with R7 as defined above.
2. A compound as in wherein:
claim 1
Ry is hydrogen, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl having 0-3 heteroatoms, C2-10 alkenyl, C1-10 alkenoyl, C6-12 aryl, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C7-24 aralkyl, C7-24 alkaryl, substituted C1-10 alkyl, substituted C1-10 alkoxy, substituted C3-10 cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C6 -C14 aryl, substituted C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C7-24 alkaryl or substituted C7-C24 aralkyl, where Ry is a substituted group, it is substituted by halogen up to per halo,
Rz is hydrogen, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl having 0-3 heteroatom, C2-10 alkenyl, C1-10 alkenoyl, C6-12 aryl, C3 -C12 hetaryl having 1-3 heteroatoms selected firom, S, N and O, C7-24 alkaryl, C7-24 aralkyl, substituted C1-10 alkyl, substituted C1-10 alkoxy, substituted C6-C14 aryl, substituted C3 -C10 cycloalkyl having 0-3 heteroatoms selected from S, N and O, substituted C3-12 hetaryl having 1-3 heteroatoms selected from S, N and O, substituted C7-24 alkaryl or substituted C7-C24 aralkyl where R, is a substituted group, it is substituted by halogen up to per halo, hydroxy, C1-10 alkyl, C3-12 cycloalkyl having 0-3 heteroatomlos selected from O, S and N, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C1-10 alkoxy, C6-12 aryl, C1-6 halo substituted alkyl up to per halo alkyl, C6-C12halo substituted aryl up to per halo aryl, C3-C12 halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted C3-C12hetaryl up to per halo hetaryl having 1-3 heteroatoms selected from 0, N and S, halo substituted C7-C24 aralkyl up to per halo aralkyl, halo substituted C7-C24 alkaryl up to per halo alkaryl, and —C(O)Rg,
Ra and Rb are,
a) independently hydrogen,
a carbon based moiety selected from te group consisting of C1-C10 alkyl, C1-C10 alkoxy, C3-10 cycloalkyl, C2-10 alkenyl, C1-10 alkenoyl, C6-12 aryl, C3-12 hetaryl having 1-3 heteroatoms selected from O, N and S, C3-12 cycloalkyl having 0-3 heteroatoms selected from N, S and O, C7-24 aralkyl, C7-C24 alkaryl, substituted C1-10 alkyl, substituted C1-10 alkoxy, substituted C3-10 cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C6-12 aryl, substituted C3-10 hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C7-24 aralkyl, substituted C7-24 alkaryl, where Ra and Rb are a substituted group, they are substituted by halogen up to per halo, hydroxy, C1-10 alkyl, C3-12 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C1-10 alkoxy, C6-12 aryl, C1-6 halo substituted alkyl up to per halo alkyl, C6-C12halo substituted aryl up to per halo aryl, C3-C12halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C3-C12 hetaryl up to per halo heteraryl, halo substituted C7-C24 aralkyl up to per halo aralkyl, halo substituted C7-C24 alkaryl up to per halo alkaryl, and —C(O)Rg; or
—OSi(Rf)3 where Rf is hydrogen, C1-10 alkyl, C1-10 alkoxy, C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C6-12 aryl, C3-C12 hetaryl having 1-3 heteroatoms selected from O, S and N, C7-24 aralkyl, substituted C1-10 alkyl, substituted C1-C10 alkoxy, substituted C3-C12cycloalkyl having 0-3 heteroatoms selected from O, S and N, substituted C3-C12 heteraryl having 1-3 heteroatoms selected from O, S, and N, substituted C6-12 aryl, and substituted C7-24 alkaryl, where Rf is a substituted group it is substituted halogen up to per halo, hydroxy, C1-10 alkyl, C3-12 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C1-10 alkoxy, C6-12 aryl, C7 -C24 alkaryl, C7 -C24 aralkyl, C1-6 halo substituted alkyl up to per halo alkyl, C6-C12halo substituted aryl up to per halo aryl, C3-C12halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C3-C12hetaryl up to per halo heteraryl, halo substituted C7-C24 aralkyl up to per halo aralkyl, halo substituted C7-C24 alkaryl up to per halo alkaryl, and —C(O)Rg,
or
b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O with substituents selected from the group consisting of halogen up to per halo, hydroxy, C1-10 alkyl, C3-12 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C1-10 alkoxy, C6-12 aryl, C7 -C24 alkaryl, C7 -C24 aralkyl, halo substituted C1-6 alkyl up to per halo alkyl, halo substituted C6-12 aryl up to per halo aryl, halo substituted C3-C12cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C3-C12hetaryl up to per halo heteraryl, halo substituted C7-C24 aralkyl up to per halo aralkyl, halo substituted C7-C24 alkaryl up to per halo alkaryl, and —C(O)Rg,
or
c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members,
wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, C1-10 alkyl, C3-12 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C3-12 hetaryl having 1-3 heteroatoms selected from N, S and O, C1-10 alkoxy, C6-12 aryl, C7 -C24 alkaryl, C7 -C24 aralkyl, C1-6 halo substituted alkyl up to per halo alkyl, C6-C21halo substituted aryl up to per halo aryl, C3-C12halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C3-C12hetaryl up to per halo heteraryl, halo substituted C7-C24 aralkyl up to per halo aralkyl, halo substituted C7-C24 alkaryl up to per halo alkaryl, and —C(O)Rg,
where Rg is C1-10 alkyl; —CN, —CO2Rd, —OR, —SRd, —NO2, —C(O) Re, —NRdRe—NRd C(O)ORe and —NRd C(O)Re, and Rd and Re are independently selected from the group consisting of hydrogen, C1-10, alkyl, C1-10 alkoxy, C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, N and S, C6-12 aryl, C3- C12 hetaryl with 1-3 heteroatoms selected from O, N and S and C7 -C24 aralkyl, C7 -C24 alkaryl, up to per halo substituted C1-C10 alkyl, up to per halo substituted C3 -C10 cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per halo substituted C6 -C14 aryl, up to per halo substituted C3 -C12hetaryl having 1-3 heteroatoms selected from O, N, and S, halo substituted C7-C24 alkaryl up to per halo alkaryl, and up to per halo substituted C7-C24 aralkyl,
W is independently selected from the group consisting of —CN, —CO2R7, —C(O)NR7R7, —C(O)—R7, —NO2, OR7, —SR7, —NR7R7, —NR7C(O)OR7, —NR7C(O)R7, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C1-C10 alkenoyl, C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C6-C14 aryl, C7-C24 alkaryl, C7 -C24 aralkyl, C3-C12heteroaryl having 1-3 heteroatoms selected from O, N and S, C4-C23 alkheteroaryl having 1-3 heteroatoms selected from O. N and S, substituted C1-C10 alkyl, substituted C1-C10 alkoxy, substituted C2-C10 alkenyl, substituted C1-C10 alkenoyl, substituted C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C6-C12aryl, substituted C3-C12 hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C7-C24 aralkyl, substituted C7-C24 alkaryl, substituted C4-C23 alkheteroaryl having 1-3 heteroatoms selected from O, N and S, and —Q— Ar;
R7 is independently selected from H, C1-C10 alkyl, C1-Cio alkoxy, C2-C10 alkenyl, C1-C10 alkenoyl, C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, S and N, C6-Cl4 aryl, C 3-C13 hetaryl having 1-3 heteroatoms selected from O, N and S, C7-C14 alkaryl, C7 -C24 aralkyl, C4-C23 alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C1-C10 alkyl, up to per-halosubstituted C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C6-C14 aryl, up to per-halosubstituted C3-C13 hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C7-C24 aralkyl, up to per-halosubstituted C7-C24 alkaryl, and up to per-halosubstituted C4-C23 alkheteroaryl; and
each Z is independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, —NO2, —OR7, —SR7 —NR7R7, —NR7C(O)R7, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C1-C10 alkenoyl, C3-C10 cycloalkyl having 0-3 heteroatorms selected from O, N and S, C6-C14 aryl, C3-C13 hetaryl having 1-3 heteroatoms selected from O, N and S, C7-C24 alkaryl, C7 -C24 aralkyl, C4-C23 alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C1-C10 alkyl, substituted C1-C10 alkoxy, substituted C2-C o alkenyl, substituted C1-C10 alkenoyl, substituted C3-C10 cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C6-C12aryl, substituted C7-C24 alkaryl, substituted C7-C24 aralkyl and substituted C4-C23 alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of —CN, —CO2R7, —COR7, —C(O)NR7R7, —OR7, —SR7, —NO2, —NR7R7 —NR7C(O)R7, and —NR7C(O)OR7.
3. A compound as in wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m, CHXa—, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, Xa is halogen and R7is as defined in .
claim 1
claim 1
4. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by—OH.
claim 1
5. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.
claim 1
6. A compound of wherein B of Formula I is a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.
claim 1
7. A compound of wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in , a pyrimidinyl group substituted by a substituent selected from the group constituting of halogen and Wn, whereas W and n are as defined in , or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and Wn wherein W and n are as defined in .
claim 1
claim 1
claim 1
claim 1
8. A compound of wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyrridyl group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of —CN, halogen, C1-C10 alkyl, C1-C10 alkoxy, —OH, up to per halo substituted C1-C10 alkyl, up to per halo substituted C1-C10 alkoxy or phenyl substituted by halogen up to per halo.
claim 6
9. A compound of , wherein L, the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfuw with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and Wn wherein W and n are as defined in .
claim 1
claim 1
10. A compound of , wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.
claim 8
11. A compound of , wherein said substituted cyclic moiety L1 comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur.
claim 1
12. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 1
13. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 3
14. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 6
15. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 8
16. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 9
17. A compound of , wherein said substituted cyclic moiety L1 is phenyl, pyridinyl or pyrimidinyl.
claim 10
18. A compound of , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m— CHXa—, CXa 2—, —S—(CH2)m— and N(R7)(CH2)m—, where m=1-3, Xa is halogen and R7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.
claim 14
19. A compound of , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, (CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m— CHXa—, —CXa 2, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, Xa is halogen and R7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.
claim 15
20. A compound of , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m—CHXa—, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, Xa is halogen and R7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.
claim 16
21. A compound of , wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, (CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m— CHXa—, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where —m=1-3, Xa is halogen and R7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.
claim 17
22. A compound of wherein L1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-C10 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 1
23. A compound of wherein L1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-C10 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 13
24. A compound of wherein L1 is additionally substituted 1 to 3 times by to one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-Ci0 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 18
25. A compound of wherein L1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-C10 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 19
26. A compound of wherein L1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-C10 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C0 alkoxy.
claim 20
27. A compound of wherein L1 is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C1-C10 alkyl, up to per halo substituted C1-C10 alkyl, —CN, —OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 21
28. A compound of wherein L1 is substituted by —C(O)Rx.
claim 1
29. A compound of wherein L1 is substituted by —SO2Rx.
claim 1
30. A compound of wherein L1 is substituted only by —C(O)Rx.
claim 1
31. A compound of wherein L1 is substituted only by —SO2Rx.
claim 1
32. A compound of wherein L1 is substituted by —C(O)Rx or —SO2Rx, wherein Rx is NRaRb.
claim 1
33. A compound of wherein L1 is substituted by —C(O)Rx or -SO2Rx, wherein Rx is NRaRb, and Ra and Rb are
claim 13
a) independently hydrogen,
a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
—OSi(Rf )3 where Rf is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carlbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
34. A compound of wherein L1 is substituted by —C(O)R, or —SO2Rx, wherein Rx is NRaRb and Ra and Rb are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
claim 18
35. A compound of wherein L1 is substituted by —C(O)Rx, wherein Rx is NRa Rb and Ra and Rb are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
claim 19
36. A compound of wherein L1 is substituted by —C(O)Rx or —SO2Rx, wherein Rx is NRaRb and Ra and Rb are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
claim 20
37. A compound of wherein L1 is substituted by —C(O)R, or —SO2Rx, wherein Rx is NRaRb and Ra and Rb are independently hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
claim 21
38. A compound of Formula I:
A—D—B (I)
or a pharmaceutically acceptable salt thereof, wherein
D is -NH—C(O)-NH—,
A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L1)q, where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and
B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,
wherein L1 is substituted by at least one substituent selected from the group consisting of —SO2Rx, —C(O)Rx and —C(NRy)Rz,
Ry is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,
Rz is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
Rx is Rz or NRaRb where Ra and Rb are
a) independently hydrogen,
a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
—OSi(Rf)3 where Rf is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic slructure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
where B is substituted, L is substituted or L1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting of —CN, —CO2R7, —C(O)NR7R7, —C(O)—R7, —NO2, —OR7, —SR7, —NR7R7,—NR7C(O)OR7, —NR7C(O)R7, —Q—Ar and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, —OR7, —SR7, — NR7R7, —NO2, —NR7C(O)R7, —NR7C(0)0R7 and halogen up to per-halo; with each R7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m—CHXa, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, and Xa is halogen;
Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Zni, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(C)NR7R7, —NO2, —OR7, —SR7 —NR7R7, —NR7C(O)OR7, —NR7C(O)R7, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of —CN, —CO2R7 —COR7 —C(O)NR7R7, —OR7, —SR7, —NO2, —NR7R7, —NR7C(O)R7, and —NR7C(O)R7, with R7 as defined above; and
wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)nS—, —(CH2)mN(R7)—, —O(CH2)n—CHXa —, CXa 2, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, Xa is halogen.
39. A compound of Formnula I:
A—D—B (I)
or a pharmaceutically acceptable salt thereof, wherein
D is -NH—C(O)-NH—,
A is a substituted moiety of up to 40 carbon atoms of the formula: —L—(M—L1)q, where L is a substituted or unsubstituted phenyl or peritoneal moiety bound directly to D, L1 comprises a substituted phenyl, peritoneal or pyrimidinyl moiety, M is a bridging group having at least one atom, q is an integer of from 1-3; and
B is a substituted or unsubstituted phenyl or pyridine group bound directly to D,
wherein L1 is substituted by at least one substituent selected from the group consisting of —SO2Rx, —C(O)R, and —C(NRy) Rz,
Ry is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and;
Rz is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
Rx is R, or NRaRb where Ra and Rb are
a) independently hydrogen,
a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or
—OSi(Rf )3 where Rf is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or
b) Ra and Rb together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, and O and are optionally substituted by halogen; or
c) one of Ra or Rb is —C(O)—, a C1-C5 divalent alkylene group or a substituted C1-C5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C1-C5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
where B is substituted, L is substituted or L1is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;
wherein each W is independently selected from the group consisting of —CN, —CO2R7, —C(O)NR7R7, —C(O)—R7, —NO2, —OR7, -SR7, —NR7R7 —NR7C(O)0R7 —NR7C(O)R7 -Q-Ar and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatorms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, —R7, —R7, —NR7R7, —NO2, —NR7C(O)R7, —NR7C(O)OR7 and halogen up to per-halo; with each R7 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is —O—, —S—, —N(R)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —,(CH2)mS—, —(CH2)mN(R7)—, —O(CH2)m- CHXa —, —CXa 2—, —S—(CH2)mand —N(R7)(CH2)m—, where m=1-3, and Xa is halogen;
Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Zni, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of —CN, —CO2R7, —C(O)R7, —C(O)NR7R7, NO2, —OR7, —SR7 —NR7R7, —NR7C(O)NR —NR7C(O)R7, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of —CN, —CO2R7, —COR7, —C(O)NR7R7, —OR7, —SR7, —NO2, —NR7R7, —NR7C(O)R7, and —NR7C(O)OR7; and
wherein M is one or more bridging groups selected from the group consisting of —O—, —S—, —N(R7)—, —(CH2)m—, —C(O)—, —CH(OH)—, —(CH2)mO—, —(CH2)mS—, —(CH2)mN(R7)—, O(CH2)m—CHXa—, —CXa 2—, —S—(CH2)m— and —N(R7)(CH2)m—, where m=1-3, Xa is halogen.
40. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by—OH.
claim 38
41. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.
claim 38
42. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by—OH.
claim 39
43. A compound as in wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by a moiety having an ionizable hydrogen and a pKa of 10 or less.
claim 39
44. A compound as in wherein substituents for B and L and additional substituents for L1, are selected from the group consisting of C1-C10 alkyl up to per halo substituted C1-C10 alkyl, CN, OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 38
45. A compound as in wherein substituents for B and L and additional substituents for L1, are selected from the group consisting of C1-C10 alkyl up to per halo substituted C1-C10 alkyl, CN, OH, halogen, C1-C10 alkoxy and up to per halo substituted C1-C10 alkoxy.
claim 39
46. A compound of wherein L1 is substituted by C(O)Rx or SO2Rx.
claim 38
47. A compound of wherein L1 is substituted by C(O)Rx or SO2Rx.
claim 39
48. A compound of wherein Rx is NRaRb and Ra and Rb are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen..
claim 46
49. A compound of wherein Rx is NRaRb and Ra and Rb are independently hydrogen and a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.
claim 47
50. A compound of which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
claim 1
and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
51. A compound of which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of
claim 2
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
52. A compound of which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of
claim 33
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
53. A compound of which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of
claim 38
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), l-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, is fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
54. A compound of which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of
claim 39
a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.
55. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.
claim 1
56. A pharmaceutical composition comprising a compound of consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
claim 2
57. A pharmaceutical composition comprising a compound of consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
claim 33
58. A pharmaceutical composition comprising a compound of consistent with formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
claim 38
59. A pharmaceutical composition comprising a compound of consistent with formula I or a pharmaceutically acceptable salt thereof and a physiologically acceptable carrier.
claim 39
60. A compound selected from the group consisting of
3-tert butyl phenyl ureas of Table 1 above;
5-tert butyl-2-methoxyphenyl ureas of Table 2 above;
5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;
3-(trifluoromethyl) - chlorophenyl ureas of Table 4 above;
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;
5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and ureas 01-103 in Table 7 above.
61. A compound selected from the group consisting of the 3-tert butyl phenyl ureas:
N-(3-tert-butylphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl urea and
N-(3-tert-butylphenyl)-N′-(4-(4-acetylphenoxy)phenyl urea;
the 5-tert-butyl-2-methoxyphenyl ureas:
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(4-methoxy-3-(N-methylcarbamoyl)phenoxy)phenyl) urea and
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl) urea;
the 2-methoxy-5-trifluoromethyl)phenyl ureas:
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyp)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5.-(tnfluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;
the 4-chloro-3-(trifluoromethyl)phenyl ureas:
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3 -(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and
N-(4-chloro-3 -(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.
the 4-romo-3-(trifluoromethyl)phenyl ureas:
N-(4-bromo-3 -(trifluoromethyl)phenyl) -N′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3 -(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and
the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbarnoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylearbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.
62. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of .
claim 1
63. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of .
claim 33
64. A method for the treatment of a cancerous cell growth mediated by r af kinase, comprising administering a compound of Formula I of .
claim 38
65. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of .
claim 39
66. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of 3-tert butyl phenyl ureas of Table 1 above;
5-tert butyl-2-methoxyphenyl ureas of Table 2 above;
5-(trifluoromethyl)-2 phenyl ureas of Table 3 above;
3-(trifluoromethyl) 4 chlorophenyl ureas of Table 4 above;
3-(trifluoromethyl)-4-bromophenyl ureas of Table 5 above;
5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ureas of Table 6 above; and ureas 101-103 in Table 7 above.
67. A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administrating a compound selected from the group consisting of the 3-tert butyl phenyl ureas:
N-(3-tert-butylphenyl)-N′-(4-(3-(N-methylcarbamoyl)phenoxy)phenyl urea and
N-(3-tert-butylphenyl)-N′-(4-(4-acetylphenoxy)phenyl urea;
the 5-tert-butyl-2-methoxyphenyl ureas:
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1,3-dioxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(1-oxoisoindolin-5-yloxy)phenyl) urea,
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(4-methoxy-3 -(N-methylcarbamoyl)phenoxy)phenyl) urea and
N-(5-tert-butyl-2-methoxyphenyl)-N′-(4-(3 -(N-methylcarbamoyl)phenoxy)phenyl) urea;
the 2-methoxy-5-trifluoromethyl)phenyl ureas:
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-N′-(3-chloro-4-(2-(N-methylcarbamcoyl)(4-pyridyloxy))phenyl) urea;
the 4-chloro-3-(trifluoromethyl)phenyl ureas:
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl )-4-pyridylox, phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2- carbamoyl-4-pyridyloxy) phenyl) urea and N-(4-chloro-3 -urea;
the 4-romo-3-(trifluoromethyl)phenyl ureas:
N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3 -(trifluoromethyl)phenyl) -N′-(3-(2-(N-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(4-bromo-3 -(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(4-bromo-3 -(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and
the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -(2-(N-methylcarbaamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(2-chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-N′-(3 -chloro-4-(2-(N-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/773,672 US20010016659A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11587799P | 1999-01-13 | 1999-01-13 | |
US25726699A | 1999-02-25 | 1999-02-25 | |
US42522899A | 1999-10-22 | 1999-10-22 | |
US09/773,672 US20010016659A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US42522899A Continuation | 1999-01-13 | 1999-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010016659A1 true US20010016659A1 (en) | 2001-08-23 |
Family
ID=56290111
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/773,604 Abandoned US20010034447A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US09/773,672 Abandoned US20010016659A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US09/773,658 Abandoned US20010027202A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors |
US09/773,675 Abandoned US20010011136A1 (en) | 1999-01-13 | 2001-02-02 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors |
US09/773,659 Abandoned US20010011135A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors |
US09/948,915 Abandoned US20020042517A1 (en) | 1999-01-13 | 2001-09-10 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US10/071,248 Expired - Fee Related US7528255B2 (en) | 1999-01-13 | 2002-02-11 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors |
US11/845,595 Abandoned US20080032979A1 (en) | 1999-01-13 | 2007-08-27 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/773,604 Abandoned US20010034447A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/773,658 Abandoned US20010027202A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors |
US09/773,675 Abandoned US20010011136A1 (en) | 1999-01-13 | 2001-02-02 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors |
US09/773,659 Abandoned US20010011135A1 (en) | 1999-01-13 | 2001-02-02 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors |
US09/948,915 Abandoned US20020042517A1 (en) | 1999-01-13 | 2001-09-10 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US10/071,248 Expired - Fee Related US7528255B2 (en) | 1999-01-13 | 2002-02-11 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors |
US11/845,595 Abandoned US20080032979A1 (en) | 1999-01-13 | 2007-08-27 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors |
Country Status (5)
Country | Link |
---|---|
US (8) | US20010034447A1 (en) |
EP (1) | EP1140840B1 (en) |
CY (2) | CY1105286T1 (en) |
FR (1) | FR06C0034I2 (en) |
WO (1) | WO2000042012A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
WO2007089445A2 (en) | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
US20080242707A1 (en) * | 2005-03-07 | 2008-10-02 | Bayer Healthcare Ag | Pharmaceutical Composition for the Treatment of Cancer |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
WO2010108665A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
WO2011130728A1 (en) | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions |
US8076488B2 (en) | 2003-02-28 | 2011-12-13 | Bayer Healthcare Llc | Bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2012044577A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
WO2012129448A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
EP2589384A1 (en) | 2004-08-27 | 2013-05-08 | Bayer Healthcare LLC | New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
PE20020506A1 (en) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS |
GB2367817A (en) * | 2000-10-09 | 2002-04-17 | Bayer Ag | Cyclic carboxylic acids as integrin antagonists |
JP3712393B2 (en) | 2000-10-20 | 2005-11-02 | エーザイ株式会社 | Nitrogen-containing aromatic ring derivatives |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1379505B1 (en) * | 2001-04-20 | 2007-02-28 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
RS52500B (en) * | 2001-12-03 | 2013-04-30 | Bayer Healthcare Llc | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US7307071B2 (en) * | 2001-12-04 | 2007-12-11 | Onyx Pharmaceuticals, Inc | RAF-MEK-ERK pathway inhibitors to treat cancer |
EP1463505A2 (en) * | 2001-12-13 | 2004-10-06 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
AU2003217182A1 (en) * | 2002-01-11 | 2003-07-30 | University Of Virginia Patent Foundation | Development of novel regulators of angiogenesis |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
CN100369898C (en) * | 2002-02-12 | 2008-02-20 | 史密丝克莱恩比彻姆公司 | Nicotinamide derivates useful as p38 inhibitors |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
EA007987B1 (en) | 2002-03-29 | 2007-02-27 | Чирон Корпорейшн | Substituted benzazoles and use thereof as raf kinase inhibitors |
TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
WO2004014870A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
US7056925B2 (en) | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
US7115644B2 (en) * | 2002-09-13 | 2006-10-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds |
EP2426122A1 (en) | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylene urea derivative as RAF kinasse inhibitors |
NZ626589A (en) * | 2003-02-21 | 2016-01-29 | Resmed Ltd | Nasal assembly |
WO2004078128A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
ES2357288T3 (en) * | 2003-02-28 | 2011-04-25 | Bayer Healthcare Llc | DERIVATIVES OF 2-OXO-1,3,5-PERHYDROTRIAZAPINE USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE ANGIOGENESIS AND INFLAMMATORY DISORDERS. |
WO2004078748A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
JP2006521304A (en) * | 2003-03-24 | 2006-09-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Oxamide derivatives useful as raf kinase inhibitors |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
KR20060025141A (en) | 2003-05-15 | 2006-03-20 | 아르퀼 인코포레이티드 | Inhibitors of p38 and methods of using the same |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
CA2531485C (en) * | 2003-07-07 | 2013-03-26 | Merck Patent Gmbh | Malonamide derivatives |
AU2013200394B2 (en) * | 2003-07-23 | 2015-07-09 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
AU2004281151A1 (en) | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and use thereof as inhibitors of Raf kinase |
US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
US20050282909A1 (en) * | 2003-11-14 | 2005-12-22 | Diks Sander H | Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction |
EP1689376A2 (en) * | 2003-11-28 | 2006-08-16 | Novartis AG | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
EP1692110A1 (en) * | 2003-12-10 | 2006-08-23 | MERCK PATENT GmbH | Diacylhydrazine derivatives |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
CA2564325A1 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
WO2006014012A2 (en) | 2004-08-06 | 2006-02-09 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
AU2011244932B9 (en) * | 2004-08-27 | 2014-06-12 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
WO2006030826A1 (en) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | Medicinal composition |
PL1797037T3 (en) | 2004-09-29 | 2015-07-31 | Bayer Healthcare Llc | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide |
SI1797038T1 (en) | 2004-09-29 | 2012-10-30 | Bayer Pharma AG | Thermodynamically stable form of bay 43-9006 tosylate |
ES2365858T3 (en) | 2004-10-13 | 2011-10-11 | Merck Patent Gmbh | FENILUREA DERIVATIVES AS INHIBITING SUBSTANCE OF TYROSINE-KINASES FOR THE TREATMENT OF TUMOR DISEASES. |
JP2008517064A (en) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Synthesis of imidazooxazole and imidazothiazole inhibitors of P38 MAP kinase |
BRPI0606480A (en) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | pharmaceutical compounds |
DE102005015253A1 (en) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets |
EP1888065A2 (en) * | 2005-05-27 | 2008-02-20 | Bayer HealthCare AG | Combination therapy comprising diaryl ureas for treating diseases |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
WO2007015578A1 (en) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
EP1921078B1 (en) | 2005-08-05 | 2013-01-09 | Chugai Seiyaku Kabushiki Kaisha | Multikinase inhibitor |
EP2289515A3 (en) | 2005-10-31 | 2012-04-11 | Bayer HealthCare LLC | Combinations comprising a diaryl urea and an interferon |
CN101321529B (en) | 2005-12-05 | 2012-09-05 | 大塚制药株式会社 | Diaryl aether derivant as antineoplastic agent |
WO2007068395A1 (en) * | 2005-12-13 | 2007-06-21 | Arpida Ag | Diphenyl urea derivatives |
WO2007075650A2 (en) * | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
CN101443009A (en) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | Antitumor agent for thyroid cancer |
WO2007139930A2 (en) | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AU2007279595A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
UA95978C2 (en) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Stat3/5 activation inhibitor |
AR062927A1 (en) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
CA2669158A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008079972A2 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer |
EP2129376B1 (en) | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
WO2008115263A2 (en) * | 2007-03-20 | 2008-09-25 | Curis, Inc. | Raf kinase inhibitors containing a zinc binding moiety |
TW200900072A (en) * | 2007-03-22 | 2009-01-01 | Arete Therapeutics Inc | Soluble epoxide hydrolase inhibitors |
GB0706932D0 (en) * | 2007-04-10 | 2007-05-16 | Univ London Pharmacy | Ureylene derivatives |
AR066845A1 (en) | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | DERIVATIVES OF TRIAZOLOPIRIDINE AND IMIDAZOPIRIDINE A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER |
CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US8344135B2 (en) | 2007-08-29 | 2013-01-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US8445687B2 (en) | 2007-09-10 | 2013-05-21 | Cipla Limited | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process |
WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
EP2231612A1 (en) | 2008-01-17 | 2010-09-29 | Sicor, Inc. | Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
CL2009000447A1 (en) * | 2008-02-29 | 2010-01-04 | Array Biopharma Inc Y Genentech Inc | Compounds derived from (1h-pyrrolo {2,3-b} pyridin-5-yl) -sulfonamido-substituted benzamide; preparation procedure; pharmaceutical composition; and its use in the treatment of cancer, through the inhibition of raf. |
KR20100117686A (en) * | 2008-02-29 | 2010-11-03 | 어레이 바이오파마 인크. | Pyrazole [3,4-b] pyridine raf inhibitors |
EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
EP2156834A1 (en) | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
TW201012467A (en) * | 2008-09-16 | 2010-04-01 | Taiho Pharmaceutical Co Ltd | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
CA2741087A1 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
WO2010064611A1 (en) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
JO3101B1 (en) * | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | Benzothiazole derivatives as anticancer agents |
CN102317293A (en) * | 2008-12-05 | 2012-01-11 | 艾科尔公司 | RAF inhibitors and their uses |
FR2943670B1 (en) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2945210B1 (en) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB |
DE202009007976U1 (en) | 2009-06-05 | 2009-08-27 | Schebo Biopharm Ag | Novel pharmaceuticals and drug formulations which inhibit tumor cell proliferation and / or tumor vascularization and their action as multi-kinase inhibitors |
DE102009024296A1 (en) | 2009-06-05 | 2010-12-09 | Schebo Biotech Ag | New 1-(4-chloro-3-trifluoromethyl-phenyl)-3-(4-(pyridin-4-yloxy)-phenyl)-urea compounds useful to treat e.g. cancer, asthma, urticaria, arthritis, osteoarthritis, rheumatoid arthritis, sepsis, autoimmune diseases and multiple sclerosis |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
WO2011036647A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Process for the preparation of sorafenib tosylate |
CA2775296A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
EP2499116A1 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
WO2011076711A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
EP2633884A1 (en) | 2010-01-07 | 2013-09-04 | Akron Molecules GmbH | Obesity small molecules |
AU2011210326B2 (en) | 2010-01-29 | 2014-10-09 | Sun Pharmaceutical Industries Limited | Sorafenib dimethyl sulphoxide solvate |
CN102190616B (en) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production |
AR081060A1 (en) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | PROCEDURE TO PREPARE 4- {4 - [({[4-CHLORINE-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] -3-FLUOROPHENOXY} -N-METHYLPIRIDIN-2-CARBOXAMIDE |
BR112012032462A2 (en) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | antitumor agent employing compounds which, in combination, have kinase inhibiting effect. |
WO2012008563A1 (en) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | Nitrogenated aromatic heterocyclic ring derivative |
EP2595628A1 (en) | 2010-07-19 | 2013-05-29 | Bayer HealthCare LLC | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2012064774A1 (en) * | 2010-11-10 | 2012-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | An ire1alpha endonuclease specific inhibitor with cytotoxic activity |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012071425A1 (en) | 2010-11-22 | 2012-05-31 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sorafenib besylate, and processes for preparations thereof |
JP2014505052A (en) | 2011-01-06 | 2014-02-27 | ベータ ファルマ カナダ インコーポレーテッド | New urea for cancer treatment and prevention |
CN103402519B (en) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | tumor therapeutic agent |
ES2705950T3 (en) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds |
US20140235678A1 (en) | 2011-06-28 | 2014-08-21 | Bayer Healthcare Llc | Topical Ophthalmological Pharmaceutical Composition containing Sorafenib |
EP3111937B1 (en) | 2011-07-08 | 2020-06-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
RU2584986C2 (en) * | 2011-08-03 | 2016-05-27 | Нэшнл Тайвань Юниверсити | Agonists of protein tyrosine phosphatase-1 containing homology-2 src domain, and methods of treating using said agonists |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | Small molecule delivery with implantable therapeutic device |
EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
ES2949817T3 (en) | 2012-01-23 | 2023-10-03 | Sandoz Ag | Pharmaceutical composition containing crystalline sorafenib tosylate |
CN103301067B (en) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | It is a kind of improve absorbent properties solid dispersions and its preparation |
EP2852574B1 (en) | 2012-05-21 | 2020-02-05 | Hetero Research Foundation | Process for sorafenib tosylate polymorph iii |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
UA115789C2 (en) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Antibody formulations and uses thereof |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
KR102340654B1 (en) | 2013-04-02 | 2021-12-16 | 옥슬러 액퀴지션즈 리미티드 | Kinase inhibitor |
CN105264380B (en) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | Pleasure is cut down for the biological marker of Buddhist nun's compound response for predicting and evaluating carcinoma of endometrium subject |
JP6612232B2 (en) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド(タイカン) | Gene expression signatures for predicting responsiveness to multikinase inhibitors of interest, and uses thereof |
CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
CN104974132B (en) | 2014-04-08 | 2017-05-17 | 北大方正集团有限公司 | Polysubstituted pyridine compound and preparation method and application thereof as well as pharmaceutical composition |
CN107106551A (en) | 2014-08-08 | 2017-08-29 | 弗赛特影像4股份有限公司 | The stabilization of receptor tyrosine kinase inhibitors and solvable preparation and its preparation method |
MX2017001980A (en) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same. |
UY36294A (en) | 2014-09-12 | 2016-04-29 | Novartis Ag | COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS |
MA40775A (en) | 2014-10-01 | 2017-08-08 | Respivert Ltd | 4- (4- (4-PHENYLUREIDO-NAPHTALÉN -1-YL) OXY-PYRIDIN-2-YL) AMINO-BENZOIC ACID USED AS A KINASE P38 INHIBITOR |
CN106999427A (en) | 2014-10-09 | 2017-08-01 | 西西里微纳米系统技术区有限责任合作公司 | For treat eye disease be used for deliver legalon and the nano-structured preparation of other active components |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
BR112017017428A2 (en) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | " method for suppressing the bitterness of quinoline derivative " |
KR20170122809A (en) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer |
KR20180018695A (en) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | Anticancer drug |
EP3109236B1 (en) | 2015-06-23 | 2017-08-09 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii |
WO2017131242A1 (en) | 2016-01-29 | 2017-08-03 | 国立大学法人北海道大学 | Intracellular substance transport system and use thereof |
CN109071505B (en) | 2016-04-06 | 2021-11-16 | 奥苏拉收购有限公司 | Kinase inhibitors |
US20200237736A1 (en) | 2017-06-23 | 2020-07-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for preventing or treating cancer resistance to egfr inhibition |
KR20200020471A (en) | 2018-08-17 | 2020-02-26 | 주식회사유한양행 | Sorafenib hemicamsylate and processes for preparation thereof |
WO2018211336A2 (en) | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Solid dosage form containing sorafenib tosylate |
EP3715473A1 (en) | 2019-03-26 | 2020-09-30 | Universidade de Santiago de Compostela | Prognostic markers, therapeutic target and treatment for acromegaly |
KR20220045189A (en) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | How to treat gastrointestinal stromal tumors |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
KR20220123058A (en) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition |
RU2766288C2 (en) * | 2020-03-30 | 2022-03-11 | Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" | Amorphous form of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide tosylate (versions), method for production and use thereof for treatment of oncological diseases |
CN112159351B (en) * | 2020-09-21 | 2021-12-07 | 广州南鑫药业有限公司 | Preparation method of multi-target antitumor drug |
EP4289427A1 (en) | 2022-06-10 | 2023-12-13 | Anagenesis Biotechnologies | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US502504A (en) * | 1893-08-01 | Hermann thoms | ||
US1742156A (en) | 1928-01-03 | 1929-12-31 | Brandau Georg | Mudguard for vehicles |
US1792156A (en) * | 1928-01-17 | 1931-02-10 | Gen Aniline Works Inc | 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them |
US2093265A (en) | 1931-03-31 | 1937-09-14 | Ici Ltd | Process for the manufacture of diaryl ureas |
US2046375A (en) | 1931-06-04 | 1936-07-07 | Ici Ltd | p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same |
US2288422A (en) | 1938-11-11 | 1942-06-30 | Gen Aniline & Film Corp | Mixed ureas |
US2973386A (en) | 1943-01-05 | 1961-02-28 | Harry A Weldon | Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea |
DE925476C (en) * | 1950-04-29 | 1955-03-21 | Variapat Ag | Process for the preparation of colorless, water-soluble, trifluoromethyl and sulfonic acid groups, aliphatic or aromatic carboxylic acid or sulfonic acid arylides |
US2683082A (en) | 1950-12-09 | 1954-07-06 | Ethyl Corp | Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels |
US2722544A (en) * | 1950-12-26 | 1955-11-01 | Variapat Ag | Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation |
US2781330A (en) | 1953-02-09 | 1957-02-12 | Monsanto Chemicals | Rubber containing urea compound as an anti-exposure cracking agent |
NL185660B (en) * | 1953-03-06 | Great Lakes Chemical Corp | PROCESS FOR PREPARING ALKALI OR ALKALINE METAL BROMIDES. | |
US2745874A (en) | 1953-06-18 | 1956-05-15 | Geigy Ag J R | Insecticidal derivatives of diphenyl urea |
NL193403A (en) | 1953-12-22 | 1924-02-17 | ||
US2877268A (en) | 1956-12-24 | 1959-03-10 | Monsanto Chemicals | Substituted ureas |
US2960488A (en) | 1958-04-25 | 1960-11-15 | Eastman Kodak Co | Poly-alpha-olefins containing substituted ureas |
NL254871A (en) | 1959-08-14 | |||
NL277511A (en) | 1961-04-21 | |||
CH428747A (en) * | 1961-09-11 | 1967-01-31 | Wander Ag Dr A | Process for the production of new urea and thiourea derivatives |
US3200035A (en) | 1962-06-01 | 1965-08-10 | Ciba Ltd | Treatment of synthetic products, especially synthetic fibers |
US3284433A (en) | 1963-07-17 | 1966-11-08 | Merck & Co Inc | 4-phenoxy-carbanilides |
US3424761A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3424762A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | Certain 3-ureidopyrrolidines |
US3424760A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3547940A (en) | 1967-10-31 | 1970-12-15 | Du Pont | Substituted ureido isoxazoles |
US3743498A (en) | 1967-10-31 | 1973-07-03 | Du Pont | Method of selectively controlling undesirable vegetation |
SE370866B (en) | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
US3754887A (en) | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
US3646059A (en) | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
BE754782A (en) | 1969-08-14 | 1971-02-12 | May & Baker Ltd | THIOPHENE DERIVATIVES WITH HERBICIDAL ACTION |
US3823161A (en) | 1970-05-07 | 1974-07-09 | Exxon Research Engineering Co | Aminothiophene derivatives |
US3860645A (en) | 1973-05-23 | 1975-01-14 | Givaudan Corp | Bacteriostatic substituted carbanilides |
US4212981A (en) | 1973-07-27 | 1980-07-15 | Shionogi & Co., Ltd. | Process for preparing 3-isoxazolylurea derivatives |
US4116671A (en) | 1973-07-27 | 1978-09-26 | Shionogi & Co., Ltd. | 3-Isoxazolylcarbamate derivatives |
US4062861A (en) | 1973-07-27 | 1977-12-13 | Shionogi & Co., Ltd. | 3-Isoxazolylurea derivatives |
US4001256A (en) | 1973-12-26 | 1977-01-04 | The Upjohn Company | Pyridylalkyl phenyl ureas and their n-oxides |
US4009847A (en) | 1974-04-17 | 1977-03-01 | E. I. Du Pont De Nemours And Company | 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents |
US3990879A (en) | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
US4111683A (en) | 1975-06-27 | 1978-09-05 | Chevron Research Company | N-alkyl or alkoxy-N'-substituted hydrocarbyl urea |
US4173637A (en) | 1976-10-29 | 1979-11-06 | Ishihara Sangyo Kaisha Ltd. | N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof |
JPS5840946B2 (en) | 1976-10-29 | 1983-09-08 | 石原産業株式会社 | N-benzoyl-N'-pyridyloxyphenylurea compounds, methods for producing them, and insecticides containing them |
US4071524A (en) | 1976-11-08 | 1978-01-31 | Riker Laboratories, Inc. | Derivatives of urea |
US4183854A (en) | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
US4042372A (en) | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
DE2817449A1 (en) | 1978-04-21 | 1979-10-31 | Bayer Ag | MEANS OF REGULATING PLANT GROWTH |
JPS5562066A (en) * | 1978-11-03 | 1980-05-10 | Toshihiko Okamoto | N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator |
JPS55124763A (en) * | 1979-03-19 | 1980-09-26 | Ishihara Sangyo Kaisha Ltd | 5-trifluoromethyl-2-pyridone derivative |
DE2928485A1 (en) | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
US4468380A (en) | 1979-12-26 | 1984-08-28 | Eli Lilly And Company | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
BR8106184A (en) | 1980-01-25 | 1981-11-24 | Reanal Finomvegyszergyar | PROCESS FOR THE PREPARATION OF N-ARYL-N 'DERIVATIVES - (MONO-OR DISSUBSTITUTED) -UREA |
US4526997A (en) | 1981-05-06 | 1985-07-02 | Doherty George O P O | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
JPS57185219A (en) * | 1981-05-12 | 1982-11-15 | Chugai Pharmaceut Co Ltd | Remedy for cancer |
US4511571A (en) | 1981-10-20 | 1985-04-16 | Ciba Geigy Corporation | N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use |
US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US4473579A (en) | 1982-01-26 | 1984-09-25 | American Cyanamid Company | Antiatherosclerotic tetrasubstituted ureas and thioureas |
DE3211851A1 (en) | 1982-03-31 | 1983-10-06 | Basf Ag | DIHYDROTHIOPHENE-CARBONESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
JPS58203957A (en) | 1982-05-25 | 1983-11-28 | Ube Ind Ltd | Preparation of urea derivative |
CA1254212A (en) | 1982-11-12 | 1989-05-16 | Shiro Hirai | Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same |
DE3540377A1 (en) | 1985-11-14 | 1987-05-21 | Bayer Ag | THIENOOXAZINONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PERFORMANCE PROVIDER |
DE3541631A1 (en) | 1985-11-26 | 1987-05-27 | Bayer Ag | SELECTIVE-FUNGICIDAL USE OF THIENYL URINE DERIVATIVES |
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
EP0255297B1 (en) | 1986-07-31 | 1993-04-21 | Beecham Group Plc | Azabicyclic compounds, process for their preparation, and their pharmaceutical use |
NZ221964A (en) | 1986-10-03 | 1990-03-27 | Ishihara Sangyo Kaisha | Benzoylurea compounds and insecticidal compositions |
EP0264904A3 (en) | 1986-10-23 | 1988-08-17 | Ishihara Sangyo Kaisha, Ltd. | Pharmaceutical compositions containing benzoyl urea derivatives |
DE3636190A1 (en) | 1986-10-24 | 1988-04-28 | Bayer Ag | METHOD FOR PRODUCING N, N-DIARYL UREAS |
JPH06100808B2 (en) * | 1987-05-28 | 1994-12-12 | 富士写真フイルム株式会社 | Processing method of silver halide color photographic light-sensitive material |
JPH0222650A (en) * | 1988-07-11 | 1990-01-25 | Konica Corp | Silver halide color photographic sensitive material |
JPH0223337A (en) * | 1988-07-12 | 1990-01-25 | Konica Corp | Silver halide photographic sensitive material containing novel coupler |
FR2639636B1 (en) | 1988-11-30 | 1994-03-04 | Novapharme | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND THERAPEUTIC COMPOSITIONS CONTAINING THEM |
JPH02196719A (en) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | Powdery drug composition |
JPH02237922A (en) | 1989-01-24 | 1990-09-20 | Green Cross Corp:The | Antiviral agent |
JP3002204B2 (en) * | 1989-03-13 | 2000-01-24 | 株式会社東芝 | Time-series signal recognition device |
US4973675A (en) * | 1989-04-13 | 1990-11-27 | University Of Tennessee Research Center | Hybrid nitrosoureidoanthracyclines having antitumor activity |
JPH0395153A (en) * | 1989-06-15 | 1991-04-19 | Mitsubishi Kasei Corp | Diphenyl urea derivative |
IL95860A0 (en) | 1989-10-13 | 1991-07-18 | Ciba Geigy Ag | Thienylthioureas,-isothioureas and-carbodiimides |
NZ238624A (en) | 1990-06-19 | 1994-08-26 | Meiji Seika Co | Pyridine derivatives, compositions, preparations and use thereof |
US5319099A (en) | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
US5185358A (en) | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
WO1993018028A1 (en) | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
JP2717481B2 (en) | 1992-08-25 | 1998-02-18 | 富士写真フイルム株式会社 | Silver halide color photographic materials |
DK41193D0 (en) | 1993-04-07 | 1993-04-07 | Neurosearch As | ion channel openers |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
JPH07141053A (en) * | 1993-11-17 | 1995-06-02 | Nec Niigata Ltd | Clock generating circuit |
CH686211A5 (en) | 1994-01-27 | 1996-02-15 | Ciba Geigy Ag | Moth and Koferschutzmittel. |
DE4412334A1 (en) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituted N-heteroaroylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5470882A (en) | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
WO1995033458A1 (en) * | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
US5597719A (en) | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
ATE220661T1 (en) | 1994-10-19 | 2002-08-15 | Novartis Erfind Verwalt Gmbh | ANTIVIRAL ETHERS OF ASPARTATE PROTEASE SUBSTRATE ISOSTERS |
CA2161376C (en) * | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
TW313568B (en) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US5814646A (en) | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
DE19512639A1 (en) * | 1995-04-05 | 1996-10-10 | Merck Patent Gmbh | Benzonitriles and fluorides |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
NO307879B1 (en) * | 1995-09-18 | 2000-06-13 | Sankyo Co | New urea derivatives with ACAT inhibitory activity and pharmaceuticals containing them |
US6075040A (en) * | 1996-09-05 | 2000-06-13 | Eli Lilly And Company | Selective β3 adrenergic agonists |
DE69622183D1 (en) * | 1995-11-07 | 2002-08-08 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLE DERIVATIVES, WHICH INHIBIT THE AUTOPHOSPHORYLATION OF THE GROWTH FACTOR RECEPTOR DERIVING FROM BLOOD PLATPLES AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AU1173997A (en) * | 1995-12-28 | 1997-07-28 | Kureha Kagaku Kogyo Kabushiki Kaisha | Process for producing pyridinecarboxamides or thiocarboxamides |
US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6211373B1 (en) * | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
CA2202578A1 (en) * | 1996-04-15 | 1997-10-15 | Mitsuru Shiraishi | Hydroxypyridine derivatives, their production and use |
JPH09301858A (en) | 1996-05-13 | 1997-11-25 | Senju Pharmaceut Co Ltd | Aqueous medicine containing stabilized cholorohexidine gluconate |
JP2000513360A (en) * | 1996-06-27 | 2000-10-10 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
AU3409197A (en) * | 1996-06-27 | 1998-01-14 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
CZ425698A3 (en) * | 1996-06-27 | 1999-06-16 | Smithkline Beecham Corporation | Il-8 receptor antagonist |
US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5965573A (en) * | 1996-10-23 | 1999-10-12 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
FR2755967B1 (en) * | 1996-11-21 | 1999-01-29 | Pf Medicament | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
US5929250A (en) * | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
EP0971894A1 (en) * | 1997-04-04 | 2000-01-19 | Pfizer Products Inc. | Nicotinamide derivatives |
DK0973735T3 (en) * | 1997-04-10 | 2003-06-23 | Upjohn Co | Polyaromatic antiviral preparations |
US6316479B1 (en) * | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
US6344476B1 (en) * | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
EP0986382B1 (en) * | 1997-05-23 | 2008-06-25 | Bayer Pharmaceuticals Corporation | Raf kinase inhibitors |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
PT1019040E (en) * | 1997-05-23 | 2005-01-31 | Bayer Pharmaceuticals Corp | INHIBITION OF THE ACTIVITY OF P38-KINASE BY MEANS OF ARILUREIAS |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
WO1999020617A1 (en) * | 1997-10-21 | 1999-04-29 | Active Biotech Ab | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6174901B1 (en) * | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
WO1999032110A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
CZ301102B6 (en) * | 1997-12-22 | 2009-11-04 | Bayer Corporation | Substituted aryl ureas, pharmaceutical compositions containing them and their use |
ATE529109T1 (en) * | 1997-12-22 | 2011-11-15 | Bayer Healthcare Llc | INHIBITION OF P38 KINASE ACTIVITY BY SUBSTITUTED HETEROCYCLIC UREAS |
JP3887769B2 (en) * | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | Inhibition of p38 kinase using symmetric and asymmetric diphenylureas |
EP0975589A2 (en) * | 1998-01-21 | 2000-02-02 | ZymoGenetics, Inc. | Dialkyl ureas as calcitonin mimetics |
US6582126B2 (en) * | 1998-06-03 | 2003-06-24 | Northmonte Partners, Lp | Bearing surface with improved wear resistance and method for making same |
UY25842A1 (en) * | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
ME00275B (en) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AU2725000A (en) * | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
TWI284642B (en) * | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
PL206627B1 (en) * | 1999-01-22 | 2010-09-30 | Kirin Pharma Kk | Quinazoline derivative, its use and pharmaceutical composition |
MXPA01009077A (en) * | 1999-03-12 | 2002-03-27 | Boehringer Ingelheim Pharma | Aromatic heterocyclic compounds as anti-inflammatory agents. |
PL350357A1 (en) * | 1999-03-12 | 2002-12-02 | Boehringer Ingelheim Pharma | Heterocyclic urea and related compounds useful as anti−inflammatory agents |
ATE312823T1 (en) * | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | METHOD FOR PRODUCING HETEROARYL-SUBSTITUTED UREA COMPOUNDS |
US6492393B1 (en) * | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
-
2000
- 2000-01-12 WO PCT/US2000/000648 patent/WO2000042012A1/en active Search and Examination
- 2000-01-12 EP EP00903239A patent/EP1140840B1/en not_active Expired - Lifetime
-
2001
- 2001-02-02 US US09/773,604 patent/US20010034447A1/en not_active Abandoned
- 2001-02-02 US US09/773,672 patent/US20010016659A1/en not_active Abandoned
- 2001-02-02 US US09/773,658 patent/US20010027202A1/en not_active Abandoned
- 2001-02-02 US US09/773,675 patent/US20010011136A1/en not_active Abandoned
- 2001-02-02 US US09/773,659 patent/US20010011135A1/en not_active Abandoned
- 2001-09-10 US US09/948,915 patent/US20020042517A1/en not_active Abandoned
-
2002
- 2002-02-11 US US10/071,248 patent/US7528255B2/en not_active Expired - Fee Related
-
2006
- 2006-05-23 CY CY20061100668T patent/CY1105286T1/en unknown
- 2006-10-27 FR FR06C0034C patent/FR06C0034I2/en active Active
-
2007
- 2007-01-18 CY CY200700002C patent/CY2007002I1/en unknown
- 2007-08-27 US US11/845,595 patent/US20080032979A1/en not_active Abandoned
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US9181188B2 (en) | 2002-02-11 | 2015-11-10 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8071616B2 (en) | 2002-02-11 | 2011-12-06 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US8076488B2 (en) | 2003-02-28 | 2011-12-13 | Bayer Healthcare Llc | Bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
EP2589384A1 (en) | 2004-08-27 | 2013-05-08 | Bayer Healthcare LLC | New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
US20080242707A1 (en) * | 2005-03-07 | 2008-10-02 | Bayer Healthcare Ag | Pharmaceutical Composition for the Treatment of Cancer |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
US20090304694A1 (en) * | 2006-01-27 | 2009-12-10 | Amgen Inc. | Ang2 and Vegf Inhibitor Combinations |
WO2007089445A2 (en) | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
WO2010108665A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
WO2011130728A1 (en) | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions |
WO2012044577A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
WO2012129448A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
US11185585B2 (en) | 2011-03-23 | 2021-11-30 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
Also Published As
Publication number | Publication date |
---|---|
US20030139605A1 (en) | 2003-07-24 |
WO2000042012A1 (en) | 2000-07-20 |
CY1105286T1 (en) | 2010-03-03 |
US20010034447A1 (en) | 2001-10-25 |
US7528255B2 (en) | 2009-05-05 |
FR06C0034I2 (en) | 2007-04-27 |
US20080032979A1 (en) | 2008-02-07 |
CY2007002I2 (en) | 2009-11-04 |
FR06C0034I1 (en) | 2006-08-12 |
US20010027202A1 (en) | 2001-10-04 |
EP1140840A4 (en) | 2002-09-18 |
US20010011135A1 (en) | 2001-08-02 |
US20020042517A1 (en) | 2002-04-11 |
CY2007002I1 (en) | 2009-11-04 |
US20010011136A1 (en) | 2001-08-02 |
EP1140840B1 (en) | 2006-03-22 |
EP1140840A1 (en) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20010016659A1 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US7235576B1 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US8841330B2 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US7351834B1 (en) | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US20030207872A1 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US7928239B2 (en) | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | |
CA2359510C (en) | .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
US20120040986A1 (en) | Omega carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
EP1690853B1 (en) | Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
AU2004200722A1 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | |
BG65158B1 (en) | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitirs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023031/0963 Effective date: 20071219 Owner name: BAYER HEALTHCARE LLC,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023031/0963 Effective date: 20071219 |